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Background and objective 
Many longitudinal studies have been conducted to evaluate the relationship 
between a variety of exposures and outcomes using only baseline data, due to the 
simplicity of statistical methods used for implementation. The failure to fully 
utilize the information that has been collected over time limits the inferences that 
could have been drawn especially with regards to changes in exposure effect. This 
thesis aims to evaluate repeated measures outcomes in epidemiology, assuming 
metabolic syndrome (MetS) as the main exposure of interest. 
Methods 
The thesis is motivated by data from the Blue Mountains Eye Study, Australia. It 
is a prospective cohort study of persons aged ≥49 years who were followed over 
10 years. A total of 3086 subjects had complete information for the factors we are 
interested in at baseline contributed to the analysis of this thesis. Among these 
3086 subjects, 2133 and 1632 subjects had complete information at the 5- and 10-
year follow-up, respectively. The survival status of each subject was evaluated at 
each follow-up and the exact time of death recorded if it had occurred. MetS 
components as defined by the International Diabetes Federation criteria, were 
measured at baseline (1992-1994), 5 (1997-1999) and 10 (2002-2004) years. The 
outcomes, which include the development of cataract and age-related macular 
degeneration (AMD), were also assessed at the 5- and 10-year follow-up visits. In 
this thesis, repeated measures of MetS components were shown to be highly 
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correlated. To account for intra-subject correlation in the analysis, we apply 
appropriate statistical methods to unravel the relationship between MetS and its 
components, with time-to-event outcome involving all-cause and cause-specific 
mortality, interval-censored outcome involving age-related cataract and binary 
outcome of AMD. The thesis comprises four studies as described below. 
Study 1 
This study evaluates the association between MetS and its components with all-
cause and cause-specific mortality. These covariates were repeatedly assessed at 
baseline, 5- and 10-year follow up and found to change with time. We thus 
evaluated the relationship between MetS (components) with all-cause and cause-
specific mortality by applying Cox proportional hazards and competing risks 
models respectively, and considered MetS and its components as time-dependent 
covariates. The time-dependent receiver-operating-characteristic curve, 
integrated-discrimination-improvement and net-reclassification-improvement 
tests were also performed to assess the predictive abilities of individual and 
combined MetS components. The effects of MetS on all-cause and cause-specific 
death changed with time. The discrimination analyses showed that different MetS 
components were associated with different causes of death. 
Study 2 
This study determines the relationship between BMI including its 5-year changes 
and mortality. It has been argued that conventional Cox regression model may 
overestimate the relationship between exposure of interest such as BMI with 
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multiple failure endpoints such as different causes of death especially among frail 
or elderly population. Therefore, we compared the results obtained using Cox and 
competing risks models. The pattern of the relationship between BMI and 
mortality was found to depend on age. Amongst the younger subjects, the 
relationship between baseline BMI and all-cause mortality was U-shaped. 
Amongst elderly persons, an L-shaped relationship was seen: only low but not 
excessive BMI was found to be associated with an increased risk of all-cause 
death. A 5-year reduction in BMI was associated with increased risk of all-cause 
and cancer mortality. The Cox regression model showed a larger magnitude of 
effect, and with wider confidence interval, as compared with competing risks 
model. 
Study 3  
This study investigates whether the effect of MetS and its components on the 
incidence of cortical, nuclear and posterior subcapsular cataract (PSC) change 
with time. In this study, the occurrence of cataract is said to be interval-censored 
since the event was only known to occur between two assessment periods, that is, 
between baseline and 5-year or between 5- and 10-year follow-up. To deal with 
interval-censoring, the random effects complementary log-log model was 
implemented. Changes in MetS predicted the 5-year incidence of cortical and PSC 
cataract. Different MetS components predicted the incidence of different cataract 






This study investigates the relationship between MetS and its components with 
the risk of early and late stage AMD. The outcomes and main exposure of 
interest, namely early or late stage AMD as well as MetS and its components 
respectively, were measured at baseline, 5- and 10-year follow-up. To explore the 
relationship between MetS with subsequent development of early or late AMD 
during 10-year follow-up, the mixed-effects logistic regression was implemented 
to account for intra-subject correlation which arose with repeated measurement. 
Changes in MetS, obesity, high glucose and high triglycerides predicted the 
incidence of late AMD during the 10-year follow-up among subjects aged ≤70 
years. 
Conclusions 
Full utilization of baseline and follow-up information in longitudinal studies 
provides a more precise and accurate estimate of the exposures on the outcomes 
of interest. Moreover, for the analysis of multiple-failure endpoints such as 
different causes of death, the competing risks model yielded a more accurate 
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CHAPTER 1 – Introduction 
 
SUMMARY 
Long-term longitudinal studies are the best instrument for exploring changes in 
effect over time. Although many longitudinal studies have been conducted to 
evaluate the relationship between a variety of exposures and outcomes, the results 
were usually evaluated using only baseline data, due to the simplicity of statistical 
methods used for implementation. The failure to fully utilize the information that 
had been collected over time limited the inferences that could have been drawn 
especially with regards to changes in exposure effect. This thesis aims to evaluate 
repeated measures outcomes in epidemiology, assuming metabolic syndrome 
(MetS) and its components as the main exposure of interest. In this thesis, MetS 
and its components, as well as the respective outcomes, age-related cataract and 
age-related macular degeneration (AMD) were repeatedly measured at baseline, 
5- and 10-year follow-up. The survival status of each subject was evaluated at 
each follow-up and the exact time of death recorded if it had occurred. We apply 
advanced statistical models that account for possible intra-class correlation to 
evaluate the longitudinal effect of MetS and its components according to the 
endpoints of interest. These included time-to-event outcomes involving all-cause 
and cause-specific mortality, interval-censored outcome involving age-related 





1.1. Examples and defining features of longitudinal studies  
In the past decade, many longitudinal studies have been conducted to evaluate the 
relationship between a variety of exposures and outcomes. However, despite the 
longitudinal nature of the study design, the relationships were evaluated using 
only baseline information. These included the Framingham study which examined 
the association between exercise blood pressure (BP) and the risk of incident 
cardiovascular disease (CVD) (Lewis et al. 2008), the study by Saczynski et al. 
(2010) on the relationship between depression syndrome and the risk of dementia, 
and the Nurses‘ Health Study which evaluated the relation between smoking, 
caffeine and alcohol with epilepsy (Dworetzky et al. 2010). These cohort studies 
assessed the relationship between baseline exposure(s) and the respective disease 
outcomes without taking into account additional information that were collected 
at subsequent follow-up visits. 
 The defining feature of longitudinal studies is that measurements of the same 
individual, for example, BP levels or occurrence of kidney disease are recorded 
repeatedly, thereby allowing the direct study of changes over time. With repeated 
measures on individuals, one can capture within individual changes in the 
response over time and the factors that influence such changes, which can only be 
achieved within a longitudinal study design (Crowder and Hand 1990; 
Fitzmaurice et al. 2004). 
 There are some advantages of full utilisation of information in longitudinal 
studies. In practice, missing data cannot be avoided in long term follow-up 
studies. This results in a reduction in power and biased estimates. In this scenario, 
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the best solution to overcome this problem is to apply longitudinal panel data 
analysis. The longitudinal panel data refers to a group of individuals who are 
surveyed repeatedly over time. Clustering of data arises when the observations are 
grouped, for example, according to individuals. Moreover, due to repeated 
measures of exposure within each subject over time, the data are usually 
correlated in such study design.  
The number of participants in this thesis at different visits varies due to loss to 
follow-up, deaths, migration or refusal to continue to participate in the study, thus 
resulting in missing observations. Of the 3654 eligible BMES participants at 
baseline, 501 refused participation. Attrition also occurred during the 5- and 10-
year follow-up visits. The response rates were at baseline 82.4%, 5-year 75.8% 
and 10-year 76.7%. Fuller details on the follow-up of study participants are 
provided in Chapter 2. In the conventional statistical approach, if a person is 
missing on a covariate, his/her observation will be excluded from the entire 
analysis. To overcome this problem, the mixed model approach is recommended 
for analysis of longitudinal data, as only the time point when the observation is 
missing will be excluded from the analysis. The remaining data will continue to 
contribute to the analysis of the outcomes. 
In this thesis, we define metabolic syndrome (MetS) and its components 
according to the International Diabetes Federation (IDF) criteria. As shown in 
Chapter 2, the prevalence of MetS and its components changed from visit to 
visit. For example, the prevalence of MetS increased slightly after 5 years follow-
up from baseline, and again decreased by 10-year follow-up. Among the 5-MetS 
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components, the prevalence of BMI >30 kg/m
2
, high glucose, high triglycerides 
(TG) and high BP levels increased from baseline to 5-year and then decreased by 
10-year. However, the prevalence of low high density lipoprotein (HDL) 
cholesterol decreased from baseline to 5-year and then increased by 10-year. As 
such, when evaluating the relationship between MetS and its components with the 
outcomes of interest, we need to consider the time-varying effect of MetS and its 
components. In addition, the information of MetS or its components at baseline 
and subsequent follow-up visits were also shown to be highly correlated. 
Therefore, accounting for intra-subject correlation between MetS (or its 
components) at different time of assessments would be appropriate.  
One approach for analyzing repeated measures data is via the mixed model 
which includes both the fixed and random effects. Random effect refers to 
subject-specific effect, while fixed effect refers to population average effect. In 
the mixed-effects model, the random effects are estimated when the data structure 
consists of repeated measures over time (Brown and Prescott 2006). The intra-
class correlation (ICC), which refers to the within-cluster correlation of the 
exposure of interest, is usually reported in such instances. The use of a mixed 
model is clearly desirable to take account of the possible intra-subject correlations 
between the repeated measurements, as well as to overcome the problem of 
missing data. Such models are more flexible in terms of repeated measures and 




Although conducting longitudinal studies involve a great deal of effort in 
study design and data collection, they offer several important benefits over cross-
sectional study (Lebowitz, 1996; Rothman et al. 2008). These include the 
recording of incident events such as incidence of age-related cataract or age-
related macular degeneration (AMD) and presenting a direct measure of risk in 
terms of hazard ratio (HR) or relative risk ratio. While cross-sectional study 
explores the effect of exposure at a particular time point since the exposure and 
outcome were assessed at the same time, longitudinal study explores the temporal 
association between the covariate of interest, for example, BP, and the outcome 
which were measured at different time points (i.e. at baseline, 5- and 10-year 
follow-up). The cohort study design thus allows us to follow the subjects up till 
the observation of the outcome regardless of their risk status during the study 
period. This unique feature is lacking in a cross-sectional study.  
 
1.2 Statistical methods for analyzing longitudinal data 
In longitudinal studies involving repeated measures data, different models may be 
implemented depending on the outcome of interest. In this thesis, we apply 
appropriate statistical models for analyzing longitudinal data relevant to each 
outcome of interest. 
Time-to-event outcome 
In time-to-event analysis, the survival status of each subject is evaluated at each 
follow-up and the exact time of death recorded if it occurs. In many instances, 
information on covariates are also collected longitudinally. For example, BP, 
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weight, disease history, and hospitalization data may be collected at periodic time 
point, for example, at baseline, 5- and 10-year follow-up. Consequently, it is 
possible to detect changes in the exposure of interest over time. If such changes 
occur, then the exposure of interest may be regarded as a time-dependent 
covariate. In such a situation, one can investigate the usefulness of the temporal 
covariate information with an appropriate statistical model. The use of time-
dependent covariates in a time-to-event analysis offers exciting opportunities for 
predicting outcomes with quantities that vary over time (Collett 2003). 
In the analysis of all-cause mortality, the time-varying effect of the 
exposure may be accounted for by implementing the Cox proportional hazards 
models with time-dependent covariate (Collett 2003). In such settings, 
implementing the conventional Cox regression model without taking into account 
the time-varying effect of exposure would fail to distinguish between the short 
and long term effect of an exposure on an outcome (Collett 2003). For example, 
in studying the association between BP and mortality, utilising only the 
information of BP at baseline would not be able to clarify whether the earlier or 
most updated status of BP best predict mortality. In addition, such studies would 
also fail to quantify the effect of its changes over time.   
Studies have shown that a time-dependent Cox regression model has the 
potential to yield a more precise estimate of exposure effect on outcome than the 
traditional Cox regression models (Boberg et al. 2002; Hartmann et al. 2012). To 
illustrate, a study on short-term prognosis in primary sclerosing cholangitis 
reported that the main exposure of interest, bilirubin, was more significant in 
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the time-dependent model than in the time-invariant analysis. The time-dependent 
regression model indicated that once the patients survived beyond the first 5 
years, the impact of bilirubin at diagnosis on prognosis ceases. The time-
dependent model was superior to the time-invariant model in assigning low 1-year 
survival probabilities to patients that actually survived less than 1 year (Boberg et 
al. 2002). 
Competing risks outcome 
Under the classical competing risks framework, a subject may be simultaneously 
exposed to several distinct events, but may eventually only fail from one of these. 
In such settings, the occurrence of a specific event would preclude the competing 
risks from being observed (Tai et al. 2001, Tai et al. 2010, Tai et al. 2011a; Tai et 
al. 2011b). In the analysis of cause-specific mortality, a subject may die from any 
of the following distinct causes: cardiovascular, cancer or other causes. These 
causes of death are therefore regarded as competing risks, as the failure of one 
precludes the occurrence of the other.  
It has been argued that the cause-specific Cox analysis is not adequate for 
modelling competing risks data because it censors the competing events. Such 
censoring is assumed to be non-informative, and this procedure fails to consider 
that those who have experienced a competing event can never experience the 
main event of interest (Tai et al. 2011a; Tai et al. 2011b). The key feature that 
distinguishes competing risks data from the usual survival data is that in the 
analysis of the former, it is essential to take into account other causes of failure, 
whereas in a standard time-to-event setting, only a single failure cause is 
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considered. Thus special methods are required for analyzing competing risks data 
(Tai et al. 2011a; Tai et al. 2011b).  
For the evaluation of outcomes involving multiple failure types such as 
cardiovascular, cancer and other causes of death, the Cox regression model is 
adequate when competing risks are rare, such as in younger adults. However, in 
the presence of strong competing risks, for example, the frail or elderly 
populations (Koller et al. 2008), the standard Cox regression model may 
substantially overestimate the absolute risk of event of interest, because subjects 
with a competing (and thus censored) event are treated as if they could experience 
the event of interest in the future (Wolbers et al. 2009; Tai et al. 2010; Tai et al. 
2011a; Tai et al. 2011b).  
In addition, predictions from a standard survival analysis in the presence 
of competing risks implicitly assumes that the risk of failing from the event of 
interest is not affected by these competing risks, which can be an unrealistic 
assumption in a real world setting (Tsiatis 1975; Kalbfleisch and Prentice 2002; 
Putter et al. 2007). In a clinical decision-making scenario, where competing risks 
do occur, accounting for these competing risks are often more relevant 
(Grunkermeier et al. 1997; Grunkemeier et al. 2007). Therefore, for analysis of 
multiple failure endpoints such as different causes of death, competing risks 
analysis provides a more robust and precise estimate of exposure on different 
causes of death in comparison with conventional cause-specific Cox-regression 





When the exact time of occurrence of outcome, such as cataract is not known, but 
the time-to-event is only known to occur between two assessment periods, for 
example, between baseline and 5-year follow-up, or between 5- and 10-year 
follow-up, then interval censoring is said to have occurred. Since the covariate of 
interest, for example, BP level may also be measured repeatedly at similar 
predefined time intervals, the repeated measures data which are recorded on each 
subject are said to be nested within clusters. Within each cluster, the exposure of 
interest is correlated and this should be accounted for in the analysis as a random 
effect. When the occurrence of outcome such as cataract is interval-censored, then 
applying the Cox model to the hazards of events in intervals along with the 
repeated measures of covariates results in a random-effects complementary log-
log regression model (Rabe-Hesketh and Skrondal 2008). In this model, the 
random-effects account for intra-subject correlation of exposure of interest which 
frequently arises in studies with repeated measurements. Studies have shown that 
interval-censored approach performs well for practical situations and would be 
applicable in real situations in medicine (Tong et al. 2008; Sun et al. 2013). Tong 
et al. (2008) conducted an experimental study in animals to investigate the 
relationship between exposure to chloroprene at different concentrations and 
adrenal tumor growth rate with an interval-censored model. They showed that 
interval-censored model provided an unbiased estimate in their simulation study. 
Similarly, in the simulation study, the outcome was regarded as an interval-
censored. The results of simulation study suggested that for most situations, the 
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proposed estimate of the regression parameter seemed unbiased and the estimate 
of the standard error was close to the sample standard deviation. Both the 
simulation and experimental study showed that the random-effects interval-
censored model would predict the associations in an unbiased manner, when the 
data were correlated and outcome was interval-censored. 
The random-effects complementary log-log regression model can also 
overcome intra-subject correlation which cannot be accounted for by the 
conventional logistic regression model. Moreover, the failure to fully utilize the 
information that have been collected over time limits the inferences that could 
have been drawn especially with regards to changes in exposure effect (Rabe-
Hesketh and Skrondal 2008; Tong et al. 2008; Sun et al. 2013). Therefore, 
interval-censored modelling provides a more robust and precise estimate of 




The mixed-effects model can be applied to continuous and categorical outcomes. 
In study 4 of this thesis, we focus on the mixed-effects logistic regression model, 
which is appropriate for a binary outcome. When the outcome is binary such as 
the presence or absence of AMD, and the data are clustered, the mixed effects 
logistic regression would be appropriate for modeling this outcome. In this 
situation, the log odds of the event is modeled as a linear combination of the 
predictor variables based on the clustered data (Agresi 2013). Previous studies 
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have shown that the mixed-effects model is an appropriate and powerful tool for 
analysis of longitudinal clustered data (Blasco-Fontecilla et al. 2012; Candel 
2012). For example, Blasco-Fontecilla et al. (2012) investigated the trends and 
correlations of changes in gross domestic product on changes in suicide rates in 
10 World Health Organisation (WHO) regions during the past 30 years. They also 
stated that the mixed-effects model allows conclusions to be drawn on the cluster 
level based on different countries. Such detailed information on effect sizes based 
on cluster level (e.g. country) cannot be obtained from standard logistic regression 
modelling technique. 
The mixed-effects model can also overcome intra-subject correlation which 
cannot be accounted for by a conventional logistic regression model. Therefore, 
mixed model provides stronger and more robust estimate of exposure on outcome 
in comparison with the conventional logistic regression model. 
 
1.3 Objectives of the thesis 
This thesis aims to evaluate repeated measures outcomes in epidemiology, 
assuming MetS as the main exposure of interest. In the past decade, many 
longitudinal studies have evaluated the relationship between MetS and its 
components with mortality or eye diseases. Despite the longitudinal nature of the 
study design, the relation between obesity and age-related eye diseases was 
assessed at a single point in time in the Beaver Dam Eye Study (Klein et al. 
2001). Other longitudinal studies on MetS also used only the baseline information 
to describe its association with all-cause and cause-specific mortality (Jaggers et 
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al. 2009; Satio et al. 2009; Zambon et al. 2009; Akbaraly et al. 2010; Salminen et 
al. 2010; Sidorenkov et al. 2010) or  age-related cataract (Tan et al. 2008).  
This thesis evaluates the longitudinal effect of MetS and its components as 
defined by the IDF criteria. It includes body mass index (BMI) as a mandatory 
component for defining MetS. We consider different morbidity and mortality 
outcomes. These included time-to-event outcomes involving all-cause and cause-
specific mortality, interval-censored outcome involving age-related cataract and 
binomial outcome involving AMD. In this thesis, MetS, its components and the 
respective outcomes were longitudinally measured over the study period, at 
baseline and again at the 5- and 10-year examinations after first recruitment. 
Details of the measurement of MetS components are provided in Chapter 2. In 
this thesis, we seek to provide a more comprehensive understanding of how 
advanced statistical methods may be used to deal with repeated measures of 
exposures and outcomes according to relevant situation involving time-to-event, 
competing risks, interval-censored or binary outcomes. 
Specifically, this thesis is divided into four different studies. Within each 
study, we describe the use of relevant statistical methods for handling the 
correlation between repeated measures as well as the presence of missing data in 
order to effectively address the respective objectives of the study. In the section 
that follows, we describe the specific objective of each study and briefly discuss 
the statistical models used. Fuller details of the methodology for each study are 




Study 1: Metabolic syndrome and mortality in the elderly: A time-dependent 
association. 
Although MetS increases with age, previous studies have shown inconsistencies 
regarding its relationship with all-cause and cause-specific mortality especially 
among elderly subjects (Hu et al. 2004; Hunt et al. 2004). To-date, no study has 
evaluated whether the relationship between MetS and mortality changes with 
time. In this study, the status of MetS and the survival status of each subject were 
evaluated at each follow-up. Further, the exact time of death was recorded if it 
had occurred. Since it was possible that the status of MetS might change from 
visit to visit, it was thus regarded as a time-dependent covariate in the analysis. In 
evaluating the relationship between MetS and its components with all-cause and 
cause-specific mortality, and determining whether the association changes with 
time, we appropriately implemented the time-dependent covariate Cox and 
competing risks models respectively.  
 As explained earlier, in the analysis of all-cause mortality, we take into 
account the time-varying effect of MetS and its components by implementing the 
Cox proportional hazards models with time-dependent covariate (Collett 2003). In 
this instance, MetS and its components were regarded as time-dependent 
covariates, whereas possible confounders such as age, sex, smoking status, pre-
existing diseases at baseline (namely, cancer, angina, acute myocardial infarction 
(AMI), stroke and chronic lung disease), whose information were collected at 




When MetS and its components were observed to change over study 
period, the competing risks model with time-dependent covariate was applied for 
analyzing cause-specific mortality such as cardiovascular-, cancer- and  other 
causes of death (Tai et al. 2010; Tai et al. 2011a; Tai et al. 2011b). 
To further evaluate the predictive performance of MetS component with 
time-to-event outcome namely all-cause and cause-specific mortality, the time-
dependent receiver operating characteristic (ROC) curve for censored survival 
data and the area under the ROC curve (AUC),  net reclassification improvement 
(NRI) and integrated discrimination improvement (IDI) tests were implemented. 
Fuller details of these methods are provided in Chapter 3.  
Study 2: The prognostic role of body mass index on mortality amongst the 
middle-aged and elderly: A competing risks analysis 
The relationship between BMI and mortality, especially in the overweight and 
obese range, amongst the elderly may be different from younger adults (Corrada 
et al. 2006). Furthermore, there are  inconsistencies in reporting with regards to 
changes in BMI over time and its associations with all-cause and cause-specific 
mortality (Breeze et al. 2006; Corrada et al. 2006; Bamia et al. 2007; Myrskylä 
and Chang 2009; Saito et al. 2009; Yun et al. 2010). Moreover, obesity is 
associated with multiple causes of death, and it has been also argued that the 
conventional survival model may overestimate the risk of the competing causes of 
death such as cardiovascular, cancer and other causes of death, especially among 
the elderly population (Wolbers et al. 2009; Tai et al. 2010; Tai et al. 2011a; Tai 
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et al. 2011b). Hence, in this study, we aim to determine whether BMI and its 
changes are associated with all-cause and cause-specific mortality amongst 
middle-aged and elderly subjects, and compare the results obtained using standard 
Cox and competing risks models.  
Study 3: Metabolic syndrome and risk of age-related cataract over time: An 
analysis of interval-censored data using random effects model. 
So far, few studies have evaluated the relationship between baseline MetS and its 
components with age-related cataract (Tan et al. 2008d; Sabanayagam et al. 
2011). Inconsistencies remain with regards to whether MetS or its components 
would predict the different types of age-related cataract, namely, cortical, nuclear 
or posterior subcapsular cataract (PSC). Besides it is questionable whether these 
associations change with time. In this study, we evaluate the effect of MetS and 
its components on the incidence of different age-related cataract sub-types, 
namely cortical, nuclear and PSC, and determine whether these associations 
change with time, using an interval-censored analysis.  
In this thesis, the outcome of interest, cataract occurrence was evaluated at 
different time-interval between baseline and 5-year follow-up or between 5- and 
10-year follow-up. Therefore, the occurrence of cataract is said to be interval-
censored. The information of MetS and its components are also available at pre-
defined time-intervals. As the within subject MetS components have been shown 
to be highly correlated in this thesis, we accounted for the intra-subject correlation 
via the random-effects complementary log-log regression model (Rabe-Hesketh 
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and Skrondal 2008). This allowed for the detection of a stronger and more robust 
estimate of MetS on the occurrence of the different types of cataract which was 
evaluated at pre-defined time-intervals. Repeated measures of MetS and its 
components were regarded as random effects, whereas age, sex, history of eye 
disease, pre-existing cardiovascular disease and family history of blindness which 
were measured at baseline, were regarded as fixed effects. 
Study 4: Metabolic syndrome and risk of age-related macular degeneration  
Atherosclerosis has long been postulated to be associated with late stage AMD 
through its effect on the choroidal circulation and possible deposition of lipids in 
the Bruch membrane (Friedman 2000). The prevalence of AMD and CVD are 
strongly age-dependent, and there have been conflicting reports about the 
independent associations of CVD, its risk factors (eg. BP or high serum lipid 
levels) and the development of AMD (Klein 2005; Klein et al. 2007). To-date, 
there has not been any study that evaluates the relationship between MetS (as a 
whole) and AMD. Hence, in this study, we investigate the age-specific 
relationship between MetS and its components with early and late stage AMD 
through the application of mixed-effects logistic regression model. 
 MetS and its components, as well as the endpoints of interest, namely 
early and late stage AMD, were repeatedly measured at baseline, 5- and 10-year 
follow-up. Since the outcome, presence or absence of AMD was binary, and the 
data were clustered within subject due to repeated measurements, the mixed 
effects logistic regression would be appropriate for modeling this type of outcome 
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(Agresi 2013). Repeated measures of MetS and its components were regarded as 
random-effects, whereas age, sex and pre-existing cardiovascular disease which 
were measured at baseline, were regarded as fixed-effects. 
It should be noted that, although age-related cataract and AMD are both  
binary outcomes, in this thesis, we have modeled the two outcomes using 
different statistical technique to provide variety in illustrating different methods of 
handling such data.  
 
1.4 Outline of the thesis 
This thesis comprised a total of seven chapters. In the remaining section of this 
chapter, we outline our contribution to medical research in terms of presentation 
at conferences and publications. In Chapter 2, we describe the Blue Mountains 
Eye Study, which provides the motivation for this thesis. It covers the study 
design, epidemiological aspects such as confounding, interaction, collinearity, 
general statistical methods that apply to most studies, as well as describes the 
study population and general strengths and limitations of the thesis not specific to 
individual studies. In Chapter 3, we examine the relationship between MetS and 
its components with all-cause and cause-specific mortality via the application of 
the Cox and competing risks models that account for MetS and its components as 
time-dependent covariate. Chapter 4 evaluates the age-specific relationship 
between BMI and its 5-year changes with all-cause and cause-specific mortality, 
and compares the results obtained using Cox regression and competing risks 
models. In Chapter 5, we explore the relationship between MetS and its 
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components with the incidence of different types of age-related cataract, namely, 
cortical, nuclear and PSC cataract. Since the exact time when a specific cataract 
developed was not known, and only the interval between two assessment times 
were recorded, we therefore implemented the random-effects complementary log-
log model to account for interval censoring. Chapter 6 investigates the 
relationship between MetS and its components and the development of early and 
late AMD. As the outcome is binary, and the data are repeatedly measured at 
baseline and subsequent follow-up visits, the mixed-effects logistic regression 
model is implemented to account for intra-subject correlation. Finally in Chapter 
7, we review the important findings reported in the four studies, discuss the 
statistical methods implemented in this thesis, as well as the strengths and 
limitations of each study. Last but not least, the thesis concludes with several 
suggestions for future work. A separate summary is also provided for each 
chapter. 
 
1.5 Contribution to medical research  
To-date, the topics relating to the thesis have resulted in seven presentations at 
conferences and three publications. A merit and a third prize was awarded for an 
oral and a poster presentation respectively. Another paper has been submitted for 
consideration to be published and is currently pending review by the editorial 
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School of Medicine, Graduate Scientific Congress 2011, Singapore, 25 Jan 
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CHAPTER 2 – The Blue Mountains Eye Study 
 
SUMMARY  
The Blue Mountains Eye Study (BMES) is a prospective population-based cohort 
study of age-related eye diseases and other health outcomes in west of Sydney, 
Australia. Persons aged ≥49 years were invited to attend a detailed examination at 
baseline (1992-1994) and after 5- (1997-1999) and 10-years (2002-2004). A 
detailed history of diseases was recorded at face-to-face interviews conducted by 
trained interviewers using a standardized questionnaire. Metabolic syndrome 
(MetS) components as defined by the International Diabetes Federation were 
measured and recorded at baseline, 5- and 10-year follow-up visits. We included 
3086 subjects who had complete information at baseline for our study factors 
including, MetS, its components, age, sex, smoking status, pre-existing diseases, 
alcohol intake and physical activity in to the analysis of this thesis. Of these, 2133 
had complete information for MetS and its components at 5-year follow-up and 
another 1632 had complete information for MetS and its components at 10-year 
follow-up. In this thesis, repeated measures of MetS components over 10-year 
follow-up were highly correlated. As such, it is important to account for intra-
subject correlation in the analysis. We apply relevant statistical methods for time-
to-event on all-cause and cause-specific mortality, interval-censored outcome on 
age-related cataract and or binary AMD outcome, to unravel their relationship 
with MetS and its components. 
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The Blue Mountains Eye Study (BMES) baseline survey (1992-1994) was 
conducted to describe the prevalence and identify the risk factors of vision loss 
and common eye diseases in a typical older Australian. The sampled subjects 
consisted of permanent residents 49 years of age or older residing in the Blue 
Mountains area, west of Sydney, New South Wales, Australia. Prospective 
follow-up at 5- (1997-1999), 10-year (2002-2004) and 15-year (2007-2010) of 
this population-based sample enabled us to assess the longer-term incidence of 
vision loss and common eye diseases, and the factors associated with increased 
risks of these common diseases among older people. So far, the findings of this 
study include the prevalence and incidence as well as assessment of risk factors 
for the above outcomes. However, previous studies using the BMES data 
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examined the relationship between exposures such as smoking, alcohol intake, 
fibrinogen and retinal vessel caliber and outcomes involving glaucoma, myopia, 
cataract, AMD, diabetes and stroke only at a single time point. This was despite 
having collected data at subsequent follow-up visits 
(http://www.cvr.org.au/bmes.htm). It should be noted that the data set for the 15-
year follow-up was not ready at the time of analysis of this thesis. Therefore, in 
this thesis, we include all available information of our primary exposures of 
interest, that is, MetS and its components, not only at baseline but also at 
subsequent follow-up visits at 5 and 10 years to unravel the relationship between 
MetS (and its components) and subsequent development of outcomes such as 
mortality, cataract and AMD, after accounting for possible intra-subject 
correlation that arose when the repeated measurements were taken at each follow-
up visit. Advanced statistical methods were implemented to analyze the data with 
full information and account for intra-subject correlation. This provides a more 
efficient and accurate estimate of the exposure(s) on the mentioned study 
outcomes. 
2.2 Study design and population  
The BMES used a door-to-door census, supplemented by electoral roll data, to 
identify all community-dwelling subjects aged over 49 years in a single postcode. 
This comprehensive sampling frame provides a rare opportunity to compare the 
characteristics of those who could have been recruited with the characteristics of 
those who could not have been recruited, using either (1) the telephone book only; 
or (2) the electoral roll only (Smith et al. 1997).  
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The original sampling frame involved an electronic database which 
contained the particulars of all residents aged 49 years and over and their postal 
code list. The study team obtained permission from the Electoral Commission to 
use the database of the state electoral roll at the time of commencement of the 
BMES study. As the state election had occurred six months earlier, the roll was 
thus considered accurate. The following data were included in the listing: name, 
address, occupation and date of birth. All telephone numbers, subscribers
‘
 names 
and addresses were downloaded from a CD-ROM containing the latest version of 
the electronic white pages (largest and most updated dictionary for finding people 
in Australia) at the time of commencement of the study. This was a computerized 
version of the white pages telephone dictionary, which was updated six-monthly.  
One urban postcode area 2780 in Katoomba, Leura and Medlow Bath, in 
the Blue Mountains region was selected as the target area. This area has a stable 
and homogeneous population representative of the state of New South Wales with 
respect to income and socioeconomic status. The population was chosen because 
its age structure was older than that of the state and it was geographically well-
defined, enhancing the potential for publicity, community support and a high 
response (Smith et al. 1997).  
 A door-to-door census was conducted by trained interviewers from 
November to December 1991 in the 28 census collector districts of postcode area 
2780. Between March and April 1993, the study was extended to a second 
postcode area 2782 in Wentworth Falls using similar methods. The census was 
preceded by local publicity in newspapers and community radio and notification 
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by mail to all dwellings in the postcode area. All non-institutionalised, permanent 
residents aged 49 years and over who were born before 1 January 1943 at the time 
of the census were eligible. Permanent residents were defined as people who had 
lived in the dwelling for more than six months of the year (Smith et al. 1997).  
 Call-back visits to each house were made until contact with a resident 
occurred, usually by door-knock but also by telephone, using an electronic 
telephone dictionary stored by street name. A final classification as ―no contact‖ 
was made if at least three door-knock calls to the house, five telephone calls at 
different times of the day and on different days of the week, and three letters to 
the household yielded no response (Smith et al. 1997).  
 The interviewers administered a short questionnaire to each eligible 
resident at doorstep (Smith et al. 1997). This questionnaire included self-reported 
vision and hearing problems and any past diagnosis of cataract, glaucoma, 
macular degeneration, diabetes or hypertension. The last visit to an 
ophthalmologist or optometrist was also recorded. A detailed information sheet 
and questionnaire is provided in Appendix 1.  
The door-to-door census, supplemented by the telephone dictionary and 
electoral roll, identified 4433 eligible residents. The number of eligible residents 
differed by only six (0.15%) from the Australian Bureau of Statistics (ABS) 
Census91 conducted 3 months earlier (Mitchell et al. 1998a). The very small 
difference between the BMES and ABS census count for the eligible age group 
provided evidence that the BMES sampling frame covered the target population 
well (Smith et al. 1997). Of the total 4433 eligible subjects in the BMES, the 
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complete response rate was 3654 (82.4%) (Figure 2.1), the partial response rate 
was 353 (8.0%), and the complete refusal rate was 148 (3.3%). The definition of 
complete response referred to eligible subjects agreeing to participate in both 
interview and examination. Partial response was defined when eligible subjects 
received a brief interview, but refused to participate in examination.  A complete 
refusal was defined when the eligible subjects refused to participate in both the 
interview and examination. When eligible households were contacted for clinic 
appointment, 68 people (1.5%) had died and 210 (4.8%) had moved out from the 
area. Thus, an additional 278 (6.3%) persons identified in the census could not be 
examined (Mitchell et al. 1998a). After excluding the people who could not be 
examined, the response rate was 3654/(4433-278) = 87.9% (Mitchell et al. 
1998a). Overall 779 (353+148+278) subjects were non-participants (Figure 2.1).  
Surviving baseline participants were invited to participate in the 5- and 10-
year follow-up examinations. Between baseline and 5-year follow-up visit 575 
had died. Of the 3079 eligible participants who survived, 745 had refused further 
follow-up or moved to another area, and so, only 2334 or 75.8% of survivors 
returned for subsequent follow-up at 5 years. Between the 5- and 10-year follow-
up visit, 535 had died. 745 persons who did not participate at the 5-year follow-up 
were again invited to participate at the 10-year follow-up. Therefore, of the 2544 
persons who were eligible for the 10-year follow-up, 592 refused further follow-
up or were no longer living in the two selected post code areas. This resulted in a 
total of 1952 subjects or 76.7% of survivors who returned for follow-up after 10 





















Figure 2.1 Flow chart of study progress of the Blue Mountains Eye Study (BMES)  
The original BMES study cohort was 98 percent White, reflecting the 
community studied. All baseline and follow-up examinations of the BMES were 
approved by the Human Research Ethics Committees of the University of Sydney 
and the Western Sydney Area Health Service, and the study was conducted 
adhering to the tenets of the Declaration of Helsinki. Signed informed consent 
was obtained from all participants at each examination visit (Mitchell et al. 1998a; 
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Only 3086 subjects had complete information at baseline for our study 
factors including, MetS, its components, age, sex, smoking status, pre-existing 
disease (cancer, hypertension, diabetes, stroke, AMI and angina), alcohol intake 
and physical activity. Of these, 2133 had complete information for MetS and its 
components at 5-year follow-up and another 1632 had complete information for 
MetS and its components at 10-year follow-up. Therefore 568, 201 and 320 
subjects who did not have complete information for the predefined study factors 
at baseline, 5- and 10-year follow-up, respectively, were excluded from this thesis 
(Figure 2.1). 
 
2.3 Data collection  
A detailed history of diseases including cancer, hypertension, diabetes, angina, 
AMI and stroke was recorded at face-to-face interviews conducted by trained 
interviewers using a standardized questionnaire (Mitchell et al. 1998a). We 
defined pre-existing disease(s) as a binary variable based on past history or 
medication of at least one of the above mentioned diseases. Current smokers were 
defined as those currently smoking manufactured cigarettes, hand-rolled 
cigarettes, cigars, or pipe tobacco. Ex-smokers were those who had ever regularly 
smoked cigarettes, cigars, or a pipe. In addition, information on alcohol 
consumption (gram per week) was collected (Attebo et al. 1996; Tsang et al. 
1998). Participants had their weight (after removal of shoes and heavy clothing) 
measured by standing on an automated scale, to which a vertical height measure 
was attached (Younan et al. 2003). BP was measured while seated prior to the 
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installation of any eye drop using a stethoscope and mercury sphygmomanometer 
(Younan et al. 2003). In addition, self-reported physical activity based on time 
spent on activities per week using the International Physical Activity 
Questionnaire (Craig et al. 2003) were collected. The activities captured included 
occupational, household and leisure activities. It should be noted that BMES data 
double entered each time and cleaned the data carefully. Any inconsistency 
detected would have been fixed before using the data.   
Fasting blood specimens and data quality control  
Fasting blood specimens were collected in the morning, centrifuged on site, and 
then transported for laboratory analysis within four hours of collection. All tests 
were performed by the Institute of Clinical Pathology and Medical Research at 
Westmead Hospital, Sydney, for hematology and clinical biochemistry 
assessment. Hematocrit and fasting plasma glucose were measured by spun 
microhematocrit and hexokinase methods, respectively. HDL cholesterol and TG 
concentrations were measured on a Reflotron reflectance photometric analyser 
(Boehringer Mannheim Diagnostics [currently Roche Diagnostics], Germany). 
The laboratories were fully accredited under the Royal College of Pathologists 
Australasia/National Association of Testing Authorities Australasia medical 
registration program appropriate for Australian laboratories (Shankar et al. 
2007b). The BMES group identified from the computerized data all subjects who 
had any missing values or any values above the 97.5th percentile or below the 
2.5th percentile for each hematological index. Their original paper records were 
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checked, and any coding mistakes were rectified to produce the data set used for 
all analyses (Tsang et al. 1998). 
2.4 Metabolic syndrome  
The combination of metabolic disturbances now known as the MetS was first 
described as the clustering of hypertension, hyperglycaemia and gout (Kylin, 
1923). It is now agreed that the well established term ‗metabolic syndrome‘ 
remains the most useful and widely accepted description of this cluster of 
metabolically related cardiovascular risk factors which also predicts a high risk of 
developing diabetes (if not already present) (Alberti et al. 2006). General features 
of MetS include abnormal body fat distribution (obesity), insulin resistance, 
dyslipidaemia (high TG and/or low HDL) and elevated BP (Alberti et al. 2006).  
 A number of expert groups have attempted to develop a unifying 
definition for MetS. The most widely accepted of these definitions are those 
provided by the World Health Organization (WHO 1999), The European Group 
for the Study of Insulin Resistance (EGIR) (Balkau et al. 1999) and the National 
Cholesterol Education Program—Third Adult Treatment Panel (NCEP ATP 3) 
(NCEP, 2001) (Table 2.1). All groups agree on the core components of MetS: 
obesity, insulin resistance, dyslipidaemia and hypertension (Alberti et al. 2006). 
However, the various definitions of MetS are not as successful in 
predicting diabetes or CVD as are some of the established predicting models such 
as the Diabetes Predicting Model and the Framingham Risk Score (Stern et al. 
2004). In May 2004, the IDF held an expert workshop to examine how the various 
available definitions of MetS could be improved and developed with the aim of 
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reaching a consensus for the introduction of a new, unifying and working 
worldwide definition. The IDF criteria is a simple diagnostic tool for use in 
clinical practice and research world-wide. This should facilitate a better 
understanding of the syndrome and targeting of care to people who would benefit 
from cardiovascular risk reduction (Alberti et al. 2006). 
In this thesis, we define MetS according to the IDF criteria as summarized 
in Table 2.1. Based on this definition, a person is defined as having MetS if he/she 
has central obesity (BMI >30 kg/m
2
) plus any two of the following four risk 
factors: 
• TG ≥1.7 mmol/l (150 mg/dl)  
• HDL-cholesterol <1.03 mmol/l (40 mg/dl) in males and <1.29 mmol/l 
(50mg/dl) in females or specific treatment for these lipid abnormalities  
• Systolic BP ≥130 or diastolic BP ≥85 mmHg or treatment of previously 
diagnosed hypertension  
• Fasting plasma glucose ≥5.6 mmol/l (100 mg/dl) or previously diagnosed type 2 
diabetes.  
 For the measurements of MetS components, all participants were asked to 
return on a morning within 4 weeks of each interview for fasting pathology tests, 
including glucose, TG, HDL-cholesterol. Seated BP, height and weight were also 
measured by trained interviewers. The BMI was calculated as weight (kg)/height 
(m
2
). Information on history of diabetes, hypertension and lipid abnormalities as 




  The baseline MetS components were measured and recorded when the 
participant entered the study (1992-1994), and again at the 5- (1997-1999) and 
10- (2002-2004) year examinations after first recruitment. Data were therefore 
available on how prevalent MetS and its components changed in each subject 
throughout the study.  
Table 2.1  Definitions of metabolic syndrome 








 Glucose intolerance, 
impaired glucose 
tolerance (IGT) or 
diabetes and / or 
insulin resistance* 






—top 25% of 
fasting insulin 
values among the 
non-diabetic 
population) plus 
any two of the 
following: 
Three or 






Central obesity plus 
any two of the 
following risk factors:      
 
Obesity  Men: waist–hip ratio > 
0.90 
Women: waist–hip 
ratio > 0.85 
and/or body mass 













If body mass index is 
>30 kg/m2 then 
central obesity can be 
assumed, and waist 
circumference does 
not need to be 
measured.            
Fasting plasma 
glucose 




≥5.6 mmol/l (100 
mg/dl) 
 
≥5.6 mmol/l (100 
mg/dl) 
or previously 
diagnosed Type 2 
diabetes  
Blood pressure  ≥140 / 90 mmHg 
 
≥140 / 90 mmHg 
or treatment 
 
≥130 / ≥85 mmHg 
 
≥130 / ≥85 mmHg 
 
or treatment  
Dyslipidaemia TG 













TG ≥1.7 mmol/l (150 
mg/dl) 
 
or treatment  
and/or 
 Men: HDL <0.9 
mmol/l (35 mg/ dl) 
Women: HDL < 1.0 





Men: HDL <1.03 
mmol/l (40 mg/ dl) 
Women: HDL <1.29 
mmol/l (50 mg/ dl) 
Men: HDL <1.03 
mmol/l (40 mg/dl) 
Women: HDL <1.29 
mmol/l (50 mg/dl)  
or treatment  
Microalbuminuria Urinary albumin 
excretion rate ≥  20 
μg/min or 
albumin:creatinine 
ratio≥ 30 mg/g 
   
*Insulin sensitivity measured under hyperinsulinaemic euglycaemic conditions, glucose uptake below lowest 




2.5 Epidemiological issues 
Confounding factors  
Confounding is one of the most important problems in observational 
epidemiological studies. Confounders can be adjusted in many ways: (a) 
restriction based on subgroup, for example, if smoking status is a confounder, 
then include only smokers or non-smokers in the study, (b) randomization, (c) 
matching and (d) stratification. There are three criteria to define confounders. 
First, a confounding factor has an effect on studied outcome. Second, it is linked 
or associated with study exposure. Third, it is not a mediator in the causal chain 
between the main exposure and the outcome. If confounding is not adjusted for, 
the results may be spurious (Rothman et al. 2008). 
In our study, we explore possible confounders by first performing 
bivariate analysis of all potential independent variables. However, to minimize 
residual confounding, we further consider other confounders which have been 
established in other earlier studies. Therefore, based on the statistical and clinical 
selection, possible confounders in this thesis were thought to include: age, sex, 
smoking status (never, ex-smoker and current smoker), alcohol intake, physical 
activity, pre-existing disease(s) at baseline (namely, hypertension, diabetes, 
angina, AMI, stroke and cancer). For outcomes involving age-related cataract and 
AMD, covariates such as family history of eye disease (cataract, AMD, myopia, 
glaucoma and blindness), patient‘s history of eye disease (cataract, myopia and 
glaucoma), eye iris color (blue, hazel/ green, tan/ brown, dark brown), and skin 
sun-tanning characteristics estimated on 4-point scale (always burn, never tan; 
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usually burn, tan with difficulty; burn and tan above average; rarely burn, tan 
above average) were further considered as possible confounders. It should be 
noted that in this thesis covariate such as sex is naturally non-varying, but some 
covariates, for example, smoking status and pre-existing disease might be time-
varying. However, these were considered as fixed covariate in the thesis as they 
have been shown not to have time-varying effect in the analysis. 
 
Collinearity 
Collinearity is one of the major concerns as high inter-correlation between 
variables might affect our findings. When collinearity happens, small changes in 
the covariate may result in significant changes in β. Therefore, we also ran 
collinearity test in our analysis to avoid this problem. For continuous variables, 
such as TG and HDL cholesterol, Pearson correlation coefficient was used, while 
for instances which considered one continuous variable and an ordered categorical 
variable, for example, systolic BP and smoking status (never, former and current 
smoker), the Spearman rank correlation coefficient was used. Association 
between two nominal variables, for example, sex and pre-existing disease(s) was 
tested by a chi-square test. 
 
Interaction  
Generally, there is always more than one factor involved in the disease etiology. 
To consider how multiple factors interact in causing a disease, we need to take 
into account effect modification. An example of an interaction effect is when the 
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incidence rate of disease in the presence of two or more risk factors differs from 
the incidence rate expected to result from their individual effects (Rothman et al. 
2008). Initially, we apply bivariate analysis to estimate the effect based on the 
measured variables such as age, sex, smoking status or pre-existing disease(s) on 
the main outcomes, namely all-cause/cause specific mortality, age-related cataract 
and AMD. Then, we perform multivariate analysis based on likelihood ratio tests 
to compare nested models. During this procedure, we also check for any dramatic 
changes in effect size as well as standard error (SE) estimates. Subsequently, we 
also tested for interactions between primary exposures of interest, namely, MetS, 
its components and BMI with other measured covariates such as age groups, 
gender, smoking status and pre-existing disease(s) at baseline. Further details are 
provided in the respective chapters.  
 
2.6 Statistical analyses  
This thesis involves repeated measurements of primary exposures, namely MetS 
and its components, and outcomes of interest such as cataract and AMD, which 
were measured at baseline and subsequent follow-up visits at 5- and 10-year after 
recruitment. In the analysis of all-cause and cause-specific mortality, the time-to-
event (measured in years) was calculated from recruitment to the time of death. 
For those who remained alive at the end of study, the follow-up time was 
censored at the study closure. We use different statistical methods relevant to 
specific outcome for the analysis. For time-to-event outcome, namely all-cause 
and cause-specific mortality, we perform Cox-regression and competing risks 
37 
 
models, respectively. However, to account for information on MetS and its 
components which were repeatedly measured at baseline, 5- and 10-year follow-
up, the Cox-regression and competing risks models with time-dependent covariate 
were implemented. For interval-censored outcome involving age-related cataract, 
the random effects complementary log-log regression model was applied. The 
mixed-effects logistic regression model was used in the analysis of binary 
outcome involving AMD. Fuller details of these methods are provided in the 
respective chapters.  
In the bivariate analysis, independent sample t-test was used to evaluate 
the relationship between continuous covariates (eg. age, alcohol intake and 
physical activity) with binary outcome such as 10-year cumulative incidence of 
age-related cataract or AMD. In addition, the chi-square test was used to examine 
the relationship between categorical covariates (eg. sex, smoking status, pre-
existing disease) with the above-mentioned outcomes. All evaluations were made 
assuming a two-sided test based on a 5% level of significance using STATA 
version 11 unless otherwise stated. 
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Table 2.2 Characteristics of the study population by metabolic syndrome (MetS) status at baseline, 5- and 10-year follow-up 
 
   Baseline  5-year 10-year 
 Total  













Mean baseline age, years 
(SD) 
65.9 (9. 5) 66.0(9.6) 65.0 (8.6)  64.8 (8.7)  63.2 (7.9)  63.1 (7.7)  61.0 (6.7) 
Sex (%) 
  Female 






















Smoking status (%) 
  Current smoker 
  Ex-smoker  

































812 (26.3) 701 (25.9) 111 (28.9)  423 (23.9) 93 (27.3)  276 (19.3)  59 (29.7) 
Statin use 101 (3.3) 90 (3.3) 11 (2.9)  53 (3.0) 12 (3.5)  43 (3.0) 8 (4.0) 
BP medication 994 (32.2) 812 (30.0) 182 (47.4)  508 (28.7) 137 (40.2)  372 (26.0) 77 (38.7) 
Mean BMI (kg/m
2
)(SD) 26.2 (4.4) 25.1 (3.4)  33.7 (3.3)  25.7 (4.4)  33.8 (3.6)  26.3 (4.2)  33.5 (3.5) 
Low HDL (%)
b
 1012 (32.8) 849 (31.4)  163 (42.5)  372 (23.2)  160 (56.9)  324 (27.3)  123 (61.8) 
High triglyceride (%)
c
 1283 (41.6) 989 (36.6)  294 (76.6)  557 (31.4)  235 (68.9)  202 (20.8)  110 (61.8) 
High BP (%)
d
 2645 (85.7) 2271 (84.1)  374 (97.4)  1574 (89.7)  339 (99.4)  1081 (80.8)  191 (96.0) 
Elevated FPG  (%)
e
 547 (17.7) 400 (14.8)  147 (38.3)  300 (19.9)  157(40.0)  126 (8.8)  77 (38.7) 
BMI=body mass index; BP=blood pressure; FPG=fasting plasma glucose; MetS=metabolic syndrome; SD=standard deviation. 
aAny pre-existing disease at baseline (namely, cancer, angina, acute myocardial infarction, stroke and chronic lung disease)  bserum HDL cholesterol <1.03 mmol/L in men and 
<1.29 mmol/L in women, or specific treatment for this lipid abnormality; c serum triglyceride level ≥ 1.7 mmol/L or specific treatment for this lipid abnormality; d systolic blood 
pressure ≥130 mmHg or diastolic blood pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension; e fasting plasma glucose ≥5.6 mmol/L, or previous diagnosis or 





2.7 Descriptive profile of the study subjects 
Table 2.2 presents the characteristics of study subjects based on MetS status at 
baseline, 5- and 10-year follow-up. The mean age of the 3086 subjects included in 
this thesis was 65.9 (standard deviation (SD) 9.5) years, and 43% were male. 
Apart from BMI, a mandatory component of the IDF criteria, a substantial 
proportion had high BP (85.7%), high TG (41.6%) and low HDL-cholesterol 
(32.8%) at baseline (Table 2.2). The prevalence of MetS increased slightly to 
16.1% (95% confidence interval (CI) 14.6 – 17.8%) after 5 years follow-up from 
12.4% (95% CI: 11.3 - 13.6%) at baseline, and was 12.2% (95% CI: 10.6 – 
13.9%) at 10-year follow-up. 
 A comparison of demographic and clinical characteristics between 
participants and non-participants in the BMES study is listed in Table 2.3. Non-
participants were less likely to wear glasses than participants. They were also 
significantly more likely to have seen an ophthalmologist. Symptomatic visual 
impairment was not significantly higher among participants, but the prevalence of 
chronic systemic diseases (hypertension and diabetes) was slightly more common 
among participants. There was no difference in gender distribution between 
participants and non-participants. The age profile showed an over-representation 
of those aged between 60-69 years; 35.8% for participants and 26.8% for non-
participants. However, elderly aged ≥80 years were more likely to be non-
participants (Attebo et al. 1996). The distributions of study characteristics of 




Table 2.3 Profile (%) of participants and non-participants in the BMES, as compared with 
thesis subjects 






    
Female 56.7 54.8  57.0 
Male  43.3 45.2  43.0 
Wears glasses ** 97.2 55.1  97.6 
Cannot read newspaper while  
wearing eye glasses 
7.9 6.3  7.6 
Cannot recognize friend across 
street  
5.4 4.2  4.7 
Age (years),     <60 
                         60-69* 
                         70-79 





































Ever seen ophthalmologist ** 49.0 56.0  51.1 
Note: In the non-participant group, information available in the following items were as follows: gender  
(n=754), wears glasses (n=544), cannot read newspaper while wearing eye glasses (n=539), cannot recognize 
friend across street (n=534), age 60-69 (n=641), history of cataract and glaucoma (n=553), AMD (n=549), 
hypertension (n=530), diabetes (n=531) and ever seen ophthalmologist (n=521). Comparison between 
participants and non-participants: *P <0.05; **P <0.01 
 
 
Figure 2.2 shows the general pattern of 10-year changes in MetS and its 
components among, participants with complete information for the study factors 
at baseline (n = 3086), 5- (n = 2133) and 10-year (n = 1632) follow-up, 
respectively. Among the 5-MetS components, the prevalence of high TG 
increased from baseline to 5-year and then decreased by 10-year. However, the 
prevalence of low HDL cholesterol decreased from baseline to 5-year and then 




Figure 2.2 Changes in prevalence of MetS and its components over 10-year follow-
up 
 
Table 2.4 shows the ICC between MetS components at baseline, 5- and 
10-year follow-up. An ICC tells us about the correlation of the respective MetS 
components within an individual (Snijders and Bosker 2012).  If the correlation is 
shown to be relatively low, then one might choose to ignore the correlation and 
analyze the data in a standard way. For example, if the outcome is continuous, 
then multiple linear regression is used or if the outcome is binary, then multiple 
logistic regression model is applied. However, if the correlation is large enough, 
then it would be more appropriate to apply statistical models which account for 
the within subject correlation between repeated measures of MetS or its 
components. An ICC of 0.3 is considered quite large. 
(http://www.ats.ucla.edu/stat/stata/library/cpsu.htm). As shown in Table 2.3, 
























High Glucose Low HDL
High Triglyceride High BP
42 
 
an ICC of 0.843 for BMI means that, around 84% of the variance in BMI is due to 
differences within individuals (Bates and Pinheiro 1998; Rabe-Hesketh and 
Skrondal 2012). Therefore, it is important to take into account the within subject 
correlation in the relationship between predefined outcomes of interest and MetS 
components which were repeatedly measured at baseline and during the study 
follow-up at 5- and 10-year.   
                   Table 2.4 Intra-class correlations between MetS components  
                   at baseline, 5- and 10-year follow-up  
 ICC  
 
95% CI  









TG 0.623 0.599-0.646 
Systolic BP 0.419 0.391-0.447 
Diastolic BP 0.371 0.343-0.402 
 BP=blood pressure; BMI= body mass index; CI=confidence interval; FPG=fasting plasma glucose; 
HDL=high density lipoprotein; ICC=intra-class correlation; TG=triglycerides.  
 
2.8 Strengths and limitations of the study 
While this study has its strength such as a representative elderly Australian 
population, long-term follow-up, full utilisation of MetS information at each visit 
as well as high quality data collection involving standardised measures at each 
examination thus eliminating bias in self-reporting, its drawbacks must also be 
noted. The overall sample size of study might result in the lack of statistical 
power to detect the relationships with small effect sizes, especially when the 
number of events was low in outcomes such as PSC cataract and late AMD. In 
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addition, epidemiological studies tend to have some degree of bias which may not 
be avoided or removed. ―Bias‖, defined as ―any systematic error in the design, 
conduct or analysis of a study that results in a mistaken estimate of an exposure‘s 
effect on the risk of disease‖ (Rothman et al. 2008), is a major issue for any kind 
of epidemiological study. In the BMES study data on which this thesis is based, 
participants were more likely to wear glasses as compared with non-participants. 
This is a potential self-selection bias (Attebo et al. 1996) that might be a concern 
for eye-disease outcome, for example, age-related cataract and AMD (Pan et al. 
2013a; Pan et al. 2013b; Pan et al. 2013c). It should be noted that although the 
selection of the two post codes for the BMES was not random, BMES participants 
covered 82.4% of all residents in that eligible age groups, or 87.9% of residents 
after excluding those who were found not to be eligible after further contact by 












CHAPTER 3— Metabolic Syndrome and Mortality in the Elderly: A Time-
Dependent Association                                                                                                                                                                                 
SUMMARY 
The metabolic syndrome (MetS) status of an individual may vary from time to 
time (i.e. at baseline, 5- and 10-year) and as such, MetS can be regarded as a time-
dependent covariate. In this study, we aim to evaluate the association between 
MetS components with all-cause and cause-specific mortality, using the Cox 
proportional hazards and the competing risks models, considering MetS as a time-
dependent covariate. In order to show whether further information of MetS at 5- 
and 10-year follow-up would provide more robust estimate in the relationships, 
we also examine the associations between baseline MetS and its components with 
all-cause and cause-specific mortality, and compare it with the time-dependent 
covariate models. The time-dependent receiver-operating-characteristic curve, 
integrated-discrimination-improvement and net-reclassification-improvement 
tests were further carried out to assess the predicting abilities of individual and 
combined MetS components. There was no association between baseline MetS 
with all-cause and cardiovascular mortality. However, baseline MetS was 
associated with an elevation in risk of cancer mortality. Utilising full information 
of MetS at follow-up, we found MetS to have a time-varying effect on all-cause 
and cause-specific mortality. The discrimination analyses showed that different 
MetS components were associated with different causes of death. The long-term 
effect of MetS on mortality in an older population was detected using time-





3.1 Literature review on the relationship between MetS and its components 
with mortality  
Table 3.1 provides a review on the association between MetS and mortality. 
Among the different MetS definitions, IDF and NCEP criteria have been used 
most frequently, and so we selected studies involving these two definitions of 
MetS in our review.  Ten cohort studies were reviewed with follow-up duration of 
between 4.4 to 16 years. In prospective cohort studies in the USA, Italy and 
France, MetS was found to be positively associated with all-cause death in all 
subjects as well as by gender (Malik et al. 2004; Mozaffarian et al. 2008; Zambon 
et al. 2009; Akbaraly et al. 2010). A collaboration of 9 cohort studies in Europe, 
found a significant adverse effect of MetS on all-cause death among men, but not 
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women (DECODE Study Group and Qiao 2006). However, in two Finnish (Wang 
et al. 2007a; Salminen et al. 2010) and one Russian study (Sidorenkov et al. 
2010), MetS had no effect on all-cause mortality regardless of gender. The Japan 
Public Health Centre-based Prospective Study showed that MetS was a predictor 
of all-cause death only among women (Satio et al. 2009a). The Investigations 
Préventives et Cliniques center (Paris, France) showed that, MetS was 
significantly associated with increased risk of all-cause death among subjects 
aged between 55-65 years, but not  over 65 years (Thomas et al. 2011).   
With regards to the relationship between MetS and cardiovascular death, 
Malik et al. (2004) and Wang et al. (2007a) found MetS to be positively 
associated with CVD death. However, Satio et al. (2009a), Sidorenkov et al. 
(2010) and Salminen et al. (2010) showed that MetS had no effect on CVD death 
regardless of gender or in the whole population.  
While Satio et al. (2009a) found MetS to have no effect on cancer death, 
Akbaraly et al. (2010) found it to be associated with increased risk of cancer 
death, whereas Jaggers et al (2009) reported such an association in males only. 
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Table 3.1 Association between metabolic syndrome and mortality  
Study, year Place N Age Follow-up 
(year) 
MetS HR (95%CI) 
All-cause      All Female Male 
Malik, 2004 USA 6255 30-75 13.3 NCEP 1.40 (1.19-1.66)   
Qiao, 2006 Europe 10269 30-89 7-16 IDF  1.20 (0.97-1.49) 1.26 (1.06-1.49) 
Wang, 2007a Finland 1025 65-74 13 IDF  1.11 (0.84-1.46) 1.09 (0.83-1.43) 
Mozafarian, 2008 USA 4258 ≥65 15 IDF 1.17 (1.06-1.29)   
Saito, 2009a Japan 34051 40-69 12.3 NCEP  1.22 (1.03-1.43) 1.06 (0.92-1.23) 
Zambon, 2009 Italy 2910 ≥65 4.4 NCEP 1.41 (1.16-1.72) 1.47 (1.13-1.91) 1.42 (1.06-1.89) 
Sidorenkov, 2010 Russia 3555 ≥18 9 IDF  1.13 (0.76-1.68) 0.76 (0.48-1.18) 
Salminen, 2010 Finland 1260 ≥64 9 IDF 0.90 (0.69-1.17)   
Akbaraly, 2010 France 7118 ≥65 7 NCEP 1.54 (1.24-1.92)   








Malik, 2004 USA 6255 30-75 13.3 NCEP 1.82 (1.40-2.37)   
Wang, 2007a Finland 1025 65-74 13 IDF 1.33 (1.03-1.72)   
Saito, 2009a Japan 34051 40-69 12.3 NCEP  1.44 (0.98-2.11) 1.41 (0.99-2.02) 
Sidorenkov, 2010 Russia 3555 ≥18 9   1.08 (0.64-1.82) 1.09 (0.63-1.89) 
Salminen, 2010 Finland 1260 ≥64 9  1.07 (0.74-1.56)   
Cancer-death         
Saito, 2009a Japan 34051 40-69 12.3 NCEP  1.17(0.92-1.49) 0.97(0.78-1.20) 
Jaggers, 2009 USA 33230 20-88 14 NCEP   1.41 (1.19-1.66) 
Akbaraly, 2010 France 7118 ≥65 7 NCEP 1.49 (1.04-2.14)   
CI=confidence interval; HR=hazard ratio; IDF=international diabetes federation; MetS=metabolic syndrome; NCEP=national cholesterol education program.  
Note: Jaggers, 2009 only included men in the studies. 
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Table 3.2 provides a review on the association between individual MetS 
components with mortality. Of the 5 MetS components, low HDL cholesterol 
(Wang et al. 2007a, Mozafarian et al. 2008, Zambon et al. 2009), hypertension 
(Mozafarian et al. 2008) and elevated glucose (Mozafarian et al. 2008, Zambon et 
al. 2009) were positively linked to increase risk of all-cause death. Further, Satio 
et al. (2009a) showed high BP and elevated glucose to be significant predictors of 
all-cause-death in both gender. However, Salminen et al. (2010) found elevated 
BP was associated with lower risk in all-cause mortality, while Thomas et al. 
(2011) showed that high BP and elevated glucose were the significant predictors 
of all-cause death only among those aged between 55-65 years.  
As for cardiovascular death, Wang et al. (2007a) found high glucose and 
low HDL were linked to increase risk of CVD death. Satio et al. (2009a) reported 
that high BP and elevated glucose were significant predictors of CVD death in 
both gender. However, Salminen et al. (2010) found none of the MetS 
components to have any effect on the risk of CVD death. 
As for cancer death, Satio et al. (2009a) showed that elevated glucose was 
a significant predictor of cancer death among women only, whereas  Jaggers et al. 
(2009) found abdominal obesity, low-HDL cholesterol and elevated glucose to be 
associated with increased risk of cancer death in men (Jaggers et al. 2009).  
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Table 3.2 Association between metabolic syndrome components and mortality 





All-cause      All Female Male 
Wang, 2007 Finland 1025 65-74 13 Low-HDL 1.71 (1.17-2.49)   







Saito, 2009a Japan 34051 40-69 12.3 High BP 
High glucose 




Zambon, 2009 Italy 2910 ≥65 4.4 High glucose 
Low HDL 
1.27 (1.02-1.59) 1.61 (1.16-2.24) 
1.48 (1.08-2.02) 
 
Salminen, 2010 Finland 1260 ≥64 9 High BP 0.65 (0.47-0.89)   


















Saito, 2009a Japan 34051 40-69 12.3 High BP 
High glucose 




Salminen, 2010 Finland 1260 ≥64 9 5 MetS Components*    
Cancer-death          
Saito, 2009a Japan 34051 40-69 12.3 High glucose  1.42 (1.03-1.94)  
Jaggers, 2009 USA 33230 20-88 14 Obesity  
Low HDL 
High glucose 
  1.25 (1.06-1.47) 
1.25 (1.06-1.46) 
1.22 (1.04-1.42) 
BP=blood pressure; CI=confidence interval; HR=hazard ratio; MetS=metabolic syndrome; TG=triglyceride.  
*P > 0.05,  Note: Jaggers, 2009 only included men in the study. 
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3.2 Significance of study 
MetS is a cluster of cardiometabolic abnormalities which is thought to predict the 
risk of developing CVD and diabetes (Alberti et al. 2006). Different MetS 
definitions, namely EGIR, NCEP ATP-3 and IDF have been proposed, but most 
of them include sets of cut-points for the same five components: abdominal 
obesity, hyperglycaemia, hypertriglyceridaemia, low HDL cholesterol and 
hypertension (Zimmet et. al 2005). Although MetS is an acknowledged predictor, 
although a weak one, on all-cause mortality in adult population, results from older 
population are conflicting (Lakka et al. 2002; Hu et al. 2004; Hunt et al. 2004). 
Clarifying this issue is important for researchers because the prevalence of MetS 
increases with increasing age.  
The utility of MetS in predicting mortality among elderly is not clearly 
understood. First, underweight elderly populations may be predisposed to an 
increased risk of mortality (Flegal et al. 2005; Berrington de Gonzalez et al. 
2010). Secondly, some MetS components, namely hypertriglyceridemia and 
diastolic BP, are not clearly related to poor health outcomes later in life (Fried et 
al. 1998; Burke et al. 2000).
 
Furthermore, the cut-off point for individual MetS 
components may not be appropriate for predicting mortality in the elderly 
population, since these distributions were often characterized based on middle-age 
populations (Wilson et al. 1998).
 
Some studies showed MetS to be a predictor of 
all-cause (Satio et al. 2009a; Zambon et al. 2009) and CVD mortality (Malik et al. 
2004; Wang et al. 2007a). However, other studies demonstrated no effects of 
MetS on either deaths in the elderly (Satio et al. 2009a; Salminen et al. 2010; 
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Sidorenkov et al. 2010). Although MetS was found to predict cancer death in 
some studies (Jaggers et al. 2009; Akbaraly et al. 2010),
 
this relationship was not 
evident in the study by Satio et al. (2009a). 
  While hypertension (Mozafarian et al. 2008), hyperglycemia (Maggi et al. 
2006; Mozafarian et al. 2008; Zambon et al. 2009; Akbaraly et al. 2010), low 
HDL (Maggi et al. 2006; Zambon et al. 2009; Akbaraly et al. 2010) and high TG 
(Satio et al. 2009a) have been shown to predict all-cause and CVD-death, there is 
inconsistency with regards to which of these components better predict mortality. 
Moreover, it remains unclear whether MetS as a whole or its individual 
components provide a better prediction of all-cause and cause-specific mortality 
(Dekker et al. 2005; Franks and Olsson 2005). Finally, no studies have clarified 
whether the earlier or most updated status of MetS best predicts all-cause and 
cause-specific mortality. 
 As demonstrated in Chapter 2, the prevalent of MetS and its components 
varied from visit to visit over the 10-year study follow-up, and thus they can be 
regarded as a time-dependent covariate. As such, it is important to appropriately 
apply a time-dependent covariate model to unravel the effect of such changes on 
all-cause and cause-specific mortality in order to establish a more robust 
relationship between MetS and its components with mortality using quantities that 
vary over time (Giorgi and Gouvernet 2005). Therefore, in this study, we evaluate 
the effect of MetS and its components on subsequent all-cause and cause-specific 
mortality in an older Australian population by fully utilizing the information on 
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MetS collected at baseline, 5-year and 10-year visits. We further determine 
whether this association changes with time. 
 
3.3 Methods 
Study design and population 
A detailed description of the study design and population of the BMES was 
provided in Chapter 2. In brief, this is a population-based cohort study of vision, 
common eye diseases and other health outcomes of a suburban population in the 
west of Sydney, Australia. Between 1992 and 1994, non-institutionalised 
permanent residents aged 49 years and older were invited to participate in this 
study, and requested to return for follow-up examinations at 5 (1997-1999) and 10 
(2002-2004) years. We included 3086 participants at baseline who had complete 
information for the study factors including MetS and its components, age, sex, 
smoking status, pre-existing diseases at baseline (namely, cancer, angina, AMI 
and stroke) (Mitchell et al. 1998a).  
Data collection 
A detailed description of the data collection was provided in Chapter 2. Briefly, 
at each visit, trained interviewers completed a comprehensive questionnaire 
comprising demographic information, smoking status, eye and general medical 
history including hypertension, diabetes, and pre-existing diseases (namely, 
cancer, angina, AMI and stroke) as well as medication used (Mitchell et al. 
1998a). Height, weight and seated BP (WHO 2003) were measured. Fasting blood 
tests, including serum total cholesterol, HDL cholesterol, TG (Cugati et al. 2003) 
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and fasting plasma glucose (FPG) (WHO 1999), were also measured within a 
month of each interview.  
Definition of metabolic syndrome  
In this thesis, we define MetS according to the IDF criteria (Zimmet et al. 2005). 
This includes obesity (ie. BMI units >30 kg/m
2
) plus any two of the following 
four factors:  
i. TG ≥1.7 mmol/L or specific treatment for this lipid abnormality;  
ii. HDL cholesterol  <1.03 mmol/L in men and <1.29 mmol/L in women, or 
specific treatment for this lipid abnormality;  
iii. Systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg, or treatment of 
previously diagnosed hypertension; or  
iv. FPG ≥5.6 mmol/L, or previous diagnosis or specific treatment for type 2 
diabetes. 
Study outcomes 
All-cause and cause-specific mortality including cardiovascular-, cancer- and 
other causes of death were our study outcomes. Deaths occurring after baseline 
recruitment (1992–1994) until 31 December 2007 were confirmed by matching 
the demographic information of the participants with the Australian National 
Death Index (NDI) using probabilistic record linkage. Causes of death were 
provided by the NDI using the International Classification of Diseases (ICD) 9
th
 
revision and the International Statistical Classification of Diseases, 10
th
 revision. 
Cardiovascular death included the following codes from ICD-9 (3949, 4029, 
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4109, 4119, 4140, 4148, 4149, 4151, 4240, 4241, 4254, 4269, 4273, 4274, 4275, 
4278, 4280, 4281, 4289, 4290, 4291, 4410, 4411, 4413, 4414, 4415, and 4439) 
and ICD-10 (I059, I10, I132, I219, I249, I251, I255, I259, I269, I271, I350, I352, 
I358, I429, I469, I48, I500, I514, I515, I516, I709, and I711). Stroke death 
(thrombotic, haemorrhagic) included the following codes from ICD-9 (430.0–
438.9) and ICD-10 (160.0–169.9). In addition, cancer death was defined as C00–
C97 in ICD-9 and C140–C234 in ICD-10. Deaths and cause(s) of death were 
confirmed by medical certifiers, which include the physician in attendance, 
coroner or medical examiner, regardless of whether the death occurred in a 
hospital or in the community. The sensitivity and specificity of the Australian 
NDI were estimated at 93.7% and 100% for all-cause deaths, and 92.5% and 
89.6%, respectively, for cardiovascular deaths. Validation of stroke- and cancer-
death was, however, not possible (Wang et al. 2006).  
Statistical analyses 
In examining the associations between baseline MetS and its components with all-
cause and cause-specific mortality, we used the Cox proportional hazards and 
competing risks model (Tai et al. 2011a; Tai et al. 2011b) respectively. Time-to-
death from any cause (year) is the primary outcome variable for all-cause 
mortality, while time-to-specific cause of death (year) is the outcome variable for 
cause-specific mortality. As previously mentioned in Chapter 1, the elderly 
population is more likely to face with multiple causes of death such as cancer- and 
cardiovascular-deaths which are regarded as competing risks. In such situations, it 
is important to appropriately account for each competing risk in the analysis by 
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applying a competing risks model to yield a more accurate estimation of the 
exposure effect (Wolbers et al. 2009; Tai et al. 2011a, Tai et al. 2011b). Of note, 
in the competing risks model, the effect estimate is summarized by the 
subdistribution hazard ratio (SHR), where the subdistribution hazard is directly 
interpretable in terms of the cumulative incidence function (Beyersmann et al. 
2007; Wolbers et al. 2009). This is in contrast to all-cause mortality where the 
effect estimate is quantified by the HR. 
  Since data were available with respect to how MetS (and its components) 
might have changed in each subject throughout the study duration, the Cox 
proportional hazards and competing risks regression models with time-dependent 
covariates (Collett 2003) were used to determine the relationship between MetS 
and its components with all-cause and cause-specific mortality (Tai et al. 2011), 
and whether the association changes with time. In these models, MetS and its 
individual components were regarded as time-dependent covariats (Collett 2003). 
  In the Cox model with MetS as the time-dependent covariate, the hazard 
function is modeled as: 
h(t)= h0(t)exp(β1*MetS + β2*MetSt) 
where h0(t) is the baseline hazard function, and β1 and β2 are the regression 
coefficients (Collett 2003).  The model contains MetS and a second term MetSt 
corresponding to an interaction between MetS and the survival time, t, which is 
defined as MetSt=MetS*t. This model can be extended to include other fixed and 
time-dependent covariates. It allows MetS to be linearly dependent on the survival 
time, and so we were able to estimate the HR of MetS at t=2, 5 or 10 years.  
56 
 
  We also explored possible interactions between MetS and its components 
with age, sex, and pre-existing disease. Additionally, the proportional hazards 
assumption underlying the Cox model was checked for individual covariates and 
globally.  
Furthermore, to assess the prognostic value of a new marker, namely MetS 
components on the risk of all-cause and cause-specific mortality, we implemented 
the time-dependent ROC curve for censored survival model (Chambless and Diao 
2006) and summarized the results of the area under the curve at time t (AUC(t)) 
using the Harrell‘s concordance index (Harrell et al. 1982; Harrell et al. 1984). 
Bootstrap method was used to compare the AUC. As the events of interest 
involving all-cause and cause-specific mortality are time-dependent, the time-
dependent ROC curves are therefore more appropriate than the conventional ROC 
which was developed for assessing the performance of a variable based on a 
binary classification (Heagerty et al. 2000; Haibe-Kains et al. 2008).  
Since the AUC may not be sensitive enough to express the improvement 
of discrimination performance, we also calculate two other performance measures 
to check the predictive value of MetS components for all-cause and cause-specific 
mortality, including net reclassification improvement (NRI) and integrated 
discrimination improvement (IDI), which provide new insight on model 
comparison and prediction (Pencina et al. 2008). Continuous NRI is the most 
objective and versatile measure of improvement in risk prediction. It defines 
upward and downward movement as any change in predicted probabilities. NRI is 
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a measure of discrimination for binary data and can be expressed in terms similar 
to the AUC. It offers immediate extension to survival data (Pencina et al. 2011): 
NRI=
  𝑃 𝑒𝑣𝑒𝑛𝑡 \𝑢𝑝  −𝑃 𝑒𝑣𝑒𝑛𝑡   .𝑃 𝑢𝑝  + 𝑃𝑒𝑣𝑒𝑛𝑡  −𝑃(𝑒𝑣𝑒𝑛𝑡 \𝑑𝑜𝑤𝑛 )).𝑃(𝑑𝑜𝑤𝑛 )
𝑃 𝑒𝑣𝑒𝑛𝑡  .(1−𝑃 𝑒𝑣𝑒𝑛𝑡  )
   (3.1) 
The IDI can be seen as similar to the continuous version of NRI, and is 
defined as a difference in discrimination slopes. Discrimination slope in the 
binary concept is defined as difference in mean predicted probabilities of events 
and non-events. The IDI was viewed as a difference between improvement in 
average sensitivity and any potential increase in average ‗one minus specificity‘ 
(Schmid and Griffith, 1998), and the statistic was a difference in Yates 
discrimination slopes between the models with and without a new marker (Yates 
1982; Schmid et al. 1998). The IDI can also be extended for survival analysis 
(Uno et al. 2009). The IDI and NRI tests therefore gauge whether a novel marker 
improves the level of discrimination between groups of individuals classified with 
and without the use of a new test. The time-dependent AUC, NRI and IDI were 
generated using R statistical package (www.r-project.org).  
 
3.4 Results  
The demographic and clinical characteristics of the 3086 study subjects were 
summarized in Chapter 2. Over a median follow-up duration of 14.6 years, 1170 
(38%) deaths were reported. Of these, 483 (41.3%) were CVD-deaths and 342 
(29.2%) were cancer-deaths.  
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Association between baseline MetS and its components with all-cause and 
cause-specific mortality  
There was no effect of baseline MetS on all-cause mortality (HR 1.18, 95% CI: 
0.99-1.40). However, among the 5-MetS components, elevated glucose (HR 1.30, 
95% CI: 1.14-1.49) and high TG (HR 1.14, 95% CI: 1.01-1.28) at baseline were 
found to be associated with an increased risk of all-cause mortality, after adjusting 
for age, sex, smoking status and pre-existing disease at baseline (Table 3.3).  
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BMI=body mass index; CI= confidence interval; FPG=fasting plasma glucose; HR=hazard ratio; 
MetS=metabolic syndrome; SHR=subdistribution hazard ratio. afasting plasma glucose ≥ 5.6 mmol/L, or 
previous diagnosis or specific treatment for type 2 diabetes.  bserum HDL cholesterol  < 1.03 mmol/L  in men 
and < 1.29 mmol/L in women, or specific treatment  for this lipid abnormality; c serum triglyceride level ≥ 1.7 
mmol/L or specific treatment  for this lipid abnormality; d systolic blood pressure ≥ 130 mmHg or diastolic 
blood pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension; Note : Models adjusted for 
age, gender, smoking status,  pre-existing disease at baseline (namely, cancer, angina, acute myocardial 
infarction and stroke) *P<0.05 and **P<0.001 
 
  With respect to cause-specific mortality, there was no evidence of effect of 
baseline MetS and its components on CVD-death. However, baseline MetS (HR 





(HR 1.35, 95% CI: 1.02-1.79), high glucose (HR 1.40, 95% CI: 1.09-1.79), low 
HDL (HR 1.04, 95% CI: 1.03-1.05) and high TG (HR 1.27, 95% CI: 1.02-1.57) 
were associated with an elevation in risk of cancer mortality (Table 3.3).  
Table 3.4 Bivariate association between fixed and time-dependent risk factors with all-cause 
and cause-specific mortality 






HR (95% CI) SHR (95% CI) SHR (95% CI) 
Fixed covariate    
Sex (Male) 1.54 (1.37-1.72)** 1.63 (1.28-2.06)** 1.51 (1.22-1.87)* 
Age 1.11 (1.10-1.12)** 1.10 (1.09-1.11)** 1.04 (1.03-1.06)* 
Smoking status 
  Non-smoker 
  Ex-smoker 

















2.20 (1.95-2.46)** 2.72 (2.15-3.44)** 1.70 (1.37-2.12)** 
Time-dependent Covariate  
MetS    
2-year  0.76 (0.55-1.04) 0.38 (0.21-0.71)* 1.42 (0.88-2.29) 
5-year  0.85 (0.68-1.05) 0.56 (0.37-0.85)* 1.14 (0.82-1.57) 
10-year  1.02 (0.84-1.25) 1.07 (0.79-1.44) 0.78 (0.49-1.24) 
BMI > 30     
2-year  0.58 (0.43-0.78)** 0.36 (0.22-0.61)** 1.00 (0.63-1.58) 
5-year  0.66 (0.54-0.80)** 0.51 (0.36-0.71)** 0.88 (0.65-1.19) 
10-year  0.81 (0.67-0.96)* 0.87 (0.67-1.14) 0.71 (0.48-1.05) 
Elevated glucose
 b
   
2-year 1.17 (0.92-1.50) 1.07 (0.73-1.58) 1.16 (0.76-1.78) 
5-year  1.21 (1.03-1.43)* 1.17 (0.90-1.51) 1.20 (0.90-1.60) 
10-year  1.28 (1.08-1.52)* 1.34 (1.04-1.73) 1.27 (0.91-1.79) 
Low HDL
 c
    
2-year 0.97 (0.78-1.20) 1.07 (0.77-1.49) 0.93 (0.63-1.36) 
5-year  0.94 (0.81-1.09) 0.98 (0.78-1.23) 0.88 (0.67-1.14) 
10-year  0.89 (0.76-1.05) 0.84 (0.66-1.08) 0.79 (0.57-1.10) 
High triglyceride
 d
   
2-year 1.21 (0.99-1.48) 0.91 (0.66-1.24) 1.79 (1.25-2.57)* 
5-year  1.15 (1.01-1.32) 0.99 (0.80-1.23) 1.42 (1.12-1.80)* 
10-year  1.07 (0.92-1.24) 1.14 (0.91-1.44) 0.96 (0.70-1.31) 
Hypertension
 e
    
2-year 1.26 (0.90-1.74) 2.20 (1.21-4.01)* 1.02 (0.60-1.74) 
5-year  1.39 (1.10-1.74) 2.21 (1.45-3.37)** 1.10 (0.76-1.58) 
10-year  1.64 (1.28-2.09)** 2.23 (1.45-3.45)** 1.25 (0.79-1.95) 
BMI=body mass index; CI=confidence interval; HR=hazard ratio; MetS=metabolic syndrome; 
SHR=subdistribution hazard ratio. a Any pre-existing disease (namely, cancer, angina, acute myocardial 
infarction and stroke ) bfasting plasma glucose ≥ 5.6 mmol/L, or previous diagnosis or specific treatment for 
type 2 diabetes.  cserum HDL cholesterol  < 1.03 mmol/L  in men and < 1.29 mmol/L in women, or specific 
treatment  for this lipid abnormality; d serum triglyceride level ≥ 1.7 mmol/L or specific treatment  for this 
lipid abnormality; e systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or treatment 




Time-dependent association between MetS and its components with all-cause 
mortality  
Among the exposures of interest that were repeatedly measured at baseline, 5-year 
and 10-year follow-up visits, without any adjustment, BMI, elevated glucose, TG 
and hypertension showed a time-dependent association with all-cause mortality 
(Table 3.4). Of the fixed covariates considered in this study, gender, age, smoking 
and pre-existing disease were associated with all-cause mortality (Table 3.4).  
Adjusting for these fixed covariates, the risk of all-cause-mortality 
increased gradually from 2-year to 10-year follow-up amongst those with MetS 
(2-year: HR 0.96 (95% CI: 0.69-1.34); 5-Year: HR 1.06 (95% CI: 0.84-1.32); 10-
year: HR 1.23 (95% CI: 1.01-1.51). However, individually, none of the MetS 
components appeared to have a significant effect on all-cause mortality (Table 
3.5). 
 
Time-dependent association between MetS and its components with cause-
specific mortality 
In bivariate analysis, hypertension was associated with increased risk of 
cardiovascular-deaths at 2-, 5- and 10-year follow-up (Table 3.4). After adjusting 
for age, sex, smoking status and pre-existing disease status at baseline, the 
association between MetS and cardiovascular-death changed with time, with 
increased risk of cardiovascular-death at 10-year (SHR 1.38, 95% CI: 1.02-1.86), 
and reduced risk at 2-year (SHR 0.53, 95% CI: 0.30-0.95) and 5-year (SHR 0.76, 
95% CI: 0.51-1.13). Of the five MetS components, BMI >30 kg/m
2
 showed a 
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time-dependent association with cardiovascular-death with lower risk at 2-year 
and increased risk by 10-year (Table 3.5).  
In contrast to cardiovascular-death, MetS was associated with a notably 
higher risk of cancer death at 2-year (SHR 1.62, 95% CI: 1.01-2.62), with 
diminished risk by 10-year (SHR 0.90, 95 % CI: 0.57-1.44). Among the 5 MetS 
components, high TG also exhibited a time-dependent association with cancer 
death, where the elevation in risk of cancer death at 2-year dissipated by the 10-
year follow-up (Table 3.5).   
62 
 
Table 3.5 Time-dependent effects of MetS and its components on all-cause and cause-specific mortality  
 2-year 5-year 10-year 
 
All-cause (n=1170) 
No. of death  HR (95% CI) No. of death  HR (95% CI) No. of death  HR (95% CI) 
MetS 152 (13.0) 0.96 (0.69-1.34) 75 (13.2) 1.06 (0.84-1.32) 21 (10.7) 1.23 (1.01-1.51)* 
BMI > 30  189 (16.2) 0.83 (0.61-1.12) 103 (18.1) 0.90 (0.74-1.11) 36 (18.3) 1.05 (0.88-1.25) 
Elevated FPG a 272 (23.3) 0.95 (0.74-1.22) 141 (29.2) 0.97 (0.82-1.14) 29 (25.2) 0.99 (0.83-1.18) 
Low HDLb 334 (28.6) 1.06 (0.85-1.32) 147 (30.4) 1.00 (0.85-1.17) 59 (36.0) 0.91 (0.76-1.07) 
High Triglyceridec 517 (44.2) 1.08 (0.89-1.32) 831 (71.0) 1.03 (0.90-1.19) 33 (27.3) 0.97 (0.83-1.13) 
Hypertensiond 1043 (89.2) 0.93 (0.66-1.30) 512 (91.3) 1.02 (0.82-1.30) 157 (80.1) 1.21 (0.94-1.55) 
Cardiovascular-death (n=384) SHR (95% CI)  SHR (95% CI)  SHR (95% CI) 
MetS 53 (34.9) 0.51 (0.27-0.94)* 29 (38.7) 0.76 (0.51-1.13) 11 (52.4) 1.38 (1.02-1.86)* 
BMI > 30  70 (37.0) 0.54 (0.32-0.91)* 43 (41.7) 0.74 (0.52-1.05) 15 (41.7) 1.23 (0.93-1.62) 
Elevated FPG a 113 (41.5) 0.86 (0.58-1.27) 55 (39.0) 0.91 (0.70-1.19) 13 (44.8) 1.01 (0.77-1.33) 
Low HDLb 134 (40.1) 1.14 (0.82-1.58) 61 (41.5) 1.05 (0.84-1.32) 19 (32.2) 0.92 (0.71-1.19) 
High Triglyceridec 212 (41.0) 0.82 (0.60-1.13) 354 (42.6) 0.90 (0.72-1.12) 16 (48.5) 1.04 (0.83-1.32) 
Hypertensiond 444 (42.6) 1.69 (0.92-3.10) 203 (39.6) 1.69 (1.10-2.60)* 56 (35.7) 1.69 (1.08-2.66)* 
Cancer-death (n=342) 
MetS 52 (34.2) 1.62 (1.01-2.62)* 19 (25.3) 1.30 (0.94-1.81) 4 (19.1) 0.90 (0.57-1.44) 
BMI > 30  64 (33.9) 1.21 (0.77-1.92) 26 (25.2) 1.08 (0.79-1.47) 11 (30.6) 0.88 (0.60-1.30) 
Elevated FPG a 87 (32.0) 0.98 (0.64-1.50) 38 (26.9) 1.02 (0.76-1.35) 5 (17.2) 1.08 (0.77-1.51) 
Low HDLb 88 (26.3) 0.98 (0.67-1.43) 41 (27.9) 0.91 (0.70-1.19) 12 (20.3) 0.81 (0.58-1.13) 
High Triglyceride c 161(31.1) 1.70 (1.19-2.43)* 239 (28.8) 1.34 (1.05-1.72)* 8 (24.2) 0.91 (0.66-1.25) 
Hypertension d 297 (28.5) 0.83 (0.48-1.43) 141 (27.5) 0.89 (0.62-1.29) 40 (25.5) 1.00 (0.63-1.57) 
BMI=body mass index; CI= confidence interval; FPG=fasting plasma glucose; HR=hazard ratio; MetS=metabolic syndrome; SHR=subdistribution hazard ratio afasting plasma 
glucose ≥ 5.6 mmol/L, or previous diagnosis or specific treatment for type 2 diabetes. bserum HDL cholesterol  <1.03 mmol/L in men and <1.29 mmol/L in women, or specific 
treatment for this lipid abnormality; c serum triglyceride level ≥1.7 mmol/L or specific treatment for this lipid abnormality;dsystolic blood pressure  ≥ 130 mmHg or diastolic blood 
pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension. Note : Models adjusted for age, gender, smoking status,  pre-existing disease at baseline (namely, cancer, 




Time-dependent ROC  
We further sought to identify the individual and specific combinations of MetS 
components that best predicted all-cause and cause-specific mortality (Table 3.6). 
Among the five individual MetS components, TG was the best single predictor of 
all-cause and cancer mortality, while high glucose was the best predictor for CVD 
death (Table 3.6). For all-cause mortality, the best model comprised three 
components and included triglyceride, HDL-cholesterol and glucose. In the case 
of cause-specific mortality, the best model consisted of the following four 
components for cancer-death: triglyceride, HDL-cholesterol, glucose and BMI. 
For CVD-death, the best model included only two- components: high glucose and 
high BP. In the evaluation of all-cause and cause-specific mortality, there was 
significant improvement to the model fit as each new component was added to the 
more parsimonious preceding model (all P < 0.05), with no further improvement 
thereafter. For example, the model for all-cause death significantly improved the 
AUC when three MetS components, namely TG, HDL-cholesterol and glucose 
were included into the model, with no further improvement when the fourth and 
fifth MetS components was added into the preceding model. Similarly for 
cardiovascular and cancer death, the results indicated that when the MetS 
components were combined, the AUC improved significantly (Model 1, Table 
3.6). However, after adjusting for age, sex, smoking status and pre-existing 
disease status at baseline, none of these models were statistically enhanced as 
compared with the preceding model (Model 2, Table 3.6).  
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Integrated discrimination improvement (IDI) and net reclassification 
improvement (NRI)  
Improvement in all-cause mortality risk reclassification was numerically better in 
the 4-component model. The components included TG, HDL-cholesterol, glucose 
and BP. The addition of BP to TG, HDL-cholesterol and glucose increased the 
difference in mean predicted probability between subjects who died and survived 
with an IDI of 0.002. The improvement in discrimination by NRI when BP was 
added to TG, HDL-cholesterol, glucose between subjects who had died and 
survived was 0.048. For cancer-death, the improvement in discrimination 
persisted in the 5-component model, while for CVD-death the improvement in 
discrimination stopped in the 2-component model (Model 1, Table 3.6). 
Generally, the results of IDI and NRI suggested that combined MetS-components 
improved the discrimination of the model significantly (Model 1) (P < 0.05) in the 
prediction of all-cause and cause-specific mortality risk among the Australian 
elderly population. However, there was no improvement in the discrimination of 
death after including age, sex, pre-existing disease and smoking status (Model 2, 










Table 3.6 Time-dependent ROC curve, integrated discrimination improvement and net reclassification improvement for prediction of all-cause and 
cause-specific mortality  














All-cause        
Best single component of MetS T 0.5281 - - 0.8207 - - 
Best 2 components of Mets T+H 0.5399
b
 0.001 0.045 0.8210 < 0.001 < 0.001 
Best 3 components of Mets T+H+G 0.5458
 b
 0.001 0.046 0.8215 < 0.001 < 0.001 




 0.8217 < 0.001 < 0.001 
5 components of Mets T+H+G+BP+BMI 0.5531 0.000 0.000 0.8218 < 0.001 < 0.001 
Cardiovascular-death        
Best single component of MetS G 0.5452 - - 0.8640 - - 






 0.8642 < 0.001 < 0.001 




 0.093 0.8649 < 0.001 < 0.001 






 0.8653 < 0.001 < 0.001 
5 components of Mets G+BP+T+BMI+H 0.5764 0.012
 
 0.103 0.8653 < 0.001 < 0.001 
Cancer-death        
Best single component of MetS T 0.5300 - - 0.8096 - - 
Best 2 components of Mets T+H 0.5418
 b
 0.001 0.010 0.8103 < 0.001 < 0.001 
Best 3 components of Mets T+H+G 0.5474
 b
 0.004 0.052 0.8111 < 0.001 < 0.001 






 0.8111 < 0.001 < 0.001 




 0.8111 < 0.001 < 0.001 
AUC(t)= time-dependent area under curve; IDI = integrated discrimination improvement; NRI = net reclassification  improvement; BMI=body mass index; BP=blood pressure; 
G=glucose;H=HDL-cholesterol; MetS=metabolic syndrome; T=triglyceride. Note: Model 1 without including age, sex, smoking status, pre-existing disease at baseline (namely, 
cancer, angina, acute myocardial infarction, stroke and chronic lung disease) and Model 2 included above covariates  
a
 P < 0.05 and 
b
 P < 0.001, for comparison of AUC(t) 
with the model immediately preceding. 
c
 confidence interval for IDI and NDI estimate was significant (P < 0.05). 
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3.5 Discussion 
In this prospective cohort study of an Australian white population participating in 
the BMES, we found the following: First, MetS, exhibited a time-dependent 
association with all-cause, CVD and cancer deaths. Secondly, the AUC(t), IDI 
and NRI analyses showed that different MetS components were associated with 
different causes of death. Finally, the inclusion of age improved the model fitting 
substantially as compared to any single or combined MetS components.  
In studies where the exposure of interest, such as MetS and its components 
vary over the study follow-up, these covariates may be regarded as time-
dependent. In such situations, it is important to take into account the changing 
effect of the covariates during the model building. To our knowledge, this is the 
first study to have fully utilised the information of MetS recorded at baseline and 
all-follow-up visits to determine whether its relationship with mortality changes 
with time. Longitudinal studies that do not account for changes in exposure over 
time will not be able to distinguish between short and long term effects, and hence 
may result in less sensitive estimates of the exposure effect on outcomes (Collett 
2003). 
In this study, we found that, the risk of all-cause- and CVD-mortality 
increased gradually from 2-year to 10-year follow-up amongst those with MetS. 
Previous studies with follow-up duration ranging between 4.4 and 12.3 years, 
examining the relationship between baseline MetS and all-cause or CVD 
mortality, have reported inconsistencies in the relationship (Fried et al. 1998; Hu 
et al. 2004; Satio et al. 2009a; Zambon et al. 2009; Akbaraly et al. 2010; 
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Berrington de Gonzalez 2010; Salminen et al. 2010; Sidorenkovet al. 2010). In 
studying whether mortality is associated with MetS, it is important to take into 
account the duration of follow-up and changes in the status of MetS over time.  
In contrast to all-cause and CVD death, MetS was more likely to be 
associated with a greater risk of early cancer death after 2 years, but this increased 
risk was attenuated over time. This argument is plausible, since people with 
cancer are more likely to lose their weight over time and as BMI is a mandatory 
component of MetS by definition, they would not be categorized as having MetS. 
However, the induction period between MetS components and the incidence of 
cancer which had been started years before cancer-death would be another main 
concern. Previous prospective studies adopting different definitions of MetS at 
baseline with follow-up duration ranging between 7 and 14 years (Jaggers et al. 
2009; Akbaraly et al. 2010) have also found it to predict cancer death. Moreover, 
uncontrolled confounding such as chronic inflammation may be present. MetS is a 
multifactorial condition and the mechanisms behind its associated increase in 
cancer mortality are not completely understood (Jaggers et al. 2009). However, 
excess glucose has been shown to promote the formation of reactive oxygen 
species, which can promote cancer development (Jaggers et al. 2009).  
When we considered only the information about MetS at baseline, without 
taking into account changes in MetS status at follow-up, we did not detect any 
positive effects of MetS on all-cause and CVD mortality even after adjustment for 
age, sex, smoking and pre-existing disease status. Therefore, the time-varying 
effects of MetS on all-cause and CVD mortality would not have been detected if 
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we had only utilized its baseline information. The results of this study underscore 
that the presence of MetS at longer term follow-up (eg. 10-year) is more likely to 
confer a better prediction of all-cause death.  
Interestingly, consistent with the increase in AUC(t), the result of IDI and 
NRI tests showed MetS and its components improved the prediction of mortality. 
TG was the best single predictor of all-cause and cancer mortality in the elderly 
Australian population, while high glucose was the best single predictor of CVD 
death. BMI, a mandatory MetS component based on the IDF criteria, on its own 
was not as good a predictor. Based on IDI and NRI tests, an additional MetS 
component, namely BP for both all-cause and cancer-death was detected in the 
model in comparison with AUC(t) test. This may be because the IDI and NRI are 
more sensitive discrimination tools than AUC (Pencina et al. 2008). The findings 
that these risk factors clustered, thus leading to an increase in mortality risk may 
be useful to physicians for risk assessment (Wilken 2005). 
Another key finding of this study was that the model fit improved 
significantly after adjusting for age and lethal diseases, with more than a 1.5-fold 
increase in AUC(t). This implied that age and lethal diseases, more than any of 
the MetS components, were   important predictors of death in the elderly. As they 
had profound effect on mortality which was not seen with MetS and its 
components, they should thus be appropriately accounted for in the analysis. On 
the other hand, the effects of MetS were close to chance alone with Harrell‘s c 
ranging between 0.52 to 0.55. 
 69 
While this study has its specific strength such as low likelihood of 
misclassification error due to high specificity and sensitivity of death registration, 
its drawbacks must also be noted. In this study, the IDF criteria for defining MetS 
was used. As mentioned in Chapter 2, the prevalence of MetS was low, and so 
this may result in inadequate statistical power. Thus, it might be better to compare 
the results obtained using IDF definition with other MetS criteria such as ATP 3.  
In conclusion, the time-dependent association found between MetS with 
all-cause, cardiovascular- and cancer deaths underscores the importance of fully 
accounting for the information about MetS collected at each follow-up in order to 
better predict all-cause and major causes of death among the elderly. Hence, time-
dependent models may be clinically more relevant, as they depict the clinical 
scenarios where MetS and its components may change over time. This allows the 










CHAPTER 4— The Prognostic Role of Body Mass Index on Mortality 
amongst the Middle-Aged and Elderly: A Competing Risk Analysis 
SUMMARY 
Studies that have examined the association between obesity and cause-specific 
mortality have failed to take into account ―competing risks‖ from other causes of 
death. This study aims to determine the relationship between body mass index 
(BMI) including its 5-year changes, with mortality using the Cox and competing 
risks models and compare the results thus obtained. We examined the pattern of 
relationship between baseline BMI and all-cause mortality using cubic spline, and 
found it to be dependent on age. Based on the competing risks model, obesity at 
baseline was associated with increased risk of cardiovascular death and a 
reduction in BMI at 5-year was linked to an increase risk of cancer death amongst 
those aged ≤ 70 years. The cause-specific Cox model showed that reduction in 
BMI at 5-year was associated with cancer-death regardless of age, and with 
cardiovascular deaths among subjects aged ≤ 70 years. The Cox regression model 
showed a larger magnitude of effect with wider confidence interval as compared 
with the competing risks model. Conditions associated with obesity are more                
likely to affect mortality among subjects aged ≤70 years, but not those aged over 
70 years. BMI reduction, a marker of disease severity, was associated with 
cancer-death and cardiovascular-death only among those aged ≤ 70 years. In the 
presence of multiple causes of death, the competing risks model allows for a more 




4.1 Literature review 
Baseline body mass index and all-cause / cause-specific mortality  
Table 4.1 shows the pattern of association between baseline BMI and all-cause 
mortality. Different studies have exhibited different patterns of relationship. For 
example, a study in U.S. found no association (Tayback et al. 1990), whereas two 
large scale cohort studies found a linear relationship between BMI and mortality 
(Lindsted and Singh 1997; Ajani et al. 2004). Yet again, a large scale cohort study 
found a U-shaped relationship between baseline BMI and mortality (Adams et al. 
2006). In contrast, a study in Denmark showed the U-shaped relationship between 
baseline BMI and mortality levelled off with advancing age in females and that 
higher BMI had no association with mortality in elderly males (Thinggaard et al. 
2008). However, Tsai and Hsiao (2012) showed an L-shaped relationship between 
BMI and mortality among elderly over 65 years in Taiwan.  
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      Table 4.1 Pattern of association between BMI and all-cause mortality 
Study, year  Place N Age Pattern 
Tayback, 1990 USA 4710 55-74 No association 
Lindsted and Singh 1997 USA 12576 55-74 Linear 
Ajani, 2004 USA 85078 40-84 Linear 
Adams, 2006 USA 527265 50-71 U-shaped 
Thinggaard, 2008 Denmark 4253 70-95 Female: U shaped 
Male:  No association 
Tsai and Hsiao, 2011 Taiwan 2892 ≥ 65 L shaped 
         
 Table 4.2 shows the magnitude of association between baseline BMI 
with all-cause and cause-specific mortality. The relationship between baseline 
BMI and mortality may be different in older adults as compared with the middle-
aged (Corrada et al. 2006). The Framingham Heart Study found high extreme of 
BMI (≥ 28.7 kg/m2) to be associated with an increased risk of death only among 
women (Harris et al. 1988). A prospective cohort study in the Netherlands showed 
a significant association between BMI ≥27.77 kg/m2 and increased risk of all-
cause mortality (Maru et al. 2004). However, the National Health and Nutritional 
Examination Survey (Flegal et al. 2005) as well as Tsai and Hsiao (2012) found 
that being underweight was a positive risk factor for all-cause death. Kuk and 
Ardern (2009) showed that being underweight had no effect on mortality, while 
obesity had an adverse effect on mortality among men and women aged 18-64 
years. A study on three cohorts showed that higher BMI was associated with 
lower mortality amongst the elderly aged 70 to 88 years (Stessman et al. 2009), 
whereas a collaborative cohort study showed that being underweight was 
associated with increased risk of all-cause death among subjects aged 60-69 years. 
However, obesity was a significant risk factor in the 50 – 69 age groups 
(Berrington et al. 2010).  
 73 
     Table 4.2 Association between baseline BMI with all-cause and cause-specific mortality  
Study, year Place N Age   HR (95% CI)                                                      HR (95% CI) 








Underweight  BMI level 
for obesity 
Obesity  
All-cause         
Harris, 1988 USA 1723 > 30 23.0-25.2  - ≥28.7 
≥28.5 
F:1.6 (1.1-2.3) 
M: 1.4 (0.9-2.2) 
Maru, 2004 Netherland 8100 50-66 ≤23.3  - ≥27.8 1.4 (1.2-1.6) 
Flegal, 2005 USA 14985 ≥ 70 18.5-24.9 < 18.5 1.69 (1.38-2.07) ≥30 1.17 (0.94-1.47) 
Kuk, 2009 USA 33994 18-64 
 
65-75 




≥32.9 M:2.85 (1.28-6.34) 
F: 4.26 (2.10-8.63)  
M:0.96 (0.25-3.64) 
F:1.23 (0.56-2.67) 
Stessman, 2009 Jerusalem 2403 70-88 18.0-24.9  - ≥30 F:0.93 (0.87-0.99) 
M:0.93 (0.88-0.98) 
Berrington, 2010 USA 900000 50-59 
60-69 
22.5-24.9 15.0-18.4 1.15 (0.90-1.46) 
1.49 (1.30-1.71) 
30.0-34.9 1.56 (1.46-1.68) 
1.34 (1.28-1.41) 
Tsai, 2012 Taiwan 4442 ≥ 53 21.0-27.0 <21.0 2.29 (1.11-4.75) >27.0 0.60 (0.27-1.31) 
Cardiovascular-death  
Maru, 2004 Netherland 8100 50-66 ≤23.3  - ≥27.8 1.8 (1.3-2.3) 
Funada, 2008 Japan 43916 40-79 22.5-24.9 <18.5 1.62 (1.19-2.19) ≥30 1.88 (1.23-2.87) 
Cancer-death         
Baade, 2011 Australia 1825 > 20 18.5-24.9 <18.5 1.74 (1.01-3.04) ≥30 0.78 (0.59-1.03) 
Parr, 2011 Asia-
Pacific 
401215 ≥ 20 18.5-24.9 <18.5 1.12 (0.96-1.31) ≥30 1.21 (1.09-1.36) 
HR= Hazard ratio; CI=confidence interval. Maru (2004) is a study involving female only. BMI units ≤23.30 kg/m2 was regarded as reference group. ―F‖ refers to female and 
―M‖ refers to male. 
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Regarding the relationship between baseline BMI and cardiovascular 
death, Maru et al. (2004) showed an increased risk of CVD mortality amongst the 
obese. Among Japanese middle-aged adults, being underweight and being obese 
were positively associated with CVD-death (Funada et al. 2008). 
A prospective study in Australia showed that being underweight was 
positively linked to cancer-specific death (Baade et al. 2011), whereas the Asia-
Pacific Cohort Studies Collaboration showed that obesity was positively 
associated with cancer-death (Parr et al. 2011). 
 
BMI changes and all-cause/cause-specific mortality  
Table 4.3 shows the literature review on the association between changes in BMI 
and mortality. A cohort study in UK showed no effect of changes in BMI on all-
cause death (Wannamethee et al. 2001). Two prospective cohort studies in the 
USA and Norway showed that BMI loss but not BMI gain was positively 
associated with all-cause death (Newman et al. 2001; Droyvold et al. 2005). 
Moreover, in London, a prospective cohort study showed that, both BMI loss and 
gain were positively associated with all-cause death (Breez et al. 2006). A large 
prospective study showed that weight loss was associated with increased risk of 
all-cause death, while weight gain was a protective factor for all-cause death 
(Satio et al. 2009b). The Health and Retirement Study found that weight loss was 
associated with excess mortality for initial BMI levels below 32 kg/m
2
, while 
large weight gains were associated with excess mortality at high BMIs. (Myrskylä 
and Chang 2009).  
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As for cardiovascular mortality, Maru et al. (2004) showed a significant 
association between BMI loss and increased risk of CVD mortality in females. 
However, Droyvold et al. (2005) found that BMI loss was associated with 
increased risk of CVD death in both genders. 
With respect to cancer-death, a large prospective study showed that weight 
loss but not weight gain was positively associated with cancer-death (Satio et al. 
2009b). 
Table 4.3 Association between BMI changes with all-cause and cause-specific mortality 
Study, year Place N Age Change 
(year) 
HR (95% CI) 
All-cause     Loss Gain 
Wannamethee, 
2001  
UK 7735 40-59 5 1.15 (0.84-1.58)  1.79 (0.89-3.61) 
Newman, 2001 USA 4255 ≥ 65 3 1.67 (1.29-2.15)  0.94 (0.65-1.46) 
Droyvold, 2005 Norway M:20542 
F:23712 
≥ 20 11 1.6 (1.4-1.8) 
1.7 (1.5-2.0) 
1.0 (0.9-1.1) 
    0.9 (0.8-1.0) 
Breez, 2006 UK 4862 40-69 5 1.26 (1.1-1.5) 1.36 (1.1-1.7)  
Satio, 2009b Japan 88419 40-69 - 1.44 (1.32-1.56) 0.89(0.82-0.97) 
Myrskylä and 
Chang, 2009 
USA 13104 50-70 2 1.61 (1.31-1.98) 1.33 (1.00-1.77) 
Cardiovascular-death 
Maru, 2004 Netherland F: 8100 50-66 1 
1.5 (1.1-2.1)  0.9 (0.6-1.3)  
Droyvold, 2005 Norway M:20542 
F:23712 




Cancer-death       
Satio, 2009b Japan 88419 40-69 - 1.27 (1.12-1.44) 0.90 (0.80-1.02) 
HR= Hazard ratio; CI=confidence interval. ―F‖ refers to  female and ―M‖ refers to male  
 
4.2 Significance of study 
The prevalence of obesity in younger adults and elderly will increase in most 
countries (Haslam and James 2005; Prospective Studies Collaboration et al. 
2009). A high incidence of obesity in the population has huge consequences for 
health care, now and in the future. An increased proportion of overweight and 
obese subjects will lead to poor health outcomes such as hypertension, diabetes, 
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CVD and disability, which place an immense strain on health and social services 
(Haslam and James 2005).  
The specific pattern of the relationship between BMI and all-cause 
mortality, especially in the overweight and obese range, is still a matter of debate. 
While some studies exhibited a U-shaped (Adams et al. 2006) or L-shaped (Tsai 
and Hsiao 2012) relationship between BMI and mortality among the middle-aged 
and elderly, others have shown a linear (Lindsted and Singh 1997; Ajani et al. 
2004) or no association (Tayback et al. 1990; Thinggaard et al. 2008). Previous 
prospective cohort studies have tried to describe the impact of obesity on all-cause 
and cause-specific mortality, however, conflicting results remain amongst the 
middle-aged and elderly, with a lack of evidence to prove the strength of 
association between obesity and mortality (Tayback et al. 1990; Lindsted and 
Singh 1997; Flegal et al. 2005; Adams et al. 2006; Corrada et al. 2006; Kuk and 
Ardern 2009; Berrington de Gonzalez et al. 2010; Teucher et al. 2010; Thinggaard 
et al. 2010; Tsai and Hsiao 2012). Variation in age of participants in different 
studies may contribute to the conflicting findings in these studies, with some 
studies suggesting that overweight and obesity may not be a risk factor for 
mortality in the elderly (Flegal et al. 2005; Kuk and Ardern 2009). Moreover, the 
impact of changing BMI over a period of time on mortality remains uncertain 
(Yun et al. 2010). Some studies reported that an increase or decrease in BMI over 
time predicts a greater risk of CVD, cancer or all-cause mortality among middle-
aged or elderly (Breeze et al. 2006; Bamia et al. 2007; Myrskylä and Chang 
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2009), while others have not noted this association (Corrada et al. 2006; Saito et 
al. 2009b). 
Although obesity is associated with an increase in risk of mortality from 
multiple causes, studies that have examined the association between obesity and 
cause-specific mortality have failed to take into account ―competing risks‖ from 
other causes of death. As mentioned in Chapter 1, when competing risks are not 
rare especially among the elderly population, the Cox-regression model may 
overestimate the relationship between exposure of interest such as BMI and 
multiple failure endpoints such as cardiovascular- and cancer-death (Koller et al. 
2008). Therefore, for analysis of different causes of death, competing risks 
analysis provides a more robust estimate of exposure on different causes of death, 
by accounting for each competing risks in the analysis (Wolbers et al. 2009; Tai et 
al. 2010; Tai et al. 2011a; Tai et al. 2011b). 
To our best knowledge, competing risk models have not been used to 
evaluate the relationship between BMI and its changes with cause-specific 
mortality. Therefore, in this study, we first sought to exhibit the pattern of the 
relationship between BMI and mortality. We then determine the association 
between baseline BMI and the 5-year change in BMI with all-cause and cause-
specific mortality in the BMES, and compare the results obtained using standard 
survival models such as the Kaplan-Meier method and Cox regression with the 





Study design and population 
A detailed description of the study design and population of the BMES was 
provided in Chapter 2. In brief, the BMES is a prospective cohort study of vision 
and other health outcomes
 
in white Australians. Two adjoining urban postcode 
areas in the Blue Mountains area, west of Sydney, in New South Wales, Australia, 
were selected as target population (Mitchell et al. 1998a).  
In this study, we included 2216 subjects with complete information on 
age, sex, smoking status, physical activity and pre-existing diseases, as well as 
BMI from both the baseline (1992-1994) and 5-year (1997-1999) examinations. 
Participants who died shortly after the study baseline visit were excluded from the 
analysis as in a previous study (Corrada et al. 2006), to control for the relation 
between reduced BMI, morbidity and early death (Wannamethee et al. 2001).  
Data collection 
A detailed description of the data collection was provided in Chapter 2. Briefly, 
at each visit, a comprehensive questionnaire comprising demographic 
information, smoking status (current, former and never smoker), alcohol intake 
(gram per week) and a detailed history of diseases, including hypertension, 
diabetes, angina, AMI, stroke and cancer as well as medication was recorded at 
face-to-face interviews conducted by trained interviewers using a standardised 
questionnaire (Mitchell et al. 1998a). We define pre-existing disease(s) as a 
binary variable based on past history or medication for at least one of the above 
mentioned diseases. In addition, self-reported physical activity based on time 
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spent on activities per week using the International Physical Activity 
Questionnaire (Craig et al. 2003) was collected. Similar to previous studies 
(Breeze et al. 2006; Saito et al. 2009b; Berrington de Gonzalez et al. 2010; 
Thinggaard et al. 2010), we define middle-aged and elderly using age ≤ 70 and    
> 70 years respectively. 
Study factor 
Participants had their weight (after removal of shoes and heavy clothing) 
measured by standing on an automated scale, to which a vertical height measure 
was attached (Younan et al. 2003). The BMI was calculated as weight (kg)/height 
(m
2
). Baseline BMI was re-categorized using the classification of the World 
Health Organization Expert Committee on Physical Status (1995): underweight: 
<18.5 kg/m
2
, normal weight: 18.5 to <25 kg/m
2
, overweight: 25 to <30 kg/m
2
, and 
obese: ≥30 kg/m2. Normal weight was considered as the reference group in all 
analyses. 
Five-year change in BMI from baseline was categorized as follows: stable: 
<1 BMI unit change, gain: ≥1 BMI unit gain, reduction: ≥1 BMI unit loss 
(Myrskylä and Chang 2009). Stable BMI was regarded as the reference group in 
all analyses involving changes in BMI from the baseline to 5-year visit. 
Study outcome 
A detailed description of the study outcome was provided in Chapter 3. Briefly, 
all-cause and cause-specific mortality including cardiovascular-, cancer- and other 
causes of death were our study outcomes in this study. Chapter 3 focused on the 
association between all-cause and cause-specific mortality assuming MetS and its 
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components were time-dependent. In this study, we focus first on the pattern of 
association between baseline BMI and all-cause death. We then evaluate the 
relationship between change in BMI over 5-year since baseline with all-cause and 
cause-specific mortality and compare the estimates obtained using Cox regression 
and Kaplan-Meier (KM) method with competing risks analysis. As mentioned in 
Chapter 3, deaths occurring after baseline recruitment (1992–1994) until 31 
December 2007 were confirmed by matching the demographic information of the 
participants with the Australian NDI, using probabilistic record linkage. Causes of 
death were provided by the NDI using the ICD 9
th
 revision and 10
th
 revision 
(Wang et al. 2006).  
Statistical analyses 
We first explored the relationship between baseline BMI (continuous) and the risk 
of death via non-parametric regression model based on cubic spline (Harrell 








 percentiles of the BMI 
distribution. In the graphical display, we selected the upper bound of the reference 
group (normal weight) at 23.5 kg/m
2 
as reference.  
In examining the associations between BMI and all-cause mortality, we 
used the Cox proportional hazards model. Time-to-death (year) is the primary 
outcome variable for all-cause mortality. We implemented the competing risks 
model (Tai et al. 2011a; Tai et al. 2011b) to study the associations between BMI 
(baseline and 5-year change) with cause-specific mortality. In the analysis of 
cause-specific mortality, the time-to-specific cause of death (year) was the 
outcome variable. We further compared the results of the competing risks 
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methods based on cumulative incidence (Tai et al. 2001; Wolbers et al. 2009; Tai 
et al. 2010; Tai et al. 2011a, Tai et al. 2011b) and competing risks regression 
(Beyersmann et al. 2007; Tai et al. 2011b) with the KM estimates and cause-
specific Cox models respectively. As explained in Chapter 1, competing risks 
models are well-suited for outcomes involving multiple failure types (such as 
cancer- and cardiovascular-deaths), as it appropriately account for each competing 
risk in the analysis, yielding a more accurate estimation of exposure such as the 
effect of BMI on different causes of death (Wolbers et al. 2009; Tai et al. 2011a; 
Tai et al. 2011b). 
Sex, smoking status and pre-existing disease(s) at baseline were 
considered as potential confounders in the multivariable analyses. We further 
explored effect modification of age, sex and pre-existing disease(s) on BMI. The 
effect estimate and its 95% CI were presented according to age groups as the 
interaction between age and BMI was significant (P < 0.05). The proportional 
hazards assumption was checked for individual covariates and globally. We also 
considered the possibility that our findings might have been confounded by the 
presence of pre-existing diseases at baseline and adjustment for it might not 
totally account for its effect as pre-existing disease might result in weight loss and 
consequently caused premature mortality. Therefore, in a supplementary analysis, 
we excluded people with pre-existing diseases at baseline and further explored the 
relationship between BMI and its changes with all-cause and cause-specific 
mortality using Cox regression and competing risks models in this subgroup of 
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subjects. The non-parametric plot of cubic spline was generated using R statistical 
package (www.r-project.org).  
 
4.4 Results 
Demographic profile of subjects  
Table 4.4 provides a description of the baseline characteristics of the 2216 
participants. Generally, underweight persons were more likely to be younger 
(65%) and predominantly female (74%). Moreover, obese persons were more 
likely to be younger (78%) or have a history of pre-existing disease(s) (58%) at 
baseline. There were 599 (27%) deaths reported until December 2007. Of these, 
234 (39%) were cardiovascular-deaths and 167 (28%) were cancer-deaths. During 
a median follow-up duration of 14.7 years, 12 (39%) underweight and 109 (29%) 
obese subjects had died.  
 
Table 4.4 Baseline characteristics of 2216 study subjects according to BMI categories 
Variable  Total 
 
















(n = 376) 
% 
P-value 
Age (year)  ≤70  


























































Diabetes  6.5 3.2 4.1 6.6 12.2 <0.001 
Hypertension  30.7 12.9 25.5 31.6 42.3 <0.001 
History of stroke  3.4 3.2 3.6 3.2 3.5 0.980 
History of angina  11.3 6.5 9.1 13.2 12.6 0.031 
History of AMI 8.0 6.5 6.7 8.9 9.1 0.257 
History of cancer 7.7 8.8 6.4 6.5 8.0 0.332 
Pre-existing disease(s)  46.2 41.3 29.0 46.6 58.5 <0.001 
Abbreviations: AMI = acute myocardial infarction; BMI = body mass index. 
Note: Figures in parentheses denote percentages. 
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Of the obese subjects who died during the study follow-up, the prevalence 
of pre-existing disease at baseline were higher amongst those aged ≤ 70 years 
than older subjects (history of diabetes 44% vs 27%, hypertension 26% vs 17%, 
stroke 13% vs 11%, angina 28% vs 9%, AMI 29% vs 12% and cancer 24% vs 
15%) (Table 4.5). 
Table 4.5 Prevalence of disease at baseline amongst subjects who died during study follow-
up according to weight status and age group 





Age ≤ 70 year      
Diabetes (n=23) 7 (30.4) 0 (0.0) 6 (26.1) 10 (43.5) 0.098 
Hypertension (n=90) 25 (27.8) 0 (0.0) 42 (46.7) 23 (25.6) 0.119 
History of stroke (n=15) 5 (33.3) 0 (0.0) 8 (53.3) 2 (13.3) 0.757 
History of angina (n=54) 15 (27.8) 0 (0.0) 24 (44.4) 15 (27.8) 0.407 
History of AMI (n=45)) 12 (26.7) 0 90.0) 20 (44.4) 13 (28.9) 0.442 
History of cancer (n=33) 9 (27.3) 0 (0.0) 16 (48.5) 8 (24.2) 0.723 
Pre-existing disease(s) 
(n=152)  
47 (30.9) 0 (0.0) 66 (43.4) 39 (25.7) 0.017 
Age > 70 year      
Diabetes (n=30) 7 (23.3) 0 (0.0) 15 (50.0) 8 (26.7) 0.013 
Hypertension (n=131) 60 (45.8) 0 (0.0) 49 (37.4) 22 (16.8) 0.151 
History of stroke (n=19) 8 (42.1) 0 (0.0) 9 (47.4) 2 (10.5)  
History of angina (n=68) 28 (41.2) 0 (0.0) 34 (50.0) 6 (8.8) 0.057 
History of AMI (n=42) 16 (38.1) 1 (2.4) 20 (47.6) 5 (11.9) 0.409 
History of cancer (n=27) 14 (51.8) 1 (3.7) 8 (29.6) 4 (14.8) 0.583 
Pre-existing disease(s) 
(n=198)  
86 (43.4) 2 (1.0) 80 (40.4) 30 (15.1) 0.150 
Abbreviation: AMI=acute myocardial infarction. Note: Figures in parentheses denote percentages. 
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Relationship between baseline BMI with all-cause and cause-specific 
mortality 
Interaction effect was noted between age and baseline BMI for all-cause 
(P=0.049) and cardiovascular- (P=0.044) death. As such, we have reported the 
results of our analysis according to age. Figure 4.1 shows the risk of all cause-
death was U shaped with the highest mortality rates at the two extreme ranges of 
BMI for all subjects as well as for those aged ≤ 70 years. However, for persons 
aged over 70 years at baseline, the L-shaped relationship suggests a higher risk of 
death amongst the underweight, with no elevation in the mortality risk for the 
overweight or obese, as compared with the normal weight.  
 
 
Figure 4.1 Cubic splines describing the nonlinear relationship between body       
mass index (kg/m
2
) and the relative hazard of death 
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Table 4.6 Age-specific associations between baseline BMI and its 5-year changes with all-cause and cause-specific mortality according to 
competing risks and cause-specific Cox regression models 
 All-cause (n=599) Cancer (n = 167) Cardiovascular (n=234) Cancer Cardiovascular  
 Cox-regression model Competing risks model Cause-specific Cox regression 
Baseline BMI (kg/m2) No. died HR (95% CI) No. died SHR (95% CI) No. died SHR (95% CI) HR (95% CI) HR (95% CI) 
Age ≤ 70          
Underweight (n=20) 6 1.82 (0.80-4.15) 2 0.95 (0.14-6.53) 2 1.34 (0.18-7.25) 0.96 (0.13-6.81) 1.73 (0.17-7.50) 
Overweight (n=710) 118 1.07 (0.82-1.41) 37 0.97 (0.61-1.54) 37 1.43 (0.84-2.42) 0.99 (0.62-1.59) 1.43 (0.85-2.41) 
Obese (n=292) 64 1.44 (1.05-1.98) 23 1.51 (0.88-2.59) 22 2.06 (1.14-3.70) 1.58 (0.98-2.68) 2.07 (1.15-3.72) 
Age > 70    
Underweight (n=11) 6 1.20 (0.53-2.72) 2 0.68 (0.09-4.94) 4 1.73 (0.55-5.40) 0.90 (0.12-6.64) 1.95 (0.60-5.45) 
Overweight (n=197) 116 0.98 (0.77-1.25) 27 1.01 (0.60-1.69) 53 0.85 (0.60-1.22) 1.02 (0.61-1.69) 0.87 (0.61-1.24) 
Obese (n=84) 45 0.94 (0.67-1.32) 11 1.07 (0.54-2.15) 20 0.78 (0.47-1.31) 1.12 (0.56-2.25) 0.81 (0.49-1.33) 
Change in 
BMI(kg/m2) 
        
Age ≤ 70 years         
Reduction  (n =169)  55 2.22 (1.60-3.09) 23 3.03 (1.76-5.23) 14 1.55 (0.83-2.89) 3.20 (1.86-5.50) 1.85 (1.02-3.46) 
Gain (n = 875)  124 0.88 (0.68-1.14) 41 1.01 (0.63-1.60) 34 0.74 (0.46-1.18) 1.01 (0.63-1.60) 0.78 (0.49-1.25) 
Age > 70 years         
Reduction (n = 109) 81 1.76 (1.32-2.35) 19 1.42 (0.78-2.60) 35 1.07 (0.69-1.65) 1.89 (1.04-3.43) 1.40 (0.92-2.14) 
Gain (n = 223) 113 0.86 (0.66-1.11) 25 0.92 (0.53-1.58) 54 0.81 (0.56-1.17) 0.92 (0.52-1.58) 0.82 (0.55-1.19) 
              Abbreviations: BMI = body mass index; CI = confidence interval; HR = hazard ratio; SHR=subdistribution hazard ratio. Note: Model is adjusted for sex, smoking status 
and pre-existing disease(s) at baseline. For baseline BMI, normal weight and for BMI changes, stable BMI regarded as reference group. Stable BMI: < ±1 unit BMI 
change, BMI gain/reduction: ± ≥ 1 unit BMI change. 
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Consistent with Figure 4.1, Table 4.6  shows that for persons aged ≤ 70 
years at baseline, there was an increased risk of all-cause mortality amongst the 
obese (HR 1.44, 95% CI: 1.05-1.98). There was also suggestion that being 
underweight may increase the risk of all-cause death. Similarly, obesity was 
associated with a greater risk of cardiovascular mortality in this age group based 
on competing risk (SHR 2.06, 95% CI: 1.14-3.70) and Cox regression (HR 2.07, 
95% CI: 1.15-3.72) analyses (Table 4.6). Amongst persons aged over 70 years, 
there was no evidence of association between baseline BMI and all-cause or 
cause-specific mortality (Table 4.6). Although the conclusions drawn based on the 
two methods were largely similar, the magnitude of effect was larger, and with 
wider CI based on the cause-specific Cox model as compared with the competing 
risk regression in most instances (Table 4.6). 
 
Changes in BMI and all-cause or cause-specific mortality  
Over the 5-year period, reduction in BMI was observed in 278 (13%) subjects, 
while 1098 (50%) of them experienced an increase in BMI. Generally, persons 
with reduced or increased BMI tended to be younger (61% and 80%, 
respectively). A higher proportion with pre-existing disease(s) at baseline was 
noted amongst those with a decrease in BMI in subsequent 5 years, as compared 






Table 4.7 Baseline characteristics of 2216 study subjects according to 5-year changes in BMI 
 Total 
(n = 2216) 
Stable BMI 
(n = 840) 
Reduction 
(n = 278) 
Gain 
(n = 1098) 
P-value 
Age (year)  ≤70  
                   >70 









































Diabetes (%) 142 (6.5) 54 (6.5) 32 (11.9) 56 (5.1) < 0.001 
Hypertension (%) 680 (30.7) 260 (30.9) 108 (38.8) 312 (28.4) 0.003 
History of stroke (%) 75 (3.4) 34 (4.1) 15 (5.4) 26 (2.4) 0.018 
History of angina (%) 250 (11.3) 91 (10.9) 42 (15.2) 117 (10.7) 0.095 
History of AMI (%) 177 (8.0) 58 (6.9) 29 (10.5) 90 (8.2) 0.162 
History of cancer (%) 170 (7.7) 66 (7.9) 25 (9.0) 79 (7.2) 0.584 
Pre-existing disease(s) (%)  1025 (46.2) 392 (46.7) 156 (56.1) 477 (43.4) 0.001 
          Abbreviations: AMI = acute myocardial infarction; BMI = body mass index. 
  Note: Stable BMI: < ±1 unit BMI change, BMI gain/reduction: ± ≥ 1 unit BMI change.  
 
The overall mortality rate was the highest amongst those with a BMI 
decrease (49%) and the lowest amongst those with a BMI increase (22%). The 
magnitude of 5-year changes in BMI according to age group is shown in Table 
4.8. In particular, the proportion with BMI reductions among elderly subjects     
(<-5 [1.5%], -5 to -3 [3.7%], <-3 to -1 [11.1%]) were higher as compared to 
younger subjects (< -5 [0.6%], -5 to -3 [1.7%], <-3 to -1 [6.4%]).  







            Table 4.8 Magnitude of 5-year BMI changes according to age group  
Unit BMI change   ≤ 70 years  > 70 year 
< -5 7 (0.6) 17 (1.5) 
-5 to -3  19 (1.7) 41 (3.7) 
< -3 to -1 72 (6.4) 122 (11.1) 
< ±1 (Stable BMI ) 411 (36.7) 429 (39.1) 
1 to < 3 404 (36.1) 374 (34.1) 
3 to 5 165 (14.7) 89 (8.1) 
>5 41 (3.7) 25 (2.3) 
 Note: The figures presented above denote frequency and percentage. 
Moreover, a higher proportion of those who were obese at baseline 
experienced BMI reduction (16.8%) while, a lower proportion of those who were 
underweight at baseline experienced BMI reduction (5.0%) among those aged      
≤ 70 years. Among the elderly subjects, the proportions with BMI reduction in the 
obese and underweight groups were 30.9% and 9.1% respectively (Table 4.9).  
 
Table 4.9  Five-year changes in BMI according to baseline BMI categories and age group 
Baseline BMI 
categories 



















Underweight 1 (5.0) 7 (35.0) 12 (60.0) 1 (9.1) 7 (63.6) 3 (27.3) 
Normal weight  35 (5.4) 247 (38.1) 367 (56.5) 34 (13.4) 107 (42.3) 112 
(44.3) 
Overweight 84 (11.8) 276 (38.9) 350 (49.3) 48 (24.4) 75 (38.1) 74 (37.6) 
Obese  49 (16.8) 97 (33.2) 146 (50.0) 26 (30.9) 24 (28.6) 34 (40.5) 
Note: The figures presented above denote frequency and percentage. 
Figure 4.2 shows the KM cumulative incidence curve for cancer- and 
cardiovascular-deaths according to changing BMI status. The estimates were 
larger than those obtained using the competing risks method for all BMI groups 
under consideration.  
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Figure 4.2 Comparison of cumulative incidence of cardiovascular and cancer mortality 
according to 5-year BMI changes: Competing risks (CR) versus Kaplan-Meier (KM) 
methods 
 
Reduced BMI was associated with a higher risk of all-cause mortality 
regardless of age (≤70 years: HR 2.22, 95% CI: 1.60-3.09; >70 years: HR 1.76, 
95% CI: 1.32-2.35) (Table 4.6). Amongst subjects aged ≤ 70 years, reduction in 
BMI was significantly associated with cardiovascular death (HR 1.85, 95% CI: 
1.02–3.46) and cancer-death (HR 3.20, 95% CI: 1.86–5.50) in the cause-specific 
Cox model, although this association was not confirmed by the competing risks 
model for cardiovascular-death (SHR 1.55, 95% CI: 0.83–2.89) (Table 4.6). 
Similarly, subjects aged >70 years with reduced BMI were also found to have an 
elevated risk of cancer death (HR 1.89, 95% CI: 1.04–3.43) in the cause-specific 
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Table 4.10  Age-specific associations between BMI changes with all-cause and cause-specific mortality in overweight/obese group according to 
competing risks and cause-specific Cox regression models  
 All-cause  
(n=343) 
Cancer  




 (n = 98) 
Cardiovascular (n=132) 
 Cox-regression model                                              Competing risks model Cause-specific Cox regression 
 No. 
died 
HR (95% CI) No.  
died 
SHR (95% CI) No.  
died 
SHR (95% CI) HR (95% CI) HR (95% CI) 
Change in BMI(kg/m2)       
Age ≤ 70 years         
Reduction  (n =181)  79 2.04 (1.38-3.01) 26 2.33 (1.21-4.48) 29 1.38 (0.67-2.78) 2.52 (1.31-4.85) 1.49 (0.73-3.03) 
Gain (n = 570)  111 0.89 (0.64-1.23) 34 0.92 (0.32-2.64) 35 0.76 (0.43-1.34) 0.88 (0.49-1.59) 0.77 (0.43-1.36) 
Age > 70 years         
Reduction (n = 158) 78 2.52 (1.70-3.73) 24 3.87 (1.69-8.90) 31 1.21 (0.68-2.17) 4.32 (1.85-10.10) 1.89 (1.08-3.32) 
Gain (n = 458) 103 1.21 (0.82-1.79) 28 0.69 (0.09-5.10) 34 0.83 (0.48-1.46) 1.59 (0.66-3.84) 0.90 (0.51-1.59) 
           Abbreviations: BMI = body mass index; CI = confidence interval; HR = hazard ratio; SHR=subdistribution hazard ratio. 
           Note: Model is adjusted for sex and smoking status and pre-existing disease(s) at baseline. Stable BMI regarded as reference group. 







Supplementary analysis amongst the subgroup of overweight/obese 
subjects showed BMI reduction to be significantly associated with all-cause (≤ 70 
years: HR 2.04, 95% CI: 1.38-3.01; > 70 years: HR 2.52, 95% CI: 1.70-3.73) and 
cancer- (≤ 70 years: SHR 2.33, 95% CI: 1.21-4.48; >70 years: SHR 3.87, 95% CI: 
1.69-8.90) death among both age groups. Cox-specific regression model 
additionally showed that BMI reduction in the overweight/obese group was 
positively linked to an increase in cardiovascular mortality (HR 1.89, 95% CI: 
1.08-3.32) among elderly subjects (Table 4.10).  
 
The associations between baseline BMI and its 5-year changes with all-cause 
and cause-specific mortality amongst subjects without baseline pre-existing 
diseases  
Of the 2216 study subjects, 1191 (54%) had no history of pre-existing disease at 
baseline. Being underweight at baseline was associated with all-cause death in 
both age groups (≤70 years: HR 3.29, 95% CI: 1.40-7.69; >70 years: HR 2.82, 
95% CI: 1.01-7.89), while obesity was linked to increase risk of cancer-death 
amongst younger subjects (SHR 2.26, 95% CI: 1.07-4.78) (Table 4.11). As 
before, the magnitude of effect was larger, and with wider CIs based on the cause-







Table 4.11 Age-specific associations between baseline BMI and its 5-year changes with all-cause and cause-specific mortality according to competing 
risks and cause-specific Cox regression models amongst subjects without pre-existing disease(s) at baseline 
 All-cause  
(n=249) 
Cancer  




 Cox-regression model                                              Competing risks model Cause-specific Cox regression 
Baseline BMI (kg/m2) No. 
died 
HR (95% CI) No. 
died 
SHR (95% CI) No 
died 
SHR (95% CI) HR (95% CI) HR (95% CI) 
Age ≤ 70          
Underweight (n=16) 6 3.29 (1.40-7.69) 1 1.49 (0.23-9.88) 1 3.25 (0.42-25.00) 1.55 (0.21-11.74) 3.43 (0.43-27.50) 
Overweight (n=409) 52 1.02 (0.69-1.51) 15 0.85 (0.43-1.68) 14 1.76 (0.73-4.28) 0.85 (0.43-1.69) 1.79 (0.70-4.33) 
Obese (n=127) 25 1.84 (1.14-2.98) 11 2.26 (1.07-4.78) 6 2.59 (0.90-7.46) 2.30 (1.08-4.87) 2.69 (0.93-7.76) 
Age > 70    
Underweight (n=6) 4 2.82 (1.01-7.89) 1 1.41 (0.19-10.69) 2 1.76 (0.32-9.72) 3.31 (0.42-25.92) 2.21 (0.51-9.51) 
Overweight (n=75) 36 0.93 (0.62-1.41) 11 1.20 (0.55-2.65) 18 1.02 (0.56-1.83) 1.27 (0.54-2.84) 1.02 (0.55-1.86) 
Obese (n=29) 15 1.23 (0.69-2.18) 4 1.30 (0.43-3.91) 7 1.01 (0.43-2.36) 1.42 (0.46-4.35) 1.07 (0.46-2.50) 
Change in BMI(kg/m2) 
 
        
Age ≤ 70 years         
Reduction  (n =87)  26 2.91 (1.78-4.75) 11 4.05 (1.78-9.22) 4 1.28 (0.41-3.96) 4.25 (1.87-9.67) 1.42 (0.47-4.36) 
Gain (n = 523)  66 1.13 (0.77-1.67) 22 1.33 (0.66-2.66) 12 0.63 (0.29-1.37) 1.34 (0.66-2.70) 0.64 (0.29-1.41) 
Age > 70 years         
Reduction (n = 35) 23 1.74 (1.05-2.88) 4 0.80 (0.25-2.52) 11 1.38 (0.64-3.00) 1.07 (0.35-3.32) 1.71 (0.82-3.55) 
Gain (n = 98) 44 0.81 (0.54-1.23) 14 1.06 (0.49-2.30) 20 0.81 (0.44-1.48) 1.06 (0.49-2.31) 0.88 (0.46-1.58) 
Abbreviations: BMI = body mass index; CI = confidence interval; HR = hazard ratio; SHR=subdistribution hazard ratio.Model is adjusted for sex and smoking status. For baseline   




With regard to BMI changes over 5-year follow-up since baseline, BMI 
reduction was associated with an increase risk in all-cause death in both age 
groups (≤70 years: HR 2.91, 95% CI: 1.78-4.75; >70 years: HR 1.74, 95% CI: 
1.05-2.88), and cancer-death amongst those aged ≤70 years (Table 4.11). For the 
latter, the Cox regression model again showed a higher magnitude of effect as 
compared with the competing risk model.   
 
4.5 Discussion  
In this population-based prospective cohort study of the Australian middle-aged 
and elderly population, we found the following: First, amongst the younger 
subjects, the relationship between baseline BMI and all-cause mortality was U-
shaped, with both the underweight and obese groups predisposed to have a greater 
risk of death; obesity was also associated with increased risk of cardiovascular 
death in this age group. Amongst elderly persons, an L-shaped relationship was 
seen: only low but not excessive BMI was found to be associated with increased 
risk of all-cause death. Second, a reduction in BMI between baseline and the 5-
year follow-up visit was associated with all-cause mortality in both age groups 
and cancer deaths among those aged ≤ 70 years. Finally, the cause-specific Cox 
regression model showed larger magnitude of effect of between 1-33%, as 
compared with the competing risks model, especially among the elderly subjects.  
All-cause mortality risk 
Our study has shown that the pattern of relationship between BMI and mortality is 
dependent on age. The U-shaped relationship between BMI and mortality in 
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subjects aged ≤ 70 years at baseline is consistent with the findings of Berrington 
et al. (2010) and Adams et al. (2006) However, this pattern of relationship was 
not noted amongst the elderly who were aged above 70 years. In particular, there 
was no elevation in risk of death amongst those who were overweight or obese in 
this age group. This observation is consistent with that reported by Tsai and Hsiao 
(2012), who found a similar L-shaped relationship between BMI and all-cause 
death among Taiwanese over 65 years old. The L-shaped association between 
baseline BMI and mortality in those > 70 years suggests that overweight/obesity 
does not predispose the elderly subjects to be at a greater risk of mortality. 
Although, it is unclear why excess weight protects older adults, we consider three 
possibilities. Firstly, the advantage of being overweight could be that fat mass 
stores energy that can be used during negative energy balance (Dahl et al. 2013). 
For example, extra weight could give older people reserves to recover from 
stresses such as surgery or pneumonia. Secondly, even though obesity is 
associated with higher rates of chronic disease such as diabetes, the impact of 
these conditions on mortality may be reduced when they occur in elderly 
individuals.  For example, Tan et al. (2004) showed that diabetes mellitus that was 
diagnosed after age of 65 was not associated with increased mortality in Scotland, 
whereas it was associated with increased mortality when diagnosed below this 
age. In the Asia Pacific Cohort Studies Collaboration, Woodward et al. (2003) 
also showed that the effect of diabetes on the risk of CVD and death decreased 
with increasing age at risk. Thirdly, we also considered the possibility that our 
findings could have been confounded by the presence of pre-existing diseases at 
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baseline that could have resulted in weight loss and caused premature mortality. 
However, we analyzed the data excluding subjects with these underlying 
conditions and again found overweight/obesity to have no association with death.   
 
Cause-specific mortality risk 
In our study, obesity was associated with increased risk of cardiovascular 
mortality in subjects aged ≤ 70 years. This was consistent with a study in the USA 
that showed obesity to be associated with coronary heart disease mortality among 
subjects aged 35-74 years (Mann et al. 2006). Obesity is associated with multiple 
cardiovascular risk factors including diabetes, hypertension and dyslipidemia 
(Sowers 2003). As BMI reduction even in obese is a risk factor for death among 
both middle-aged and elderly subjects and obesity is associated with all-cause and 
cardiovascular death amongst subjects aged ≤ 70 years, it may be important to 
control weight and modify lifestyle years before the ageing process sets in. 
However, our data does not necessarily suggest that weight loss may be 
detrimental in some instances in older individuals because inference of causality 
between BMI reduction and mortality cannot be fully established. 
A unique aspect of our study is the ability to demonstrate changes in BMI 
over time. BMI changes in fact occurred in about 60% of the study population 
over the 5-year period since baseline. As in previous studies (Newmann et al. 
2001; Myrskylä and Chang 2009; Bamia et al. 2010),
 
we also found that a 
reduction in BMI was associated with an increased risk in all-cause mortality 
amongst both the middle-aged and the elderly. Further, BMI reduction was a 
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predictor for cancer related mortality amongst those ≤70 years. In general, a 
decrease in BMI prior to death in the elderly is more likely to be related to the 
underlying health status (Wannamethee et al. 2001). We therefore excluded 
participants who died shortly after the study baseline visits in the analysis, as did 
a previous study (Corrada et al. 2006), and included only subjects who were alive 
at the 5-year follow-up visit with a minimum follow-up duration of 4 years. We 
also consider possible effect modification of disease status as well as medication 
used on BMI but found no evidence of their interactions with either baseline pre-
existing disease status (no disease, prevalent disease) or status of pre-existing 
disease over 5-year follow-up (no disease, prevalent disease, incident disease). 
These analyses do not exclude the possibility that other disease could have 
developed during follow up that could have resulted in both weight loss and 
increased mortality. Considering only subjects who were free of pre-existing 
disease at baseline, obesity was found to be associated with cancer death only 
among the subgroup of healthy subjects aged ≤ 70 years.  
It is postulated that BMI and its changes may be associated with different 
causes of death such as cardiovascular- and cancer-deaths which are regarded as 
competing risks. Therefore, in such situations, it is important to apply an 
appropriate statistical technique such as the competing risks methods, to 
appropriately account for each competing risk in the analysis, to yield a more 




Importantly, consistent with previous studies (Tai et al. 2001; Wolbers et 
al. 2009; Tai et al. 2010; Tai et al. 2011a; Tai et al. 2011b), when we analyzed the 
relationship between baseline BMI and its 5-year changes using cause-specific 
Cox regression model, the effect estimates were larger than those of the 
competing risks model by as much as 1-33%. The differences were appreciable 
especially in the older age group for cancer- (31%) and cardiovascular-death 
(33%). This finding suggests that as population ages, the presence of competing 
risks would be more common especially among the frail population. Hence, we 
encourage the use competing risks models as a standard tool for developing 
predictive models involving competing risks endpoints especially among elderly 
population, to provide a more accurate estimate of exposure (Wolbers et al. 2009). 
The specific limitations of this study need to be considered. First, there 
was limited number of underweight subjects resulting in low statistical power. 
Thus, the findings relating to the underweight should be interpreted with caution. 
In addition, the possibility of Type II error may exist especially when we analyzed 
the data amongst the subgroup of healthy subjects. Further, when the P-value 
reported in our study is less than 0.05, we may make Type I error due to chance as 
several endpoints and subgroups were evaluated. Second, the results could have 
been biased by residual confounding factors, such as varying levels of body 
composition, visceral adiposity or physical fitness (Flegal et al. 2005), which were 
not measured in this study. Third, we had no information about whether BMI loss 
was achieved intentionally or unintentionally. Fourth, as mentioned in Chapter 3, 
the cause of mortality which was determined by the NDI and the death certificates 
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may be biased by the choices of the physicians who filled them out. The strengths 
of this study are as discussed in Chapters 2 and 3.  
In conclusion, we have shown that the pattern and association between 
BMI and mortality are modified by age. Amongst the younger subjects, the 
relationship between baseline BMI and all-cause mortality was U-shaped, with 
both the underweight and obese groups predisposed to have a greater risk of 
death. Amongst elderly persons, an L-shaped relationship was seen: only low but 
not excessive BMI was found to be associated with increased risk of all-cause 
death. Moreover, obesity was associated with greater risk of all-cause and 
cardiovascular-specific mortality amongst subjects ≤70 years old. With respect to 
changes in BMI over 5 years, BMI reduction, a marker of greater severity of 
mortality-related diseases, was associated with increased risk of all-cause 
mortality regardless of age, and cancer-related mortality amongst subjects aged 
≤70 years. Competing risk model appears to provide more accurate and precise 










CHAPTER 5— Metabolic Syndrome and Risk of Age-related Cataract over 
Time: An Analysis of Interval-Censored Data using Random Effects Model                                                                             
SUMMARY 
This study aims to investigate whether the effect of MetS and its components on 
the incidence of different cataract sub-types (cortical, nuclear and posterior 
subcapsular cataract [PSC]) change with time. In this study, the occurrence of 
cataract is said to be interval-censored since the event was only known to occur 
between two assessment periods, that is, between baseline and 5-year or between 
5- and 10-year follow-up. To deal with interval-censoring, the random effects 
complementary log log model was implemented. In order to evaluate whether 
accounting for further follow-up information of MetS and its components would 
provide a more accurate and efficient estimate of their relationships with age-
related cataract, the logistic regression was performed to evaluate the association 
between baseline MetS and its components with the 10-year cumulative incidence 
of age-related cataract. It showed that baseline MetS was linked to an increased 
risk of 10-year cumulative incidence of cortical and PSC cataract. The 
complementary log-log model showed that changes in MetS were associated with 
the 5-year incidence of cortical and PSC cataract. Different MetS components 
were associated with the incidence of different cataract sub-types at varying time-
intervals. This underscores the importance of fully accounting for covariate 
information collected at each follow-up visit in order for physicians to better 
predict the risk of different cataract sub-types in older persons at varying time-






5.1 Types of cataract  
A cataract is a clouding of the natural intraocular crystalline lens that focuses the 
light entering the eye onto the retina. This cloudiness can cause a decrease in 
vision and may lead to eventual blindness if left untreated. Cataracts often 
develop slowly and painlessly, so vision and lifestyle can be affected without a 
person realizing it. There are three principal cataract sub-types:  
1. Nuclear cataract or nuclear sclerosis is the most common type of cataract 
that occurs in age-related cataract and in patients with diabetic mellitus. It 
occurs in the centre of the lens.  
2. Cortical cataract is the second most common cataract and from its name it 
occurs in the cortex or the outer part of the lens.  
3. PSC cataract occurs in the posterior part of the lens and it occurs mostly 
with corticosteroid. However, it can occur also in diabetic patients.  
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Sometimes more than one of the above described varieties of cataract may 
occur together in a lens. In general, a cataract will start as one type but eventually 
become mixed as the other lens regions become involved in the degenerative 
process (http://www.online-eye-info.com/cataract-definition.html).  
 
5.2 Literature review on the relationship between metabolic syndrome and 
its components with age-related cataract 
Table 5.1 summarizes the literature review on the association between MetS and 
age-related cataract. A survey in Lithunia showed a significant and positive 
association between any cataract and MetS in women aged 45-64 years 
(Paunksnis et al. 2007). The BMES, using the WHO criteria for defining MetS, 
reported baseline MetS to be associated with increased risk of all three types of 
cataract namely, cortical, nuclear and PSC cataract (Tan et al. 2008d). A cross-
sectional study amongst Malay in Singapore found that MetS was positively 
associated with prevalent cortical cataract (Sabanayagam et al. 2011). 
 
Table 5.1  Association between metabolic syndrome and age-related cataract 
Study, 
year 




Odds ratio (95%CI) 
 
 








NCEP Any cataract: 1.59 (0.77-3.26) 




Australia 1920 ≥ 49 WHO 1.73(1.12-2.68) 1.71(1.07-2.73) 1.94(1.07-3.54) 
Sabanayag
am, 2011  
Singapore 2794 40-80 NCEP 1.48(1.23-1.79) 0.83(0.66-1.05) 1.12(0.90-1.40) 
CI=confidence interval; F=female; M=male; Mets=metabolic syndrome; PSC=posterior subcapsular cataract; 
WHO=World Health Organization; NCEP=National Cholesterol Education Program. 
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Table 5.2 shows the literature review on the association between MetS 
components and age-related cataract. Paunksnis et al. (2007) showed that cataract 
was significantly associated with central obesity for men aged 55-64 years, and 
with central obesity, higher arterial pressure and elevated level of serum 
triglycerides in women aged 45-64 years. The BMES also showed baseline 
impaired fasting glucose (IFG) and diabetes to predict cortical and nuclear 
cataract respectively. Each SD increase in glucose and BMI were also positively 
associated with cortical and PSC cataract respectively (Tan et al. 2008d). 
Moreover, Sabanayagam et al. (2011) found high BP was positively associated 
with all three cataract types; diabetes was associated with cortical and PSC 
cataract; and low HDL and BMI ≥ 25 kg/m2 were associated with cortical 
cataract. However, BMI ≥ 25 kg/m2 was a protective factor for nuclear cataract.  
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   Table 5.2 Association between metabolic syndrome components and age-related cataract 
Study, year Place N Age 
(year) 
Mets components Cortical 
Odds ratio (95% CI) 
Nuclear 
Odds ratio (95% CI) 
PSC 
Odds ratio (95% CI) 




























Australia 1920 ≥49 IFG 
Glucose per unit increase 
Diabetes  













Sabanayagam, 2011  Singapore 2794 40-80 BP 
Diabetes 
BMI ≥25  
HDL 
1.46 (1.18-1.81) 
2.28 (1.83-2.83)   















5.3 Significance of study  
Age-related cataract is a leading cause of blindness and poor vision and a major 
public health concern globally (Attebo et al. 1996). Worldwide, cataract is the 
number one cause of preventable blindness. There is no medical treatment to 
prevent the development or progression of cataract. Several studies have found 
associations between age-related cataract and increased risk in mortality (Hennis 
et al. 2001). This suggests that cataract may share similar pathogenesis with 
systemic diseases associated with ageing and reduced survival, particularly CVD 
(Tan et al. 2008d).  
So far, a few studies have investigated the association between cataract 
and MetS, and whether some individual components are more important risk 
factors than others for specific cataract sub-types. While Tan et al. (2008d) found 
MetS was a significant risk factor for all three subtypes of cataract, Sabanayagam 
et al. (2011) found MetS to be a risk factor for cortical cataract only. Further, both 
studies have reported that baseline BMI, high BP, diabetes or low HDL to be 
associated with age-related cataract, while Paunksnis et al. (2007) suggested 
elevated serum TG was a predictor of cataract among women.  
However, there are a number of unanswered questions. First, previous 
studies used different definitions for MetS, namely, WHO and NCEP ATP-3, and 
it has been reported that these definitions were not as successful in predicting 
diabetes, cardiovascular disease and other health outcomes (Balkau and Charles 
1999; WHO 1999; NCEP 2001; Stern et al. 2004). Thus in this study, we define 
MetS based on the IDF criteria (Alberti et al. 2006). Second, previous studies, 
105 
 
including earlier report of BMES (Tan et al. 2008d) used only MetS data at 
baseline in the evaluation of its relationship with cataract. However, experimental 
studies in rats and human have shown that the effect of glucose and lipid 
abnormalities on cataract formation may change over time (Jacob and Mason 
2005; Kyselová et al. 2005). This therefore underscores the importance of 
collecting further information on glucose and lipid abnormalities beyond baseline 
measurements to better detect cataract formation.  
In order to evaluate whether accounting for further follow-up information 
of MetS and its components in addition to baseline information would provide a 
more accurate and efficient estimate of their relationships with age-related 
cataract, the logistic regression was firstly performed to examine the association 
between baseline MetS and its components with the 10-year cumulative incidence 
of age-related cataract. In this study, repeated measures of MetS and its 
components have been shown to be highly correlated. As such, it is natural to 
apply statistical technique which appropriately accounts for intra-subject 
correlation, to yield a more robust estimate of the effect of MetS and its 
components on subtypes of cataract. Further, since the outcome, different cataract 
sub-types, was measured in discrete time interval, we implement the random 
effects complementary log-log regression as it would be more appropriate for 
detecting stronger and more robust relationships (Neuhaus 1992; Rabe-Hesketh 
and Skrondal 2008) between individual MetS components than the logistic 
regression as used in previous studies. Thus to evaluate the effect of MetS and its 
components on the incidence of different age-related cataract sub-types (namely 
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cortical, nuclear and PSC) more precisely, and to determine whether these 
associations differed at varying time intervals (i.e. 0-5 years or 5-10 years), we 
utilized full information that was collected at each follow-up and implemented 
appropriate statistical models to better describe the relationships.  
 
5.4 Methods 
Study design and population 
A detailed description of the study design and population of the BMES has been 
provided in Chapter 2. In brief, the BMES is a population-based prospective 
cohort study of vision, common eye diseases and other health outcomes in a 
suburban Australian population west of Sydney (Mitchell et al. 1998a). Between 
1992 and 1994, non-institutionalized permanent residents aged 49 years and older 
were invited to participate, and were requested to return for follow-up 
examinations after 5 (1997-1999) and 10 years (2002-2004). A total of 2564 
participants were examined for eye examination at least once after baseline (Tan 
et al. 2008d). Of these, 1997 subjects with complete information for the study 
factors namely, MetS and its components, age, sex, smoking status, pre-existing 
cardiovascular diseases, patient‘s history of eye diseases and family history of eye 
disease, family history of blindness, eye iris color and skin sun-tanning 
characteristics at baseline contributed to the analysis of age-related cataract. 
Specifically, 1820 individuals contributed information for the analysis of cortical 





A detailed description of the data collection has been provided in Chapter 2. 
Briefly, at each visit, trained interviewers completed a comprehensive 
questionnaire comprising demographic information, eye and general medical 
history including hypertension, diabetes, and cardiovascular pre-existing diseases 
(namely, angina, acute AMI and stroke) as well as medication used. Height, 
weight and seated BP
 
(WHO 2003) were measured. Fasting pathology tests, 
including HDL cholesterol, TG (Cugati et al. 2007) and FPG (WHO 1999) were 
also measured within two months of each interview. In addition, information on 
smoking (never, former and current smoker) and alcohol intake were collected. 
Moreover, history of eye diseases including cataract, AMD, myopia and 
glaucoma as well as family history of eye disease or blindness were obtained and 
recorded (Tan et al. 2008d). Eye iris color and skin sun-tanning characteristics 
were also estimated on a 4-point scale (Always burn, never tan; Usually burn, tan 
with difficulty; Burn and tan above average; Rarely burn, tan above average) 
(Mitchell et al. 1998b).   
 As mentioned in Chapter 2, we define MetS according to the IDF criteria 
(Zimmet et al. 2005) as obesity (ie. BMI units >30 kg/m
2
) plus any two of the 
following four factors:  
v. TG ≥1.7 mmol/L or specific treatment for this lipid abnormality;  
vi. HDL cholesterol  <1.03 mmol/L in men and <1.29 mmol/L in women, or 
specific treatment for this lipid abnormality;  
108 
 
vii. Systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg, or treatment of 
previously diagnosed hypertension; or  
viii. FPG ≥5.6 mmol/L, or previous diagnosis or specific treatment for type 2 
diabetes. 
Cataract grading  
All participants examined underwent a detailed eye examination, which included 
subjective refraction using a LogMar chart. The type and extent of the three major 
types of cataract (nuclear, cortical and PSC) were assessed by graders from two 
types of lens photographs taken during the study using Ektachrome 200 color film 
(Kodak, Rochester, New York). The protocol developed from the Beaver Dam 
Eye Study (Klein et al. 1990a) was followed closely. Slit-lamp photographs of the 
lens katen using the Topcon SL-7E photograph slit-lamp camera (Topcon Optical 
Co., Tokyo, Japan) were used to assess nuclear cataract. Retroillumination lens 
photographs, taken using the Neitz CT-R cataract camera (Neitz Instruments Co., 
Tokyo, Japan) were used to assess cortical and posterior subcapsular opacities. 
Both cameras had fixation target modifications provided courtesy of Michael 
Neider, University of Wisconsin Madison (Magli et al. 1990).   
 The population at risk for cataract comprised participants who had at least 
one follow-up visit, but whose lens photographs were retrospectively shown not 
to show signs of cataract at baseline. They also had complete information to 
define MetS at baseline. Different sub-types of cataract were determined using 
standard photographic grading at each of the three examinations. The Wisconsin 
Cataract Grading System was used to perform masked grading of the lens 
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photographs. Two masked graders used a five-point scale to assess the presence 
and severity of nuclear cataract by comparing participant photographs of each eye 
with the set of four Wisconsin standards (Klein et al. 1990b). A decimalized 
system of nuclear grading was also employed, (Bailey et al. 1991) in which the 
grader estimated the score on a continuous scale between each standard (e.g., 3.8). 
Nuclear cataract was defined as nuclear opacity worse than standard 3. The 
presence and severity of cortical lens opacities were graded from Neitz 
photographs using a circular circle. Graders estimated the percentage of area in 
each of the nine segments involved by cortical opacities. The presence and 
severity of PSC cataract were also recorded if any definite typical PSC cataract 
was present on the Neitz photographs. Both the nuclear standards and the grid for 
assessing cortical and PSC opacities were provided by Dr. Barbara E. K. Klein, 
University of Wisconsin-Madison. Cortical opacity involving at least 5% of the 
total lens area or the presence of any PSC opacity was used to define the presence 
of the respective cataract sub-types (Tan et al. 2008d). Thus, distinct types of 
cataract were categorized and analyzed independently. 
Reproducibility  
Intergrader and intragrader reproducibilities of lens grading were assessed by the 
BMES group using quadratic weighted kappa (K) statistics (Kanthan et al. 2008). 
Of note, Quadratic Weighting is formulated as follow: 









where i-j is the difference between the row category on the scale and the column 
category on the scale (the number of categories of disagreement), for the cell 
concerned, and k is the number of points on the scale (Sim and Wright 2005). 
A single grader assessed baseline cortical cataract and PSC, with 
adjudication provided by a senior ophthalmologist. Two graders performed 
nuclear cataract grading of both the baseline and 5-year follow-up lens 
photographs. Weighted K for intragrader and intergrader reliability were above 
0.70 for all cataracts. The 10-year follow-up photographs were graded by one 
examiner for all 3 types of cataract, with all positive cortical cataract cases also 
graded by another senior grader and nuclear cataract and PSC cases also graded 
by a senior researcher. The same examiner graded a random sample of baseline 
photographs to compare intergrader reproducibilities. This gave weighted K 
values above 0.70 for cortical and PSC cataract and 0.52 for nuclear cataract 
(Kanthan et al. 2008).  
Statistical analyses 
The logistic regression was performed to evaluate the association between 
baseline MetS and its components with the 10-year cumulative incidence of age-
related cataract. As mentioned in Chapter 1, an individual's MetS and cataract 
status were prospectively evaluated at pre-defined time intervals (ie. baseline, 5- 
and 10-year). Hence, the exact time that cataract developed was not known. Such 
information was interval-censored, and thus the effect of 10-year changes in MetS 
and its components on the incidence of each cataract sub-type was modeled using 
a random effects complementary log-log regression model (Neuhaus 1992; Rabe-
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Hesketh and Skrondal 2008). This statistical technique is readily available for 
survival analysis with discrete time, and is one of the most frequently used 
discrete-time hazard functions (Singer and Willett 2003). In this study, the 
outcomes of interest, time-to-development of different cataract sub-types, were 
included in the model based on discrete-time intervals (i.e. 0-5 years or 5-10 
years), in accordance to the follow-up schedule. This approach includes indicator 
variables for the examination time-interval (0-5, 5-10 years) as covariates (Allison 
1982; Neuhaus 1992; Lecaire et al. 2006; Rabe-Hesketh and Skrondal 2008). The 
random effects model accounts for possible intra-subject correlation in the 
assessment of MetS and its components which were repeatedly measured at 
baseline, 5- and 10-year.  
In the simplest form the random-effects complementary log-log regression 
model for cataract can be modelled as follow:     
log[-log{1 - Pij(t)}]= β0
*
 + βMetS MetSij + ij 
where Pij(t) is probability of developing cataract at time t for an individual i at the 
j
th
 visit. This model is fitted assuming a random intercept, β0
*
, and the slope 
parameter, βMetS, is considered as a fixed effect. The component, ij, estimates the 
SD of the random intercept and the residual variation. It can be extended to allow 
the slope to assume a random effect as well as to adjust for other covariates 
(Collett 2003). 
 Of note, when the dichotomous outcome is rare, the complementary log-









have suggested that when a binary outcome is common, the 
complementary log-log regression model may also fit the data well.  
 Age, sex, smoking, pre-existing disease (namely angina, AMI and stroke), 
family history of eye disease (namely; cataract, AMD, myopia, glaucoma and 
blindness), history of eye disease (namely AMD, myopia and glaucoma), eye iris 
color and skin sun-tanning characteristics, were considered as possible 
confounders in the model building. Furthermore, we included interactions 
between MetS (as well as its components) and the time-interval in order to 
evaluate whether its relationship with the different cataract sub-types varied 
according to the 5- and 10-year time-intervals (Allison 1982; Lecaire et al. 2006). 
We further explored possible interaction between age and sex with MetS and its 
components. It should be noted that for each cataract sub-type, the control group 
included participants without the same cataract sub-type.  
 
5.5 Results 
Description of study population 
Table 5.3 presents the baseline characteristics of the study subjects according to 
the cumulative incidence of cataract at 10 years. Over the 10-year follow-up, 857 
(42.9%) persons developed incident cataract. Of these, 455 (25.0%) were cortical 
cataract, 436 (32.1%) were nuclear cataract and 135 (6.9%) were PSC cataract.  
 Of the 455 persons with incident cortical cataract, 242 (53.2%) had more than 
5% and less than 10% severity and 213 (46.8%) had 10% or more severity in the 
worse eye. Of the 135 persons with incident PSC cataract, 104 (77.0%) had less 
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than 5% severity and 31 (23.0%) had 5% or more severity in the worse eye. The 
mean age of participants was 63.9 (SD 8.3) years with a female predominance 
(57.7%).  
 
Table 5.3 Baseline characteristics of study population according to 10-year cumulative 








Baseline mean age (SD) 63.9 (8.3) 62.3 (8.3) 65.9 (7.8) < 0.001 
Sex (%),     Male  








Family history of blindness (%) 83 (4.2) 39 (3.4) 44 (5.1) 0.058 
Family history of any eye disease (%)
a
 643 (32.2) 366 (32.1) 277 (32.3) 0.918 




400 (20.0) 221 (19.4) 179 (20.9) 0.407 
Pre-existing disease (%)
c
 308 (15.4) 161 (14.1) 147 (17.2) 0.064 
Smoking status (%),   Non-smoker 
                                   Ex-smoker       











Eye iris color (%),      Blue 
                                   Hazel/Green 
                                   Tan/Brown  














Sun skin-burned (%) 
      Always burn, never tan 
      Usually burn, tan with difficulty 
      Burn and tan above average  


















MetS (%) 246 (12.3) 119 (10.4) 127 (14.8) 0.004 
BMI >30 (%) 346 (17.3) 173 (15.2) 173 (20.2) 0.004 
High glucose (%)
d
 306 (15.3) 149 (13.1) 157 (18.3) 0.001 
Low-HDL (%)
e
 591 (29.6) 318 (27.9) 273 (31.9) 0.055 
High triglyceride (%)
f
 815 (40.8) 461 (40.4) 354 (41.3) 0.713 
High BP (%)
g
 1689 (84.6) 941 (82.5) 748 (87.3) 0.004 
BMI=body mass index; BP=blood pressure; MetS=metabolic syndrome. 
aIncludes family history of cataract, glaucoma, macular and blindness, bIncludes history of age-related 
macular degeneration, myopia and glaucoma at baseline, cIncludes history of angina, stroke and acute 
myocardial infarction at baseline, dfasting plasma glucose ≥5.6 mmol/L, or previous diagnosis or specific 
treatment for type 2 diabetes; eserum HDL cholesterol <1.03 mmol/L in men and <1.29 mmol/L in women, or 
specific treatment for this lipid abnormality; fserum triglyceride level ≥1.7 mmol/L or specific treatment for 
this lipid abnormality; gsystolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or 
treatment of previously diagnosed hypertension. 
 
   
Figure 5.1 shows the changes in MetS and its components at baseline, 5- 
and 10-year follow-up among individuals with different cataract sub-types. 
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Generally, a lower proportion of individuals with nuclear cataract had MetS or its 
components as compared with cortical or PSC cataract. MetS increased from 
baseline to 5-year follow-up and decreased by 10-year follow-up for all 3 
subtypes of cataract. This may be due to people with MetS dying after 5-year 
follow-up and decreased prevalent MetS at 10-year follow-up. 
 
Figure 5.1 Changes in prevalent metabolic syndrome and its components among 
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Baseline MetS and its components and 10-year cumulative incidence of age-
related cataract 
After controlling for age, sex, eye disease at baseline, pre-existing disease at 
baseline and family history of blindness, baseline MetS (HR 1.44, 95% CI: 1.06-
1.96) and high glucose (HR 1.52, 95% CI: 1.15-2.03) were linked to an increased 
risk of the 10-year cumulative incidence of cortical cataract (Table 5.4). There 
was no evidence of association between baseline MetS and any of its components 
with the 10-year cumulative incidence of nuclear cataract. However, MetS was 
found to be associated with the 10-year cumulative incidence of PSC cataract (HR 
1.76, 95% CI: 1.11-2.78) (Table 5.4). 
 
Table 5.4 Effects of baseline MetS and its components on the 10-year cumulative 
incidence of age-related cataract  





 HR (95% CI)
 a
 HR (95% CI)
 a
 
MetS 1.44 (1.06-1.96)* 1.25 (0.86-1.81) 1.76 (1.11-2.78)* 
BMI >30 1.26 (0.96-1.66) 1.30 (0.95-1.79) 1.32 (0.85-2.03) 
Elevated glucose
b
 1.52 (1.15-2.03)** 1.14 (0.81-1.60) 1.41 (0.90-2.21) 
Low-HDL
c
 1.23 (0.97-1.56) 1.00 (0.75-1.30) 1.40 (0.96-2.05) 
Hyper TG
d
 1.15 (0.93-1.44) 0.89 (0.69-1.15) 1.21 (0.85-1.73) 
High BP
e
 0.94 (0.70-1.28) 1.41 (0.95-2.07) 1.04 (0.61-1.76) 
BP=blood pressure; BMI=body mass index; CI=confidence interval; HR=hazard ratio; MetS=metabolic 
syndrome; PSC=posterior subcapsular cataract; TG=triglycerides.  
aAdjusted for age, sex, eye disease at baseline (namely: myopia, macular and glaucoma), pre-existing disease 
at baseline (namely: acute myocardial infarction, angina and stroke) and family history of blindness. 
bfasting plasma glucose ≥5.6 mmol/L, or previous diagnosis or specific treatment for type 2 diabetes; cserum 
HDL cholesterol <1.03 mmol/L in men and <1.29 mmol/L in women, or specific treatment for this lipid 
abnormality; dserum triglyceride level ≥1.7 mmol/L or specific treatment for this lipid abnormality; esystolic 
blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or treatment of previously diagnosed 






MetS and its components and the incidence of age-related cataract at varying 
time-interval 
We found MetS (HR 1.48, 95% CI: 1.05-2.09), BMI >30 kg/m
2
 (HR 1.59, 95% 
CI: 1.16-2.17) and elevated glucose (HR 1.60, 95% CI: 1.15-2.23) to be 
associated with increased 5-year incidence of cortical cataract, while, low-HDL 
cholesterol (HR 1.57, 95% CI: 1.10-2.24) was associated with an excess in 
incidence of cortical cataract at 10-year (Table 5.5). 
 
 
Table 5.5 Effect of MetS and its components on the incidence of age-related cataract 








 HR (95% CI)
 a
 HR (95% CI)
 a
 
Incidence at 5-year 
 
MetS 1.48 (1.05-2.09)* 1.01 (0.75-1.36) 1.75 (1.01-3.04)* 
BMI >30 1.59 (1.16-2.17)** 0.84 (0.64-1.10) 1.30 (0.76-2.20) 
Elevated glucose
b
 1.60 (1.15-2.23)** 1.13 (0.87-1.56) 1.59 (0.93-2.72) 
Low-HDL
c
 1.14 (0.82-1.58) 0.94 (0.73-1.22) 1.43 (0.84-2.45) 
Hyper TG
d
 1.09 (0.82-1.44) 0.98 (0.78-1.23) 1.44 (0.90-2.32) 
High BP
e
 1.12 (0.67-1.89) 1.08 (0.70-1.68) 1.10 (0.44-2.74) 
Incidence at 10-year  
 
MetS 1.40 (0.88-2.20) 0.93 (0.54-1.61) 1.39 (0.70-2.76) 
BMI >30 1.44 (1.00-2.09) 1.24 (0.84-1.86) 1.52 (0.89-2.60) 
Elevated glucose
b
 1.24 (0.79-1.97) 1.30 (0.81-2.08) 1.90 (1.01-3.61)* 
Low-HDL
c
 1.57 (1.10-2.24)* 1.03 (0.69-1.54) 1.45 (0.85-2.46) 
Hyper TG
d
 0.76 (0.49-1.16) 0.97 (0.63-1.51) 1.50 (0.81-2.76) 
High BP
e
 0.96 (0.63-1.47) 1.27 (0.75-2.15) 1.11 (0.56-2.19) 
BP=blood pressure; BMI=body mass index; CI=confidence interval; HR=hazard ratio; MetS=metabolic 
syndrome; PSC=posterior subcapsular cataract; TG=triglycerides.  
aAdjusted for age, sex, eye disease at baseline (namely: myopia, macular and glaucoma), pre-existing disease 
at baseline (namely: acute myocardial infarction, angina and stroke) and family history of blindness. 
bfasting plasma glucose ≥5.6 mmol/L, or previous diagnosis or specific treatment for type 2 diabetes; cserum 
HDL cholesterol <1.03 mmol/L in men and <1.29 mmol/L in women, or specific treatment for this lipid 
abnormality; dserum triglyceride level ≥1.7 mmol/L or specific treatment for this lipid abnormality; esystolic 
blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or treatment of previously diagnosed 




However, there was no association between MetS or any of its 
components with the incidence of nuclear cataract at either 5 or 10 years, even 
after accounting for information of MetS and its components at baseline and 
subsequent follow-up visits as well as controlling for confounders. 
Similarly, MetS was associated with an increase in 5-year incidence of 
PSC cataract (HR 1.75, 95% CI: 1.01-3.04), whereas elevated glucose was 
associated with an increase in 10-year incidence of PSC cataract (HR 1.90, 95% 
CI: 1.01-3.61) (Table 5.5).  
 
5.6 DISCUSSION 
In this prospective cohort study of an Australian white population participating in 
the BMES, we found the following: First, after accounting for baseline and further 
follow-up information on MetS and its components as defined by the IDF criteria, 
MetS, elevated glucose and BMI >30 kg/m
2
 contributed to an increase in 5-year 
incidence of cortical cataract, while low-HDL cholesterol was linked to an 
increase in 10-year incidence of cortical cataract. Second, MetS and elevated 
glucose were positively associated with the incidence of PSC cataract at 5-year 
and 10-year, respectively. 
The association between elevated glucose and the incidence of cortical and 
PSC cataract at different time-intervals, suggests that glucose was associated with 
late incidence of PSC cataract, and early incidence of cortical cataract. 
Mechanisms connecting hyperglycemia with cataract include advanced glycation 
of lens proteins (Stitt 2001), hyperosmotic effects of sorbitol on lens fibers via the 
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aldose reductase pathway (Kador and Kinoshita 1984) with induction of apoptosis 
in lens epithelial cells leading to the development of cataract (Pollreisz and  
Schmidt-Erfurth 2010).  
Additionally, our study demonstrated that BMI >30 kg/m
2
 was associated 
with the 5-year incidence of cortical cataract, suggesting that the contribution of 
obesity to cortical cataract formation may reduce over time. In the Singapore 
Malay Eye Study (Sabanayagam et al. 2011) and the study by Lim et al. (2009), 
baseline BMI have been shown to contribute to a higher risk of cortical cataract 
and PSC cataract (Lim et al. 2009). The underlying mechanism behind the 
relationship between obesity and cataract is unclear (Cheung and Wong 2007). 
To-date, there has not been any study that examined how changes in BMI over 
time would affect cataract formation. However, it has been suggested that obesity 
was related to cataract by its associated complications such as diabetes,
 
glucose 
intolerance, insulin resistance, hyperlipidemia, inflammation and hormonal 
differences (Cheung and Wong 2007). Moreover, it has been shown that the 
relationship between glucose and cholesterol with cataract formation changed 
over time (Jacob and Mason 2005; Kyselová et al. 2005). Therefore, this may 
partly explain why the relationship between obesity and incidence of cataract may 
also change with time.  
  Studies have suggested that inflammation and oxidative stress resulting 
from low-HDL cholesterol levels might contribute to cataract formation (Varma 
et al. 1984; Klimov et al. 1993; von Eckardstein et al. 2005). Our finding has 
shown an association between low-HDL cholesterol and an excess in 10-year 
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incidence of cortical cataract, suggesting that it takes a longer observation time 
for low-HDL cholesterol to be confirmed as a predictor of cortical cataract. 
Previous BMES report which considered only baseline information using logistic 
regression (Tan et al. 2008d) failed to detect such a relationship. This finding thus 
suggests the importance of full utilization of baseline and follow-up data, to better 
describe the discrete time-to-development of cataract using random-effects 
complementary log-log model.  
Finally, as a specific entity, our finding demonstrated a positive 
association between MetS and 5-year incidence of cortical and PSC cataract. In 
particular, MetS as a whole rather than its individual components, best predicted 
PSC cataract at 5 years. Interestingly, when we considered only the effect of Mets 
components at baseline without accounting for its changing status at follow-up, 
we did not detect any effects of BMI or low-HDL cholesterol on cortical cataract 
even after adjusting for age, sex, eye-diseases and pre-existing disease status. 
Therefore, the effects of MetS and its components on the incidence of cortical 
cataract at different time-intervals would not have been detected if we had only 
utilized the baseline data.  
However, based on previous report of BMES (Tan et al. 2008d), MetS as 
defined by the WHO criteria, was a predictor of nuclear cataract, although our 
study did not confirm this association. We further analyzed the data by defining 
MetS based on the WHO criteria in accordance with previous report of BMES. 
Using the random-effects complementary log-log regression model, regardless of 
whether the IDF and WHO criteria was used, similar results were reported for 
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nuclear cataract. There was no association between MetS or any of its 
components with the incidence of nuclear cataract at either 5 or 10 years, even 
after accounting for information on MetS and its components at baseline and 
subsequent follow-up visits, despite adjustment for confounders (result not 
shown). Therefore, this difference between our study and the study by Tan et al. 
(2008d) may be due to differences in technique and sample size. Moreover, BMI 
has been shown to have different relationships with nuclear cataract, with lower 
BMI being an independent risk factor for nuclear cataract (Cheung and Wong 
2007).
 
This suggests the possibility of distinct etiological pathways for different 
cataract sub-types (Cheung and Wong 2007). Since obesity was a mandatory 
component in defining MetS in our study, this may partially explain why there 
was no effect of MetS on nuclear cataract.  
The specific strengths of this study include (1) applying random effects 
complementary log-log regression model which can detect stronger and more 
robust relationships (Neuhaus 1992; Rabe-Hesketh and Skrondal 2008) between 
individual MetS components and cataract sub-types where occurrences are 
measured in discrete time interval, and (2) cataract diagnosis based on 
standardized lens photographic grading, which have been shown to have high 
reproducibility (Panchapakesan et al. 1997; Kanthan et al. 2008). However, some 
specific drawbacks should also be noted. Statistical significance was not achieved 
for the relationship between MetS components and PSC cataract, mainly because 
of the lack of statistical power due to the limited number of PSC cases. This 
warrants further investigation in studies with more PSC cases.  
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In conclusion, changes in MetS were associated with the 5-year incidence 
of cortical and PSC cataract. Different MetS components were associated with the 
incidence of different cataract sub-types at varying time-intervals. This 
underscores the importance of fully accounting for the data on MetS components 
collected at each follow-up visit in order for physicians to better predict the risk of 




















CHAPTER 6- Metabolic Syndrome and Risk of Age-related Macular 
Degeneration  
SUMMARY 
This study aims to investigate the relationship between metabolic syndrome 
(MetS) and its components with the risk of early and late stage age-related 
macular degeneration (AMD). Individuals aged ≥ 49 years were followed up over 
a period of 10 years in the Blue Mountains Eye Study. The outcomes and main 
exposure of interest, namely early or late stage AMD as well as MetS and its 
components respectively, were measured at baseline, 5- and 10-year follow-up. 
Conventional logistic regression was used to evaluate the relation between 
baseline MetS with 10-year cumulative incidence of early or late AMD. To 
explore the relationship between MetS with subsequent development of early or 
late AMD during 10-year follow-up, the mixed-effects logistic regression was 
implemented to account for intra-subject correlation which arose with repeated 
measurement. The logistic regression model found only baseline glucose to be 
associated with 10-year cumulative incidence of late AMD amongst those aged   
≤70 years. The mixed-effects logistic model showed that amongst subjects aged  
≤70 years, MetS, obesity, high glucose and high TG were associated with 
increased incidence of late AMD during the 10-year follow-up.  Full utilization of 
follow-up data via the mixed model provides a more robust and stronger 
relationship between MetS (and its components) with late AMD in comparison 
with the conventional logistic regression model. These data also provide 




6.1 Forms of age-related macular degeneration 
AMD is a disease affecting the elderly that gradually destroys the macula 
resulting in loss of sharp, central vision. The retina is the light-sensitive tissue at 
the back of the eye, similar to that of a film in a camera. It is made up of many 
cells, called photoreceptors. Images are captured by these photoreceptors on the 
retina or 'film'. They are converted to nerve signals and sent to the brain to be 
viewed as pictures. The centre of the retina is called the macula. It enables us to 
see fine detail and differentiate colour. It also enables us in our daily detailed 
activities like reading, writing and driving (Alfaro 2006).  
There are two forms of AMD: Dry and Wet (Alfaro 2006):  
 Dry or non-exudative AMD is the more common form, affecting 
majority of patients with AMD, and has three stages — early, 
intermediate, and advanced. The pathogenesis of macular degeneration has  
always been a confounding aspect of the disease. However, recently, other 
processes of macular degeneration have been hypothesized. These include: 
oxidative damage, abnormal lipid metabolism, apoptosis, structural 
abnormalities of photoreceptor outer segments, dysfunction of ion 
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channels in the retinal pigment epithelium, choroidal neovascularization, 
abnormalities of the extracellular matrix and variation in the immune 
system (Stone 2007). As a person gets older, these photoreceptors slowly 
fail to function properly. This results in abnormal deposits or debris called 
drusen, and is one of the most common early signs of dry AMD to 
accumulate under the retina. Fortunately, these deposits rarely cause visual 
loss or blindness. However, in some patients, the photoreceptors slowly 
degenerate with time, resulting in an advanced form of dry AMD called 
geographical atrophy (GA). In a small group of patients, drusen can 
progress to develop to wet AMD. The GA is the advanced (late) form of 
dry AMD.  
 Wet or exudative AMD accounts for 10 to 15% of cases of late AMD. 
This is due to growth of abnormal blood vessels under the retina called 
choroidal neovascularization. These new blood vessels are very fragile and 
may leak fluid or blood. This results in scarring that causes rapid and 
severe visual loss. Neovascular or exudative AMD is the ―wet‖ form of 
advanced (late) AMD.  
Both advanced form of dry AMD and wet AMD can cause visual loss. 
 
6.2 Literature review on the relationship between cardiovascular disease risk 
factors and age-related macular disease  
Table 6.1 summarizes the relationship between CVD risk factors and AMD. A 
cross-sectional study of the BMES showed that obesity was the only factor which 
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was significantly and positively associated with prevalent early AMD (Smith et 
al. 1998). The BMES also showed that only prevalent GA, a subtype of late 
AMD, was significantly and positively associated with diabetes (Mitchell and 
Wang 1999). Yet again, the BMES indicated that increasing HDL cholesterol was 
inversely related to incident late AMD per SD increase. Elevated total/HDL 
cholesterol ratio was associated with late AMD and GA, while diabetes was 
associated with incident GA, but not neovascular AMD, a subtype of late AMD 
(Tan et al. 2007). 
  Moreover, in a population based study of residents of Séte (South of 
France), obese subjects were found to have increased risk of late AMD in 
comparison with lean subjects. The risk of soft drusen, a subtype of early AMD 
was increased with elevated levels of HDL-cholesterol (Delcourt et al. 2001). 
Additionally, after pooling the data of BMES (Attebo et al. 1996), Beaver Dam 
Eye Study (Klein et al. 1997) and Rotterdam Study (Hofman et al. 1991), total 
serum cholesterol was shown to be associated directly with incident GA, a 
subtype of late AMD (Tomany et al. 2004). Further, in the Age-related Eye 
Disease Study, obesity was significantly and positively associated with GA, a 
subtype of late AMD (Clemons et al. 2005). A population-based cohort study, 
among African participants, also reported a direct and significant association 
between elevated systolic BP and diabetes history with late AMD (Leske et al. 
2006). The Women's Health Initiative Sight Examination suggested that self-
reported history of diabetes and obesity were risk factors for late AMD in women, 
whereas systolic BP was a protective factor for late AMD (Klein et al. 2007). 
126 
 
Table 6.1 Literature review on the relationship between cardiovascular risk factors and age-related macular degeneration 




Smith W, 1998 
   
Australia 3654 ≥49 Obesity 1.78 (1.19-2.68)  
Mitchell and  
Wang, 1999 
 





France 2584 60-95 High HDL 
Obesity 






















2793 >40 Systolic BP 
History of diabetes 





USA 4288 ≥63 Obesity  
History of diabetes 
Systolic BP 
 
 1.05 (1.001- 1.10) 
2.00 (1.01-3.96) 
0.84 (0.71-0.995) 






AMD=age related macular degeneration; BP=blood pressure; CI=confidence interval; CVD=cardiovascular disease; GA=geographic atrophy;  




6.3 Significance of study   
AMD is the leading cause of blindness and poor vision amongst elderly 
Caucasians in the United States (McCarty et al. 2008), Australia (Shankar et al. 
2007a) and other western nations, with a significant impact on the quality of life 
of those afflicted (Brown et al. 2003). Despite the magnitude of this problem, the 
pathogenesis of AMD remains poorly understood. Atherosclerosis has long been 
postulated to be associated with late stage AMD. This association may relate to 
atherosclerosis which may cause CVD (Friedman 2000). There is also a growing 
body of evidence that among risk factors that promote atherosclerosis, MetS is a 
powerful and prevalent predictor of cardiovascular events (Mathieu et al. 2006).  
However, there have been conflicting results on the relationship between CVD 
risks factors such as BP and lipid abnormalities and AMD. So far, no studies have 
looked at the relationship between MetS (as a whole) and AMD.  
There are contradictory reports about the independent associations of 
CVD risk factors such as diabetes, BP or serum lipid and the risk of AMD. For 
example, Smith et al. (1998) found obesity to be associated with the prevalence of 
early AMD,
 
while Tan et al. (2007) showed total and HDL serum cholesterol to 
be associated with incident late AMD. Tomany et al. (2004) reported total serum 
cholesterol was inversely associated with incident neovascular AMD but 
positively associated with incident GA.
 
To date, epidemiological data have not 
been consistent regarding the association between diabetes and AMD (Klein et al. 
1992; Klein et al. 1997; Michell and Wang 1999; Clemons et al. 2005; Leske et 
al. 2006; Chiang et al. 2013). Furthermore, previous studies on AMD analyzed its 
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association with individual MetS risk factors, usually measured at baseline, and in 
isolation (Smith et al. 1998; Tan et al. 2007). Thus, there is uncertainty with 
regards to the relationship between MetS as defined based on a combination of 
risk factors, and AMD.  
In order to evaluate whether accounting for further follow-up information 
of MetS and its components would provide a more powerful and precise estimate 
of their relationships with early or late AMD, the conventional logistic regression 
was first performed to evaluate the association between baseline MetS and its 
components with the 10-year cumulative incidence of early or late AMD. As 
shown in Chapter 2, MetS (and its components) at baseline, 5- and 10-year 
follow-up were highly correlated. As such, it is important to apply statistical 
technique which appropriately account for intra-subject correlation which arose 
with repeated measurements, to yield a more robust estimate of MetS on AMD 
(Brown and Prescott 2006; Li et al. 2011).  
Therefore, the aim of this study is to examine the relationship between 
MetS as defined according to the IDF criteria and the risk of AMD. We further 
explore the age-specific (≤70 versus >70 years) relationship between MetS and its 
components, which were repeatedly measured at baseline, 5- and 10-year follow-
up with the subsequent development of early or late AMD via the mixed-model, 
thus accounting for intra-subject correlation to yield a more precise estimate of 






Study design and participants 
A detailed description of the study design and population was provided in 
Chapter 2. Briefly, the BMES is a population-based cohort study of vision, 
common eye diseases and other health outcomes of a suburban Australian 
population in the west of Sydney. Between 1992 and 1994, non-institutionalized 
permanent residents aged 49 years and older were recruited into the study. The 
survivors were asked to return for follow-up examinations at 5 (1997-1999) and 
10 (2002-2004) years (Mitchell et al. 1998a). Participants, who did not return for 
the 5-year follow-up, were also invited to attend the 10-year follow-up 
examination and had color retinal photographs for the assessment of AMD lesions 
(Tan et al. 2007). A total of 2564 participants had eye examination at least once 
after baseline (Tan et al. 2008d). Overall, 2218 subjects with complete 
information for the study factors at baseline including Mets and its components, 
age, sex, smoking status, pre-existing cardiovascular disease (angina, AMI and 
stroke), family history of eye disease (cataract, AMD, myopia, glaucoma and 
blindness), patient‘s history of eye disease (cataract, myopia and glaucoma), eye 
iris color, and skin sun-tanning characteristics contributed to the analysis of 10-
year cumulative incidence of AMD in this study. Specifically, 2114 participants 







A detailed description of the data collection was provided in Chapter 2. Briefly, 
at each visit, trained interviewers filled out a comprehensive questionnaire 
comprising demographic information, eye and general medical history as well as 
medications used (Mitchell et al. 1998a). Height, weight and seated BP (WHO 
2003) were measured. Fasting pathology tests, including total cholesterol 
(mmo/L), HDL cholesterol (mmo/L), TG (mmo/L) (Cugati et al. 2007) and FPG 
(mmo/L) (WHO 1999), were measured within a month of each interview and 
delivered by courier within the same day to Westmead Hospital Sydney for 
hematology and clinical biochemistry assessment (Shankar et al. 2007b). In 
addition, information on smoking, alcohol consumption (gram / week), history of 
eye diseases including cataract, AMD, myopia and glaucoma as well as family 
history of these eye diseases and blindness were obtained and recorded (Tan et al. 
2007). Eye iris color (blue, hazel/ green, tan/ brown, dark brown) and skin sun-
tanning characteristics were also estimated on a 4-point scale (always burn, never 
tan; usually burn, tan with difficulty; burn and tan above average; rarely burn, tan 
above average) (Mitchell et al. 1998b).  
 
Definition of metabolic syndrome  
As mentioned in Chapter 2, we define MetS according to the IDF criteria 
(Zimmet et al. 2005) as obesity (ie. BMI >30 kg/m
2
) plus any two of the 
following four factors:  
ix. TG ≥1.7 mmol/L or specific treatment for this lipid abnormality;  
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x. HDL cholesterol  <1.03 mmol/L in men and <1.29 mmol/L in women, or 
specific treatment for this lipid abnormality;  
xi. Systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg, or treatment of 
previously diagnosed hypertension; or  
xii. FPG ≥5.6 mmol/L, or previous diagnosis or specific treatment for type 2 
diabetes. 
 
Age-related macular degeneration grading  
Population at risk for AMD comprised participants who had at least one follow-up 
visit, and whose retinal photographs were retrospectively shown not to contain 
AMD at baseline. At each visit, 30° stereoscopic retinal photographs of the 
macula and other retinal fields of both eyes were taken, using an FF3 fundus 
camera (Carl Zeiss, Oberkochen, Germany). Photographs were obtained for both 
eyes in 98%, or at least one eye in 99%, of the baseline and 5-year examination 
participants, and for both eyes in 85% (1649/1952), or at least one eye in 87% 
(1689/1952), of the 10-year examination participants (Wang et al. 2007b). The 
photographic grading for AMD lesions closely followed that of the Wisconsin 
age-related maculopathy grading system (Klein et al. 1991; Mitchell et al. 1995) 
(Table 6.2). All photographs taken from each examination were graded initially in 
a masked manner. Side-by-side grading of the baseline and 5-year photographs 
(Mitchell et al. 2002) and of the baseline and 10-year photographs (Wang et al. 
2007b) was performed for participants with lesions identified after each follow-up 
examination. Assessments of inter-grader and intra-grader reliability showed good 
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agreement for AMD grading (Mitchell et al. 1995). Late-stage AMD was defined 
to include neovascular AMD and GA, the 2 late-stage lesions described in the 
International AMD classification (Bird et al. 1995). All late AMD cases detected 
from each examination were adjudicated and confirmed by a retinal specialist. 
Early-stage AMD was defined as the absence of late-stage AMD and presence of 
either (1) large (_125 _m diameter) indistinct soft or reticular drusen or (2) both 
large distinct soft drusen and retinal pigmentary abnormalities (hyperpigmentation 
or hypopigmentation) (Bird et al. 1995; Mitchell et al. 1995), within the macular 
area (Klein et al. 1991). Incident late AMD was defined by the appearance at 
either follow-up examination of neovascular AMD or GA in either eye of persons 
in whom no late AMD lesions were present in either eye at baseline. Incident 
early AMD was defined by the appearance at the follow-up examinations of either 
indistinct soft or reticular drusen or the co-presence of both distinct soft drusen 
and retinal pigmentary abnormalities, in either eye of persons in whom no late or 
early AMD was present in either eye at baseline. Patients with only distinct soft 
drusen or retinal pigmentary abnormalities, but not both lesions, at baseline who 
went on to develop complementary lesions that together comprised a diagnosis of 






As mentioned in Chapter 2, the χ2 test was used to determine the bivariate 
relationship between categorical covariates included in this study and the 10-year 
cumulative incidence of both early and late stage AMD. The association between 
baseline Mets and its components with 10-year cumulative incidence of early or 
late AMD was quantified using the odds ratio (OR) estimate via the conventional 
logistic regression model (fixed-effects model). Ten-year cumulative incidence of 
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early or late AMD was the primary outcome in the conventional logistic 
regression model.  
Mixed-effects logistic regression model (Agresti 2013) with repeated 
measurements of MetS (or its components) at baseline, 5- and 10-year follow-up 
visits, was later used to explore the relationship between Mets and its components 
with the subsequent development of early or late AMD over 10-year follow-up. 
Early or late AMD which was measured repeatedly at baseline, 5- and 10-year 
follow-up, was the outcome for mixed-effects logistic regression model. As 
mentioned in Chapter 1, the mixed-effects model comprises both the fixed and 
random effects. The random effects are estimated when the data structure consists 
of repeated measures over time within each individual, in this case, MetS and its 
components at baseline, 5- and 10-year. Age, sex, smoking, pre-existing 
cardiovascular disease (angina, AMI and stroke), family history of eye disease 
(cataract, AMD, myopia, glaucoma and blindness), patient‘s history of eye 
disease (cataract, myopia and glaucoma), eye iris color, and skin sun-tanning 
characteristics were regarded as fixed covariates in the model. The regression 
coefficients in the fixed-effects model may be interpreted as a population average 
measure of the cumulative effects of MetS (and its components) on AMD, while 
those in the mixed-effects model may be interpreted as the subject-specific 
estimate of its effect on AMD. The random-effects model adjust for possible 
intra-subject correlation to achieve a more robust and stronger results (Brown and 
Prescott 2006; Agresti 2013).     
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In the simplest form the mixed-effects logistic regression for AMD can be 
modelled as follow:     
logit (AMDij)=β0
*
 + βMetS MetSij + ij 
where AMDij is a binary variable taking values 0 or 1 for an individual i at the j
th
 
visit. This model is fitted assuming a random intercept, β0
*
, and the slope 
parameter, βMetS, is considered as a fixed effect. The component, ij, estimates the 
SD of the random intercept and the residual variation. It can be extended to allow 
the slope to assume a random effect as well as to adjust for other covariates (Tai 
and Machin 2014).      
However, among the fixed effects covariates mentioned, only age, sex and 
pre-existing cardiovascular disease were statistically significant in the bivariate 
model. We further explored possible interaction between age and sex with MetS 
or its components in these logistic regression models.  
 
6.5 Results  
Over the 10-year follow-up, 262 (12.4%) cases of early AMD and 70 (3.2%) 
cases of late AMD were detected. Of the participants included in the present 
study, 76.5% were aged ≤70 years at baseline and 58% were females. Age, sex 
and pre-existing cardiovascular disease were associated with both early and late 
AMD (Table 6.3).  
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Table 6.3 Baseline characteristics of study subjects according to 10-year cumulative incidence of age-related macular degeneration  
 Total 
(n=2218) 
Early AMD  
(n=2114) 













Age (year) (%),   ≤ 70 












Sex (%), Male  












Smoking status (%),     Never 
                                      Former  

















Pre-existing cardiovascular disease (%)a 359 (16.2) 268 (14.5) 65 (24.8) < 0.001 342 (15.9) 17 (24.3) 0.062 
Sun skin-burned (%)  
   Always burn, never tan 
   Usually burn, tab with difficulty  
   Burn and tab above average 






























Eye iris color (%) 
    Blue 
    Hazel/Green 
   Tan\Brown  






























Family history of any eye disease (%)b 695 (31.3) 582 (31.4) 81 (30.9) 0.868 667 (31.0) 28 (40.0) 0.112 
History of any eye disease at baseline (%)c 914 (41.2) 737 (39.8) 119 (45.4) 0.083 879 (40.9) 35 (50.0) 0.129 
MetS (%) 271 (12.2) 236 (12.7) 24 (9.2) 0.098 263 (12.2) 8 (11.4) 0.838 
BMI > 30 (%) 386 (17.4) 329 (17.8) 38 (14.5) 0.192 373 (17.4) 13 (18.6) 0.793 
High glucose (%)d 345 (15.5) 291 (15.7) 40 (15.3) 0.853 330 (15.4) 15 (21.4) 0.168 
Low-HDL (%)e 664 (29.9) 564 (30.4) 72 (27.5) 0.326 637 (29.7) 27 (38.6) 0.109 
High triglyceride (%)f 916 (41.3) 765 (41.3) 110 (42.0) 0.835 882 (41.1) 34 (48.6) 0.209 
High BP (%)g 1890 (85.2) 1565 (84.5) 229 (87.4) 0.220 1825 (85.0) 65 (92.9) 0.067 
AMD= age-related macular degeneration; BMI=body mass index; MetS=metabolic syndrome; HDL=high density lipoprotein; BP=blood pressure; a Includes history of angina, 
stroke and AMI; bIncludes family history of cataract, glaucoma, macular and blindness;  c Includes history of cataract, myopia and glaucoma ; d fasting plasma glucose ≥ 5.6 
mmol/L, or previous diagnosis or specific treatment for type 2 diabetes;  e serum HDL cholesterol  < 1.03 mmol/L in men and < 1.29 mmol/L in women, or specific treatment  for 
this lipid abnormality; f serum triglyceride level ≥ 1.7 mmol/L or specific treatment for this lipid abnormality; g systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 
85 mmHg, or treatment of previously diagnosed hypertension. 
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Amongst those who developed late AMD and were aged ≤70 years 
(n=32), there were notably higher proportions with MetS, increased BMI, high 
glucose and high TG over time. However, amongst those who developed early 
AMD and were aged ≤ 70 years, the changing status of MetS and its components 
was not appreciable. The observation was similar for those who developed early 
AMD and were aged >70 years, although declines in some Mets components were 
noted over time for early AMD (Figure 6.1). 
 
 
AMD=age-related macular degeneration; BMI=body mass index; BP=blood pressure; MetS=metabolic 
syndrome; HDL=high density lipoprotein. 
Figure 6.1 Prevalence of metabolic syndrome and its components at baseline, 5- and 
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Baseline MetS and its components and early or late AMD  
Generally, amongst both age groups, there was no evidence of relationship 
between baseline MetS and its components with early stage AMD (Table 6.4). 
However, the interaction between glucose and age group in the relationship with 
late stage AMD was significant (P < 0.05). After adjustment for sex, pre-existing 
cardiovascular diseases, baseline glucose was found to be significantly associated 
with 10-year cumulative incidence of late AMD amongst those aged ≤ 70 years 
(OR 2.29, 95% CI: 1.09-4.80) (Table 6.4).  
Table 6.4 Age-specific associations between baseline metabolic syndrome and its components 
with 10-year cumulative incidence of early and late AMD  
 Age ≤ 70 years  Age > 70 years 
 OR (95% CI)
 
 P-value OR (95% CI)
 
 P-value 
Early AMD     
MetS 0.58 (0.33-1.02) 0.056 0.98 (0.46-2.07) 0.952 
BMI > 30  0.74 (0.47-1.16) 0.187 0.84 (0.43-1.63) 0.608 
High glucose
 a
 0.75 (0.46-1.23) 0.253 1.51 (0.85-2.70) 0.162 
Low-HDL
 b
 0.82 (0.57-1.18) 0.284 0.91 (0.54-1.52) 0.727 
High triglyceride
 c
 0.91 (0.66-1.27) 0.593 1.28 (0.80-2.03) 0.298 
High BP
 d
 1.07 (0.69-1.66) 0.764 0.75 (0.30-1.87) 0.537 
Late AMD     
MetS 1.50 (0.61-3.70) 0.375 0.43 (0.10-1.86) 0.258 
BMI > 30  1.67 (0.76-3.66) 0.198 0.61 (0.21-1.79) 0.367 
High glucose
 a
 2.29 (1.09-4.80) 0.029 0.61 (0.21-1.79) 0.368 
Low-HDL
b
 1.84 (0.91-3.75) 0.091 1.35 (0.66-2.77) 0.410 
High triglyceride
 c
 1.22 (0.60-2.49) 0.589 1.01 (0.50-2.00) 0.994 
High BP
 d
 1.96 (0.59-6.48) 0.270 1.07 (0.24-4.76) 0.931 
AMD= age-related macular degeneration; BMI=body mass index; BP=blood pressure; HDL=high density 
lipoprotein; CI=confidence interval; OR=odds ratio. a fasting plasma glucose ≥ 5.6 mmol/L, or previous 
diagnosis or specific treatment for type 2 diabetes; b serum HDL cholesterol < 1.03 mmol/L in men and         
< 1.29 mmol/L in women, or specific treatment for this lipid abnormality; c serum triglyceride level ≥ 1.7 
mmol/L or specific treatment for this lipid abnormality; d systolic blood pressure ≥ 130 mmHg or diastolic 
blood pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension. Adjusted for sex, pre-existing 
cardiovascular disease (namely, angina, acute myocardial infarction and stroke) and including interaction 





Longitudinal information of MetS and its components and early or late AMD  
There was no evidence of any relationship between MetS and its components with 
early AMD in the mixed model (Table 6.5). However, there was an evidence of 
interaction effect between MetS, obesity and high glucose with age group in their 
relationship with late AMD (all P < 0.05). After adjusting for sex, pre-existing 
cardiovascular diseases, we found MetS to be significantly associated with late 
AMD only amongst those aged ≤70 years (OR 2.16, 95% CI: 1.01-4.65) (Table 
6.5). Furthermore, amongst the five MetS components, after adjusting for sex, 
pre-existing cardiovascular diseases, we found BMI >30 kg/m
2
 (OR 2.22, 95% 
CI: 1.09-4.49); high glucose (OR 3.12, 95% CI: 1.48-6.56) and high TG (OR 
2.06, 95% CI: 1.01-4.22) were positively linked to the incidence of late AMD 
amongst those aged ≤ 70 years during the 10-year follow-up period (Table 6.5). 
Table 6.5 Age-specific associations between metabolic syndrome and its components on 
incidence of early and late AMD over 10-year follow-up according to age  
 Age ≤ 70 years  Age > 70 years 
 OR (95% CI)
 
 P-value OR (95% CI)
 
 P-value 
Early AMD     
MetS 0.93 (0.59-1.45) 0.733 0.91 (0.44-1.90) 0.806 
BMI > 30  0.88 (0.60-1.30) 0.521 0.95 (0.51-1.79) 0.879 
High glucose
 a
 0.77 (0.49-1.22) 0.271 1.05 (0.61-1.83) 0.855 
Low-HDL
 b
 0.84 (0.59-1.19) 0.324 0.66 (0.38-1.14) 0.141 
High triglyceride
 c
 0.60 (0.41-0.88) 0.009 1.37 (0.85-2.20) 0.202 
High BP
 d
 1.18 (0.74-1.87) 0.496 0.56 (0.27-1.13) 0.107 
Late AMD     
MetS 2.16 (1.01-4.65) 0.049 0.42 (0.09-1.91) 0.260 
BMI > 30  2.22 (1.09-4.49) 0.027 0.24 (0.05-1.11) 0.068 
High glucose
 a
 3.12 (1.48-6.56) 0.003 1.03 (0.38-2.76) 0.956 
Low-HDL
b
 1.78 (0.89-3.57) 0.103 0.61 (0.25-1.49) 0.275 
High triglyceride
 c
 2.06 (1.01-4.22) 0.047 1.03 (0.47-2.25) 0.943 
High BP
 d
 0.84 (0.34-2.06) 0.696 0.56 (0.19-1.61) 0.278 
AMD= age-related macular degeneration; BMI=body mass index; BP=blood pressure; HDL=high density 
lipoprotein; CI=confidence interval; OR=odds ratio. afasting plasma glucose ≥5.6 mmol/L, or previous 
diagnosis or specific treatment for type 2 diabetes; bserum HDL cholesterol <1.03 mmol/L in men and <1.29 
mmol/L in women, or specific treatment for this lipid abnormality; c serum triglyceride level ≥1.7 mmol/L or 
specific treatment for this lipid abnormality; d systolic blood pressure ≥130 mmHg or diastolic blood pressure 
≥85 mmHg, or treatment of previously diagnosed hypertension. Adjusted for sex, pre-existing cardiovascular 
disease (namely, angina, acute myocardial infarction and stroke) and including interaction between age group 
and MetS (or its components) 
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6.6 Discussion  
Our study investigated the relationship between MetS and the subsequent 
development of AMD over a 10-year period in a cohort of Australian white 
persons. We found that age modified the relationship between MetS, obesity and 
high glucose with late stage AMD. Amongst younger participants aged ≤ 70 
years, MetS was associated with an increase in incidence of late AMD during the 
10-year follow-up. Amongst the MetS components, obesity (i.e. BMI >30 kg/m
2
), 
high glucose and high TG were found to be significant predictors of incidence of 
late AMD in the younger age group. No relationship was seen for MetS and early 
AMD. 
The finding that the associations between MetS and its components with 
late AMD emerged during the 10-year follow-up, and that, this was observed only 
in those aged ≤ 70 years at baseline add the importance of the age modification in 
the relationship between MetS, obesity and high glucose with late stage AMD to 
the existing literature. While Delcourt et al. (2001) and Clemons et al. (2005) 
have shown a significant association between obesity and late AMD, others have 
not confirmed this association (Smith et al. 1998; Klein et al. 2001). The 
mechanism connecting obesity and AMD formation may be possibly explained by 
an increase in oxidative damage and inflammation in obese persons (Klein et al. 
2007). Obesity is also associated with an increase in C-reactive protein, a marker 
for systemic inflammation which in turn is also significantly associated with 
AMD (Seddon et al. 2004). 
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 We also observed an association between high glucose and late AMD in 
this age group. The Beaver Dam Eye Study (Klein et al. 1992; Klein et al. 1997) 
and the Barbados Eye Study (Leske et al. 2006) have also demonstrated an 
association between prevalent diabetes mellitus and any AMD. The mechanism 
behind the association between diabetes and AMD has been shown in eyes of 
long-term diabetic persons through the thickening of basement membrane of the 
choriocapillaris walls, luminal narrowing, dropout of the choriocapillaris, and 
thickening of Bruch‘s membrane which has been attributed to hyperglycemia 
(Hidayat and Fine 1985; Fryczkowski et al. 1988).    
We further observed a positive association between high TG and increased 
incidence of late AMD during the 10-year follow-up among those aged ≤70 years. 
The observed relationship may be explained by the vascular model which 
suggests that AMD is the result of the accumulation of lipid in the sclera and the 
Bruch membrane, thus progressively increasing the stiffness of these tissues 
(Friedman et al. 2000). 
Importantly, our study utilized full follow-up information and thus 
possible changes in MetS over time in contrast to previous studies which used 
only baseline information of MetS components (Smith et al. 1998; Delcourt et al. 
2001; Tomany et al. 2004; Clemons et al. 2005; Leske et al. 2006; Klein et al. 
2007; Tan et al. 2007). When we analyzed baseline data using the conventional 
logistic regression model, only high glucose was significantly associated with 10-
year cumulative incidence of late AMD amongst those aged ≤ 70 years. This was 
in contrast to the mixed model which detected significant interaction not only 
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between high glucose and age, but also between MetS and obesity with age, with 
the OR for MetS, obesity, high glucose and high TG reaching statistical 
significance amongst those aged ≤ 70 years. Hence, our current analysis which 
considered all available information of Mets components at baseline and 
subsequent follow-up visits, provided a more comprehensive understanding of the 
risks of AMD and its association with MetS and its components. 
The specific strengths of this study include (1) exploring the relationship 
between MetS and its components with early or late stage AMD, where its 
occurrence as well as those of the study main exposure, were repeatedly measured 
during the study follow-up at baseline, 5- and 10-year through applying the 
mixed-effects logistic regression. This model accounts for intra-subject 
correlation to yield a more robust and stronger estimate of the relationships 
(Brown and Prescott 2006; Agresti 2012), and; (2) use of standard method for 
assessing AMD incidence, including photographic grading by the same personnel 
at all examinations, and a detailed side-by-side comparison of baseline and 
follow-up examination photographs to ensure negligible misclassification for 
AMD diagnosis (Tan et al. 2007).  
However, the drawbacks of this study should be noted. As mentioned in 
Chapter 2, the overall sample size of study which included limited number of 
subjects with MetS may limit our ability to detect the relationship between MetS 
and early AMD. In addition, the possibility of chance finding exists, especially 
when we analyzed the data related to late AMD in age group ≤ 70 years which 
involved small number of cases. Further, the possibility of residual confounding 
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effect cannot be ruled out, and the observed associations might have been due to 
other confounding factors such as genetic factors (Wei et al. 2013) or diet 
(Montgomery et al. 2010), not the MetS or its components per se.   
Our study demonstrated that MetS and three of its components, namely 
BMI >30 kg/m
2
, high glucose and high TG were predictors of progression to late-
stage AMD amongst younger Australian white population aged ≤ 70 years. The 
findings also demonstrate the efficiency of mixed-effects model and the use of 


















CHAPTER 7- Conclusion 
SUMMARY 
Many longitudinal studies have been conducted to evaluate the relationship 
between various exposures and different morbidities and mortality. However, 
very often, only the baseline information was accounted for in the analysis due to 
the simplicity of statistical methods for evaluating data at a single time point. 
Such studies did not fully utilize the information of exposure that had been 
collected longitudinally at different time points, and hence limited the inferences 
that could be drawn from changes in exposure effect over time. The results of this 
thesis clearly demonstrated that accounting for baseline and further follow-up 
information of the exposure of interest such as metabolic syndrome (MetS) and its 
components, allowed for a more precise estimation of its effect on the respective 
outcomes. We thus encourage researchers to fully account for information 
involving multiple time points in longitudinal data analysis. Moreover, in the 
presence of multiple failure endpoints such as cause-specific mortality, we 
recommend the use of competing risks model especially among the elderly and 
frail population, to obtain a precise estimate of exposure effect as compared with 









In the past decade, longitudinal studies commonly used only the baseline 
information in the evaluation of the association between exposures and health 
related outcomes, due to simplicity of statistical methods used for such data 
(Lewis et al. 2008; Dworetzky et al. 2010; Saczynski et al. 2010). Such studies 
did not fully utilize the information of exposure such as depression syndrome, BP 
or caffeine that had been collected longitudinally at different time points in their 
association with respective outcomes such as dementia, CVD or epilepsy. This 
limited the inferences that could have been drawn from changes in exposure effect 
over time.  
To our best knowledge, this is the first study to fully utilize the 
information on MetS and its components including BMI, collected at baseline, 5- 
and 10-year visits to unravel their relationship with outcomes involving all-cause 
and cause-specific mortality, age-related cataract as well as AMD among the 
white Australian population.  
First, we explored the effect of MetS and its components on subsequent 
all-cause and cause-specific mortality, and determined whether these associations 
change with time. When we analyzed only the information of MetS at baseline, 
without taking into account changes in MetS status at follow-up using the 
conventional Cox or competing risks regression models, we did not detect any 
effect of MetS on all-cause and CVD mortality. Accounting for further 
information of MetS at 5- and 10-year follow-up in addition to baseline 
information, by regarding it as a time-dependent covariate, the effects of MetS on 
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all-cause, cardiovascular- as well as cancer death was found to change over the 
study period. For example, the risk of all-cause-mortality increased gradually 
from 2-year to 10-year follow-up amongst those with MetS. The association 
between MetS and cardiovascular-death also changed with time, with increased 
risk of cardiovascular-death at 10-year and reduced risk at 2-year and 5-year. In 
contrast to cardiovascular-death, MetS was associated with a notably higher risk 
of cancer death at 2-year, with diminished risk by 10-year. This underscores that 
full utilization of MetS information at all assessments allows the detection of 
changing effect of MetS on all-cause and cause-specific mortality which would 
otherwise be impossible to detect if only baseline information were accounted for 
in the analysis. Therefore, the time-dependent models may also be clinically more 
relevant, as they reflect the actual clinical scenarios where MetS are likely to 
change over time, thus allowing the physicians to better evaluate and manage the 
elderly.   
We also evaluated the age-specific association between baseline BMI 
(1992–1994) and 5-year changes in BMI (1997–1999) on the one hand, and 
overall and cause-specific mortality on the other, among the white Australian 
population. The results obtained using conventional Cox survival model were 
compared with those of the competing risks model. The association between BMI 
and mortality was found to be modified by age, with obesity being associated with 
greater risk of all-cause and cardiovascular-specific mortality amongst middle 
aged subjects ≤70 years, but not >70 years. With respect to changes in BMI over 
5 years since baseline, BMI loss, a marker of greater severity of mortality-related 
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diseases, was associated with increased risk of all-cause mortality regardless of 
age, and cancer and cardiovascular-related mortality amongst subjects aged ≤ 70 
years. Importantly, when we analyzed the relationship between baseline BMI and 
its 5-year changes using the cause-specific Cox regression model, the effect 
estimates were larger than those of the competing risks model. The differences 
were appreciable especially in the older age group for cancer- and cardiovascular-
death. 
In the third study, we evaluated the effect of MetS and its components on 
the incidence of different age-related cataract sub-types, namely cortical, nuclear 
and PSC cataract. In order to determine whether estimation of the effects differed 
at varying time interval, we utilized full information of the exposure that was 
collected at each follow-up and implemented the random-effects complementary 
log-log regression model to better describe the relationships. When we considered 
only the effect of MetS components at baseline without accounting for further 
follow-up information using the conventional logistic regression model, we did 
not detect any effects of obesity or HDL cholesterol on cortical cataract. 
However, after accounting for further information of MetS components at 5- and 
10-year follow-up, the results showed that MetS was associated with the 5-year 
incidence of cortical and PSC cataract, and different MetS components were 
associated with the incidence of different cataract sub-types at varying time-
intervals. Hence, full utilization of data provides a more robust estimate of the 
effect of MetS on age-related cataract, than baseline information only.  
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In the fourth study, we explored the longitudinal effect of MetS and its 
components on subsequent development of early or late stage AMD via the mixed 
model. Our study demonstrated that MetS and three of its components, namely 
BMI >30 kg/m
2
, high glucose and high TG were predictors of progression to late-
stage AMD amongst younger Australian white population aged ≤ 70 years. When 
we accounted for only baseline MetS components using the conventional logistic 
regression model, only high glucose was significantly associated with an 
increased 10-year cumulative incidence of late AMD amongst those aged ≤ 70 
years. However, when we considered information of MetS and its components not 
only at baseline, but also at subsequent follow-up visits, the mixed-effects logistic 
regression model detected significant interaction not only between high glucose 
and age, but also between MetS and obesity with age, with the OR for MetS, 
obesity, high glucose and high TG reaching statistical significance amongst those 
aged ≤70 years. Hence, the mixed-effects logistic regression analysis which 
considered all available information of MetS components at baseline and 
subsequent follow-up visits, provided a more comprehensive understanding of the 
risks of AMD and its association with MetS and its components.  
 
7.2 Discussion  
Time-to-event outcome 
From a statistical point of view, statistical methods for time-to-event data have 
long been staples of medical research. Within this class of methods, the 
proportional hazards model proposed by Cox (1972) is certainly among the most 
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important, with a variety of its extensions (Anderson and Gill 1982;  Hougaard 
2000; Therneau and Grambsch 2000; Collett 2005) and related diagnostic 
techniques (Therneau and Grambsch 2000; Collett 2005) becoming standard 
components of the medical researcher‘s toolbox (Finch et al. 2006; Gogas et al. 
2006; Okin et al. 2006; Freedman et al. 2009; Ananthakrishnan et al. 2012). 
Largely, because of the increasing availability of data from longitudinal studies, 
which collect measurements of the same units at different time points, one class of 
extensions that has received a great deal of attention in recent years is the Cox 
proportional hazards model that includes time-dependent covariates (Aydemire et 
al. 1999; Fisher and Lin 1999). Like in the present thesis, the time-dependent 
approach makes it possible to incorporate all temporal information available by 
full utilization of data. In our study, applying conventional Cox regression model, 
using the baseline information of MetS only, failed to detect the relationship 
between MetS with all-cause and CVD-death. However, after accounting for 
further follow-up information of MetS during the entire study follow-up, the time-
dependent model showed the relationship between MetS with all-cause and cause-
specific mortality changed with time. Indeed, it has been shown that ignoring the 
changes in covariate values such as changes in MetS over the entire study follow-
up may result in bias when estimating baseline effect only (Aydemire et al. 1999; 
Dancourt et al. 2004) and therefore, it is necessary to use appropriate method to 
adjust for a time-dependent covariate (Giorgi  and Gouvernet 2005). 
The use of time-dependent covariate in a time-to-event analysis offers 
exciting opportunities for exploring associations and potentially causal 
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mechanisms for exploring predictive relationships by using quantities that vary 
over time. This model also allows us to account for intra-subject correlation 
which arose with repeated measurements. Moreover, similar to our finding, the 
time-dependent model allows us to distinguish short from long term effect of 
exposure on outcome such as the effect of MetS on mortality at 2-, 5- and 10-year 
follow-up, while conventional Cox regression model fails to detect such changes 
over time (Collet 2003). Our study has also shown that earlier status of MetS was 
associated with cancer-death, while updated status of MetS was associated with 
all-cause and CVD-death. Indeed, utilising only the information of exposure at 
baseline would not be able to clarify whether earlier or most updated status of 
exposure associated with outcome. In addition, such studies would fail to assess 
the effect of changes in exposure over time. These underscore the importance of 
fully accounting for covariate information collected at each follow-up in order to 
better predict all-cause and major causes of death.  
 
Competing risks outcome 
Consistent with our result on the comparison between conventional Cox 
regression and competing risks models, several studies (Koller et al. 2008; 
Wolbers et al. 2009; Tai et al. 2010; Tai et al. 2011a; Tai et al. 2011b) have 
pointed out that for evaluation of multiple failure outcomes which can be regarded 
as competing risks, the cause-specific Cox regression model may substantially 
overestimate the risk of outcome of interest, because subjects with a specific 
event may experience other competing events in the future. They have also shown 
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that the use of competing risks method provides a more accurate and precise 
evaluation of the association between exposure and different causes of death, 
especially among the elderly population. This is due to the fact that competing 
risks model estimates the absolute risk after taking into account the presence of 
other competing events, while the conventional Cox model censors the competing 
event at the time when it occurs. The presence of competing events is an 
important issue in studies involving the elderly population, as the elderly tends to 
experience several major clinical outcomes at the same time since the prevalence 
of major chronic diseases tends to increase with increased age (Wolbers et al. 
2009). As such, the competing risk based model helps us to reduce biases in 
estimates, and these biases are usually contributed by ignoring the competing 
event(s) (Putter et al. 2007). Our finding showed that conventional cause-specific 
Cox regression model overestimated the relationship between BMI and different 
causes of death in comparison with competing risks model. Hence, the 
implementation of the competing risks model avoids overestimation of the impact 
of exposure such as BMI on the multiple-event endpoint, as the model 
appropriately account for each competing risk in the analysis (Wolbers et al. 
2009; Tai et al. 2010; Tai et al. 2011a; Tai et al. 2011b).  
 
Interval-censored outcome 
In epidemiological studies where subjects are seen periodically on follow-up 
visits, interval-censored data occur naturally (Zuma et al. 2007). In clinical or 
epidemiological studies, individual are repeatedly evaluated during the follow-up 
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schedules based on time interval (e.g. at baseline, 5- or 10-year). In such scenario, 
there is a probability to contract the disease (i.e. age-related cataract) during this 
time interval (i.e. between baseline to 5-year or between 5- to 10-year), and the 
exact date of the outcome/event may not be captured in this interval, and it is 
treated as an interval-censored data (Sun 1997). This situation is common in 
epidemiological and clinical studies. In such situations, the random-effects 
interval-censored modelling should be used to model the dependence of the onset 
of diseases within the interval among individuals with repeated measurements of 
observations (Sun 1997; Zuma et al. 2007). As explained in Chapter 2, in this 
thesis repeated measures of MetS and its components over the entire study follow-
up have been shown to be highly correlated. The random-effects interval censored 
method accounts for intra-subject correlation which naturally arose with repeated 
measurements (Lam et al. 2010). Our finding also showed that when we 
considered only the effect of MetS components at baseline without accounting for 
its changing status at follow-up, we did not detect any effects of obesity or low-
HDL cholesterol on cortical cataract. Indeed, the conventional fixed-effects 
approach ignores correlation in the data for clustered interval-censored data. As 
such, the standard errors thus obtained may lead to invalid statistical inference 
(Zuma et al. 2007). Moreover, failure to fully utilize the information that had been 
collected over time limits the inferences that could have been drawn especially 
with regards to changes in exposure effect (Rabe-Hesketh and Skrondal 2008; 
Tong et al. 2008; Sun et al. 2013). It is therefore important to fully accounting for 
covariate information collected at each follow-up visit in order for physicians to 
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better predict the risk of morbidities such as different types of cataract in persons 
at varying time-intervals.  
 
Binomial outcome  
The mixed-effects model allows repeated observations of the same person at 
different points in time during the overall analysis, and provides greater ﬂexibility 
and more stable estimate than the traditional analysis by selecting the best-ﬁtting 
structure for the data while accounting for intra-subject correlation (Margolin and 
Wampold 1981; Iacobucci and Wasserman 1988; Ozechowski 2007). In addition, 
this model is commonly used for the analysis of datasets with missing data 
(Verbeke and Molenberghs 2000; Gueorguieva and Krystal 2004; Torng et al. 
2007). In longitudinal study design, since subjects are evaluated over time at 
different time periods, confronting with missing data during the follow-up period 
is inevitable, and it would be appropriate to adopt a mixed-effects model with 
such design. Our findings have shown that conventional logistic regression failed 
to detect the relationship between MetS, glucose and TG on late stage AMD, 
while these associations were found through applying mixed-effects logistic 
regression model. This is due to the fact that, traditional regression techniques do 
not recognize the clustered structure and will cause the standard errors of 
regression coefficients to be wrongly estimated, leading to an overstatement or 
understatement of statistical significance for the coefficients of both the higher 
and lower-level covariates. Therefore, mixed-effects logistic regression model 
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provides a more accurate estimate of the exposure with multiple measurements to 
detect associations with the risk of binary disease (Li et al. 2011). 
 
7.3 Overall strengths and limitations of the study 
As explained in Chapter 2, the strength of this study include a representative 
elderly Australian population, long-term follow-up, full utilisation of MetS 
information at each visit as well as high quality data collection involving 
standardised measures at each examination thus eliminating bias in self-reporting. 
Moreover, cataract diagnosis was based on standardized lens photographic 
grading, which have been shown to have high reproducibility (Panchapakesan et 
al. 1997; Kanthan et al. 2008), and the use of standard method for assessing AMD 
incidence and a detailed side-by-side comparison of baseline and follow-up 
examination photographs ensure negligible misclassification for AMD diagnosis 
(Tan et al. 2007). Moreover, missing data and loss to follow-up cannot be avoided 
in complex epidemiological studies involving long term follow-up. Missing data 
may result in a reduction in power and biased estimates, thus affecting the 
statistical findings. In this thesis, we applied longitudinal panel data analysis to 
overcome this problem. 
However, the drawbacks of this study include the possibility of Type II 
error and hence lack of statistical power, which may exist especially when we 
analyzed the data amongst the subgroup of subjects with PSC cataract and late 
AMD. Further, when the p-value reported in our study is less than 0.05, we may 
make Type I error due to chance as several endpoints and subgroups were 
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evaluated. Moreover, the results could have been biased by residual confounding 
factors, such as varying levels of body composition, visceral adiposity or physical 
fitness which were not measured in this study. In addition, risk factors earlier in 
life (even in childhood) may have a different impact that cannot be assessed in 
this study. Also, assessment a few decades earlier would not be as prone to 
reverse causation by pre-clinical ill health.   
There is also the possibility that our findings relating to the relationship 
between MetS (and its components) with mortality, cataract or AMD might have 
been confounded by the presence of pre-existing diseases such as cancer at 
baseline and adjustment for it might not totally account for its effect as the pre-
existing disease might result in weight loss and consequently caused premature 
mortality. It should be noted that the magnitude of association between MetS and 
the respective outcomes remained unaltered regardless of whether we adjusted for 
the presence of each pre-existing disease such as cancer, AMI, angina and stroke 
individually or as a composite variable including  'any pre-existing diseases. As 
such, in this thesis, we presented only the results based on the composite variable 
of 'any pre-existing diseases'. 
 It would be possible that different cataract sub-types may be treated as a 
multinomial outcome. Moreover, it is natural that more than one type of cataract 
occurs in one subject (mixed cataract). Therefore, we encounter with different 
combination of cataract sub-types in each subject. In study 3, we considered 
interval-censored modelling for different sub-types of cataract as separate binary 
outcomes. We would not able to apply multinomial modelling, since the number 
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of events for mixed cataract sub-types were limited, and suggesting low statistical 
power to detect the actual relationships. Furthermore, early stage AMD may 
progress to late stage AMD, since late stage AMD is considered to be an 
advanced stage of AMD. As such, AMD may be treated as an ordinal outcome 
based on the severity of disease states such as no AMD, early AMD and late 
AMD to explore more complex relationships on different stages of AMD. In 
Study 4, we considered early or late stage AMD as separate binary outcomes, 
since the assumption for proportionality of odds across response categories was 
violated. In addition, although we have information on the eye (left or right) in 
which the outcomes of interest occur, the number of cortical, nuclear and PSC 
cataract events as well as early or late stage AMD were limited for each eye (left 
or right). As such, we would not be able to analyze the relationship between MetS 
and cataract or AMD according to the eye (ie. left or right). Moreover, subjects 
wearing glasses were more likely to participate in the BMES study as compared 
to the subjects who were not wearing glasses and refused to participate in this 
study. This will certainly create self-selection bias that might result in bias in 
estimating the effect measures for an eye disease outcome such as age-related 
cataract and AMD (Pan et al. 2013a; Pan et al. 2013b; Pan et al. 2013c). 
 
7.4 Scope for future work 
In this section, we elaborate on the implications this research has overall and 
where this work will lead to in further research and future epidemiological and 
clinical practice. The method for analysis of repeated measures outcomes is not 
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limited to those we have applied in this thesis. In medical research, we also 
encounter other types of outcomes: ordinal, multinomial or count data. In this 
section we recommend suggestions for future studies involving other outcomes 
which have been not evaluated in this thesis.  
 
Ordinal outcome    
Previous studies on the evaluation of exposures such as dietary fatty acid, 
physical activity, cardiovascular risk factor or white blood cell count with early or 
late stage of AMD have considered AMD as a binary outcome (Knudtson et al. 
2006; Shankar et al. 2007a; Tan et al. 2007; Tan et al. 2009). Moreover, these 
studies have only evaluated the baseline effect of the mentioned exposures on 
AMD despite the longitudinal nature of data. As explained earlier, early stage 
AMD may progress to late stage AMD which is more severe than early stage 
AMD and so, it may be treated as an ordinal outcome.  
 The mixed-effects ordinal logistic regression may be implemented for 
ordinal outcomes which are repeatedly measured over the study period. Similar to 
the mixed-effects logistic regression model, this approach provides a more precise 
estimate in comparison with conventional ordinal logistic regression, by 
appropriately accounting for intra-subject correlation which commonly arose with 
repeated measures of observations. Moreover, this model can overcome missing 
data by full utilization of data (Li et al. 2011).  
 Hierarchical, multilevel or clustered data structures are often encountered 
in epidemiological and medical research. For example, in studying the 
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relationship between birth weight and maternal age, the data may be collected 
from a large number of maternity units located in different hospitals. Here, the 
individuals are said to be nested within the maternity units, and the maternity 
units nested within different hospitals (Goldstein et al. 2002). The maternity units 
may have different mean birth weights, so that knowledge of the maternity unit 
already conveys some information about the baby. Multilevel data structures also 
arise in longitudinal studies where measurements are clustered within individuals 
(Li et al. 2011). For example, different stage of AMD may occur in the right or 
left eye, although most previous studies evaluated the relationships in any eye 
(Knudtson et al. 2006; Shankar et al. 2007a; Tan et al. 2007; Tan et al. 2009). 
Nevertheless, in the medical literature, multilevel data are often analyzed using 
fixed effects models (Peter et al. 2003). In the case of AMD, it would be useful to 
apply hierarchical modelling with more than one level of random-effects; first 
level within individuals and second level involving the site or eye where the 
outcome occurs. Thus the mixed-effects ordinal logistic regression modelling may 
be further extended to data involving hierarchical structure (Li et al. 2011). 
 
Multinomial outcome  
There have been many longitudinal studies which have investigated the 
relationship between different exposures such as FPG, alcohol consumption, 
smoking, retinal vessel caliber, antioxidant nutrient intake or cardiovascular risk 
factors with risk of different sub-types of cataract, namely nuclear, cortical and 
PSC, cross-sectionally, despite the longitudinal nature of study design. These 
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studies have all considered the different cataract subtypes as separate binary 
outcomes (Klein et al. 1998; Kanthan et al. 2010; Kanthan et al. 2011; Tan et al. 
2008a; Tan et al. 2008b; Tan et al. 2008c) although the classification of cataract 
subtypes, cortical, nuclear and PSC cataract, may be treated as a multinomial 
outcome. If the observations are independent, the multinomial or polychotomous 
logistic regression model (Cox 1970; Bock 1970; Nerlove and Press 1973; Placket 
1974; Agresti 2012) can be used to assess the influence of covariates on the 
development of cataract which is classified on a nominal scale. However, in the 
BMES study, the subjects were repeatedly measured at scheduled follow-ups. In 
this case, the use of the ordinary multinomial logistic regression model assuming 
independence of observations would be problematic, since observations from the 
same cluster or subject are usually correlated (Hedeker et al. 2003). A mixed-
effects multinomial logistic regression model would be appropriate for such 
analysis and it appropriately accounts for intra-subject correlation which arose in 
repeated measures data (Hedeker 2003). The analysis may also be extended to 
account for the occurrence of cataract in the right or left eye by means of 




Count data frequently occurs in epidemiology and medicine. Some examples of 
count outcome include number of new enhancing lesions seen on monthly 
magnetic resonance imaging (MRI) of the brain, number of hospitalizations over a 
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period of time or number of patients ―at risk‖ with a differing years of exposure. 
Suicide is also an example of count outcome, in which the time of happening is 
not predictable, but we only know how many events occur during a period of 
time, for example during a year. In longitudinal study design, where the exposure 
of interest such as emotional mood or drug abuse status were repeatedly measured 
over the study period, it would be useful to study the relationship between 
emotional mood or drug abuse with suicide by applying the mixed-effects Poisson 
regression model (Gibbons et al. 2008). The mixed-effects Poisson regression 
model accounts for intra-subject correlation arising from repeated measures, 
yielding a more robust estimate of the effect of interest as compared with the 
conventional Poisson regression model (Böckenholt et al. 2003). 
 
7.5 Conclusion  
The results of this thesis clearly demonstrate that accounting for baseline and 
further follow-up information allow for a more accurate and precise estimation of 
the effect of MetS and its components on all-cause and cause-specific mortality, 
age-related cataract as well as AMD. Moreover, in the analysis of competing risks 
outcomes, the competing risks model in comparison with the conventional cause-
specific regression showed narrower 95% CIs. This avoids the potential problem 
of extreme parameter estimates occurring due to chance when the estimates are 
based on small numbers. 
The advanced statistical modelling techniques, such as Cox regression 
model with time-dependent covariate allow researchers to handle time-dependent 
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covariate in order to evaluate the effect of changes in MetS over time on mortality 
at different time points after accounting for all available covariate information 
over the entire duration of study follow-up. This model also allows us to 
distinguish short from long term effect of MetS on mortality. Moreover, random-
effects complementary log-log regression model used in this proposed thesis 
allows us to handle interval-censored data to explore the effect of changes in 
MetS over time on sub-types of cataract at different time intervals, after 
accounting for all available exposure information over the entire duration of study 
follow-up. This model also allows us to capture effect at varying time interval on 
different subtypes of cataract. 
In addition, the proposed advanced models provide a more flexible 
modelling framework in terms of repeated measures, and are able to overcome the 
problem with missing data. Besides, they account for intra-subject correlation 
which arose with repeated measures, thus yielding a more accurate and stronger 
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Blue Mountains Eye Study
Time-dependent
a b s t r a c t
Aims: To evaluate the association between metabolic syndrome (MetS) components and
mortality over time.
Methods: 3086 residents aged 49 years were followed in the Blue Mountains Eye Study,
Australia. MetS components as defined by the International Diabetes Federation criteria
were measured at baseline (1992–1994), 5-year (1997–1999) and 10-year (2002–2004). Using
Cox proportional hazards and competing risks models with MetS as a time-dependent
covariate, we estimated the effects of MetS on all-cause and cause-specific mortality. Time-
dependent receiver-operating-characteristic curve, integrated-discrimination-improve-
ment and net-reclassification-improvement tests assessed predicting abilities of individual
and combined MetS components.
Results: Effect of MetS on mortality increased with time: all cause: 2-year: adjusted hazard
ratio 0.96 [95% confidence interval 0.69–1.34]; 5-year: 1.06 [0.84–1.32]; 10-year: 1.23 [1.01–1.51];
and CHD: 2-year: 0.46 [0.20–1.03]; 5-year: 0.70 [0.41–1.21]; 10-year: 1.62 [1.02–2.59]. Conversely,
MetS was associated with an increased risk of cancer death at 2-year only: 1.62 [1.01–2.62];
but not 5-year: 1.30 [0.94–1.81] or 10-year: 0.90 [0.57–1.44]. The discrimination analyses
showed that different MetS components were associated with different causes of death.
Conclusions: The long-term effect of MetS on all-cause and CHD mortality in an older
population was detected using time-dependent models while simulating the real scenarios
of MetS changes over time.
# 2012 Elsevier Ireland Ltd. All rights reserved.
Contents available at Sciverse ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier.com/locate/diabres1. Introduction
Metabolic syndrome (MetS) was first described in the 1920s as
the clustering of hypertension, hyperglycemia and gout [1],* Corresponding author at: Saw Swee Hock School of Public Health, Na
117597, Singapore. Tel.: +65 65164973; fax: +65 67791489.
E-mail address: ephtbc@nus.edu.sg (B.C. Tai).
0168-8227/$ – see front matter # 2012 Elsevier Ireland Ltd. All rights 
http://dx.doi.org/10.1016/j.diabres.2012.11.005with current definitions, namely European Group for the Study
of Insulin Resistance (EGIR), World Health Organisation
(WHO), Third Report of the National Cholesterol Education
Program Adult Treatment Panel (ATP-3), and the International
Diabetes Federation (IDF) [2], including components of obesity,tional University of Singapore, 16 Medical Drive (MD3), Singapore
reserved.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 9 9 ( 2 0 1 3 ) 2 0 9 – 2 1 6210insulin resistance, dyslipidemia and hypertension [1]. In
middle-age populations, the adverse effect of Mets on
morbidity and mortality has been established [3–5], but the
utility of MetS in predicting mortality amongst the elderly is
doubtful. First, underweight elderly populations may be
predisposed to an increased risk of mortality [6,7]. Secondly,
some MetS components, namely hypertriglyceridemia and
diastolic blood pressure (BP), are not clearly related to poor
health outcomes later in life [8,9]. Furthermore, the cut-off
point for individual MetS components may not be appropriate
for predicting mortality in the elderly population, since these
distributions were often characterized in middle-age popula-
tions [10].
While many studies have examined the relationship
between MetS and mortality, there are still key unanswered
questions. First, the relationship between MetS with all-cause
and cause-specific mortality remains unclear. Some studies
showed MetS to be a predictor of all-cause [11,12] and coronary
heart disease (CHD) mortality [11–13], whereas other studies
demonstrated no effects of MetS on all-cause [14,15], CHD
[14,15] or cardiovascular disease (CVD) [12,14,15] deaths in the
elderly. Although MetS was found to predict cancer death in
some studies [13,16], this relationship was not evident in one
study [12].
Second, individual MetS components may have different
effects on mortality. While hypertension [17], hyperglyce-
mia [11,13,17,18], low HDL [11,13,18] and high triglyceride
levels [12] have been shown to predict all-cause and
CVD-death, there is inconsistency with regards to which
of these MetS components better predicts mortality. Third,
it remains unclear whether MetS as a whole or its
individual components provide a better prediction of all-
cause and cause-specific mortality [19,20]. Finally, no
studies have clarified whether earlier or most updated
status of MetS best predicts all-cause and cause-specific
mortality.
In this study, we evaluated the effect of MetS and its
components on subsequent all-cause and cause-specific
mortality in an older Australian population. We fully utilized
the information on MetS collected at baseline, 5-year and 10-
year visits to unravel the relationship between MetS and
mortality, and to determine whether this association changes
with time.
2. Materials and methods
2.1. Study design
The Blue Mountains Eye Study (BMES) is a population-based
cohort study of vision, common eye diseases and other
health outcomes of a suburban population in the west of
Sydney, Australia [21]. Between 1992 and 1994, non-
institutionalised permanent residents aged 49 years and
older were invited to participate in this study, and were
requested to return for follow-up examinations at 5-year
(1997–1999) and 10-year (2002–2004). We included 3086
participants at baseline who had complete information for
the study factors. The BMES was approved by the Human
Research Ethics Committee of the University of Sydney andconducted according to the Helsinki Declaration. Written
informed consent was obtained from all participants at each
examination. Recruitment details have been previously
described [21].
2.2. Exposure measurements
At each visit, trained interviewers completed a comprehen-
sive questionnaire comprising demographic information,
smoking status, eye and general medical history including
hypertension, diabetes, and pre-existing diseases (namely,
cancer, angina, acute myocardial infarction (AMI), stroke
and chronic lung disease) as well as medication used.
Height, weight and seated BP [22] were measured. Fasting
pathology tests, including total cholesterol, HDL cholesterol
and triglycerides [23] and fasting plasma glucose (FPG) [24],
were also measured within a month of each interview.
2.3. Definition of metabolic syndrome
It has been reported that EGIR, WHO and ATP-3 definitions for
MetS were not as successful in predicting diabetes and
cardiovascular disease as compared to IDF definition [2].
Thus, in this study, we define MetS based on the IDF criteria.
This is a diagnostic tool for both research purpose and clinical
practice and can be used relatively easily in any country by any
physician to identify patients at increased risk of developing
health related outcomes. Moreover, studies have suggested
that the IDF criteria is more reliable for diagnosing MetS in
predictive model for coronary clinical status in type 2 diabetes
populations [2,25].
MetS was defined according to the IDF criteria [2] as obesity
(i.e. body mass index (BMI) >30 kg/m2) plus any two of the
following four factors: serum triglyceride level 1.7 mmol/L or
specific treatment for this lipid abnormality; serum HDL
cholesterol <1.03 mmol/L in men and <1.29 mmol/L in
women, or specific treatment for this lipid abnormality;
systolic BP 130 mmHg or diastolic BP 85 mmHg, or
treatment of previously diagnosed hypertension; or FPG
5.6 mmol/L, or previous diagnosis or specific treatment for
type 2 diabetes.
2.4. Mortality
Deaths occurring between the baseline examination (1992–
1994) and 31 December 2007 were confirmed by matching
the demographic information of the participants with the
Australian National Death Index (NDI), using probabilistic
record linkage [26]. The causes of death were provided by
the NDI using the International Classification of Diseases
(ICD) 9th revision and the International Statistical Classifi-
cation of Diseases, 10th revision. For example, ICD-9 codes
430.0–438.9 and ICD-10 codes 160.0–169.9 were classified as
stroke-related deaths, whereas ICD-9 codes 410.0-9, 411.0-8,
412, 414.0-9, and ICD-10 codes 121.0-9, 122.0-9, 123.0-8,
124.0-9, 125.0-9 were classified as cardiovascular related
deaths. The sensitivity and specificity of the Australian
NDI have been estimated as 93.7% and 100% for all deaths,
and 92.5% and 89.6% respectively, for cardiovascular deaths
[26].
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Independent sample t-test and chi-square tests were used to
evaluate the relation between continuous and categorical
covariates with MetS status, respectively. We utilized all
information on MetS and its components that were recorded
for each subject at baseline, 5-year and 10-year follow-up visits
in the analysis. Data were thus available with respect to how
MetS (components) might have changed in each subject
throughout the study duration. Therefore, the Cox propor-
tional hazards and competing risks regression models with
time-dependent covariates [27] were used to determine
the relationship between MetS and its components with
all-cause and cause-specific mortality [28], and evaluate
whether the association changes with time. In these models,
MetS and its individual components were regarded as time-
dependent covariables [27], whereas potential confounders
such as age, sex, smoking, alcohol consumption, physical
activity and pre-existing disease status (namely, cancer,
angina, AMI, stroke and chronic lung disease), which were
collected at baseline, were considered as fixed covariates.
To account for the situation where MetS, may change over
time, we implemented the Cox model with time-dependent
covariate and modeled the hazard function as [27]:
hðtÞ ¼ expðb1  MetS þ b2  MetStÞ  h0ðtÞ
where h0(t) is the baseline hazard function, and b1 and b2 are
the regression coefficients. The model contains MetS and a
second term MetSt corresponding to an interaction between
MetS and the survival time. The interaction term is formed
from the product of MetS and the survival time t, that is,
MetSt = MetS  t. This model can be extended to include other
fixed and time-dependent covariates. It allows MetS to beTable 1 – Characteristics of the study population by metabolic 
up.
Total (n = 3086) Baselin
No MetS
(n = 2702)
Mean baseline age in years (SD) 65.9 (9.5) 66.0(9.6) 
Sex (%)
Female 1759 (57.0) 1509 (55.8)f
Male 1327 (43.0) 1193 (44.2) 
Smoking status (%)
Current smoker 439 (14.2) 389 (14.4) 
Ex-smoker 1122 (36.4) 980 (36.3) 
Non-smoker 1525 (49.4) 1333 (49.3) 
Any pre-existing diseasea (%) 812 (26.3) 701 (25.9) 
Mean BMI (kg/m2)(SD) 26.2 (4.4) 25.1 (3.4)f
Low HDL (%)b 1012 (32.8) 849 (31.4)f
High triglyceride (%)c 1283 (41.6) 989 (36.6)f
Hypertension (%)d 2645 (85.7) 2271 (84.1)f
Elevated FPG (%)e 547 (17.7) 400 (14.8)f
BMI: body mass index; FPG: fasting plasma glucose; MetS: metabolic syn
a Any pre-existing disease (namely, cancer, angina, acute myocardial in
b Serum HDL cholesterol <1.03 mmol/L in men and <1.29 mmol/L in wo
c Serum triglyceride level 1.7 mmol/L or specific treatment for this lipid
d Systolic blood pressure 130 mmHg or diastolic blood pressure 85 mm
e Fasting plasma glucose5.6 mmol/L, or previous diagnosis or specific t
f P < 0.05.linearly dependent on the survival time, so we were able to
estimate the hazard ratio (HR) of MetS for t = 2, 5 or 10 years.
We also explored possible interactions between time-
dependent MetS and its components with age, sex, and pre-
existing disease. Additionally, the proportional hazards
assumption underlying the Cox model was checked for
individual covariates and globally.
Furthermore, to assess the prognostic value of MetS
components on the risk of all-cause and cause-specific
mortality, we implemented the time-dependent receiver-
operating-characteristic (ROC) curve for censored survival
model [29] and summarized the results of area under the curve
at time t (AUC(t)) using the Harrell’s concordance index [30,31].
Bootstrap model was used to compare the AUC.
Since the AUC may not be sensitive enough to express the
improvement of discrimination performance, we also used
two other methods, namely the net reclassification improve-
ment (NRI) and integrated discrimination improvement (IDI)
as described by Pencina et al. [32], for censored survival model
[33,34] to evaluate the prediction of MetS components on all-
cause and cause-specific mortality risk.
All statistical evaluations were made assuming a two-sided
test based on a 5% level of significance using STATA version 11
and R statistical package (www.r-project.org).
3. Results
Table 1 presents the characteristics of study subjects based on
MetS status at baseline, 5- and 10-year follow-up. The mean
age of the 3086 subjects was 65.9 (standard deviation (SD) 9.5)
years, and 43% were male. Apart from BMI, a mandatory












65.0 (8.6) 64.8 (8.7)f 63.2 (7.9) 63.1 (7.7)f 61.0 (6.7)
250 (65.1) 1003 (56.6)f 217 (63.6) 837 (58.4) 130 (65.3)
134 (34.9) 769 (43.4) 124 (36.4) 596 (41.6) 69 (34.7)
50 (13.0) 224 (12.6) 36 (10.6) 162 (11.3) 25 (12.6)
142 (37.0) 619 (34.9) 132 (38.7) 489 (34.1) 66 (33.2)
192 (50.0) 929 (52.4) 173 (50.7) 782 (54.6) 108 (54.2)
111 (28.9) 423 (23.9) 93 (27.3) 276 (19.3)f 59 (29.7)
33.7 (3.3) 25.7 (4.4)f 33.8 (3.6) 26.3 (4.2)f 33.5 (3.5)
163 (42.5) 372 (23.2)f 160 (56.9) 324 (27.3)f 123 (61.8)
294 (76.6) 557 (31.4)f 235 (68.9) 202 (20.8)f 110 (61.8)
374 (97.4) 1574 (89.7)f 339 (99.4) 1081 (80.8)f 191 (96.0)
147 (38.3) 300 (19.9)f 157(40.0) 126 (8.8)f 77 (38.7)
drome; SD: standard deviation.
farction, stroke and chronic lung disease).
men, or specific treatment for this lipid abnormality.
 abnormality.
Hg, or treatment of previously diagnosed hypertension.
reatment for type 2 diabetes.
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cholesterol (32.8%) at baseline (Table 1). The prevalence of
MetS increased slightly to 16.1% (95% confidence interval (CI)
14.6–17.8%) after 5 years follow-up from 12.4% (95% CI 11.3–
13.6%) at baseline, and was 12.2% (95% CI 10.6–13.9%) after 10
years follow-up.
3.1. All-cause mortality
Over a median follow-up duration of 14.6 years, 1170 (38%)
deaths were reported. Among the covariates that were
repeatedly measured at the baseline, 5-year and 10-year
follow-up visits, without any adjustment, elevated glucose,
hypertension, triglyceride and BMI showed a time-dependent
association with all-cause mortality (Table 2).
Among the fixed covariates considered in this study,
gender, age, pre-existing disease and smoking wereTable 2 – Bivariate association between fixed and time-depend
All-cause (n = 1170) CHD (n = 279
HR (95% CI) P-value HR (95% CI) P
Fixed covariate
Sex (Male) 1.54 (1.37–1.72) <0.001 1.63 (1.28–2.06) <
Age 1.11 (1.10–1.12) <0.001 1.10 (1.09–1.11) <
Smoking status
Non-smoker Reference (1) Reference (1) 
Ex-smoker 1.39 (1.22–1.57) <0.001 1.11 (0.86–1.44) 0
Current smoker 1.46 (1.24–1.73) <0.001 1.13 (0.79–1.59) 0
Any, pre-existing
diseasea
2.20 (1.95–2.46) <0.001 2.72 (2.15–3.44) <
Time-dependent covariate
MetS
2-year 0.76 (0.55–1.04) 0.090 0.35 (0.16–0.78) 0
5-year 0.85 (0.68–1.05) 0.133 0.54 (0.32–0.93) 0
10-year 1.02 (0.84–1.25) 0.822 1.31 (0.83–2.08) 0
BMI >30
2-year 0.58 (0.43–0.78) <0.001 0.45 (0.25–0.82) 0
5-year 0.66 (0.54–0.80) <0.001 0.60 (0.40–0.90) 0
10-year 0.81 (0.67–0.96) 0.017 0.98 (0.68–1.41) 0
Elevated glucoseb
2-year 1.17 (0.92–1.50) 0.207 1.32 (0.83–2.11) 0
5-year 1.21 (1.03–1.43) 0.024 1.34 (0.98–1.82) 0
10-year 1.28 (1.08–1.52) 0.005 1.36 (0.94–1.96) 0
Low HDLc
2-year 0.97 (0.78–1.20) 0.751 1.03 (0.68–1.56) 0
5-year 0.94 (0.81–1.09) 0.397 0.90 (0.68–1.20) 0
10-year 0.89 (0.76–1.05) 0.164 0.73 (0.50–1.05) 0
High triglycerided
2-year 1.21 (0.99–1.48) 0.069 0.93 (0.63–1.39) 0
5-year 1.15 (1.01–1.32) 0.044 1.05 (0.80–1.37) 0
10-year 1.07 (0.92–1.24) 0.389 1.27 (0.92–1.74) 0
Hypertensione
2-year 1.26 (0.90–1.74) 0.174 1.41 (0.73–2.75) 0
5-year 1.39 (1.10–1.74) 0.443 1.52 (0.96–2.40) 0
10-year 1.64 (1.28–2.09) <0.001 1.72 (0.98–3.04) 0
BMI: body mass index; CHD: coronary heart disease; CI: confidence inter
a Any pre-existing disease (namely, cancer, angina, acute myocardial in
b Fasting plasma glucose 5.6 mmol/L, or previous diagnosis or specific 
c Serum HDL cholesterol <1.03 mmol/L in men and <1.29 mmol/L in wo
d Serum triglyceride level 1.7 mmol/L or specific treatment for this lipi
e Systolic blood pressure 130 mmHg or diastolic blood pressure 85 mmassociated with all-cause mortality (Table 2). Adjusting for
these fixed covariates, the risk of all-cause-mortality
increased gradually from 2-year to 10-year follow-up
amongst those with MetS (2-year: HR 0.96 [95% CI 0.69–
1.34]; 5-year: HR 1.06 [95% CI 0.84–1.32]; 10-year: HR 1.23
[95% CI 1.01–1.51]) (Table 3). However, individually, none of
the MetS components appeared to have a significant effect
on all-cause mortality.
3.2. Cause-specific mortality
Of the 1170 reported deaths, 279 (23.9%) were CHD-deaths,
130 (11.1%) were stroke-deaths and 342 (29.2%) were cancer-
deaths. Individually, hypertension and high triglyceride
showed a time-dependent association with stroke and
cancer deaths, respectively. Further, BMI >30 was inversely
associated with CHD- and stroke-deaths, with notablyent risk factors with all-cause and cause-specific mortality.
) Stroke (n = 130) Cancer (n = 342)
-value HR (95% CI) P-value HR (95% CI) P-value
0.001 1.01 (0.71–1.42) 0.978 1.51 (1.22–1.87) <0.001
0.001 1.10 (1.08–1.12) <0.001 1.04 (1.03–1.06) <0.001
Reference (1) Reference (1)
.412 0.78 (0.53–1.15) 0.208 1.46 (1.16–1.85) 0.001
.514 0.88 (0.52–1.48) 0.628 1.62 (1.20–2.18) 0.002
0.001 1.61 (1.13–2.31) 0.009 1.70 (1.37–2.12) <0.001
.010 0.16 (0.03–0.90) 0.037 1.42 (0.88–2.29) 0.152
.025 0.26 (0.08–0.86) 0.027 1.14 (0.82–1.57) 0.443
.245 0.58 (0.30–1.11) 0.103 0.78 (0.49–1.24) 0.229
.009 0.07 (0.01–0.49) 0.007 1.00 (0.63–1.58) 0.996
.013 0.14 (0.04–0.52) 0.003 0.88 (0.65–1.19) 0.409
.906 0.40 (0.22–0.75) 0.004 0.71 (0.48–1.05) 0.084
.245 0.42 (0.16–1.09) 0.074 1.16 (0.76–1.78) 0.489
.067 0.61 (0.31–1.18) 0.142 1.20 (0.90–1.60) 0.205
.099 1.14 (0.72–1.78) 0.578 1.27 (0.91–1.79) 0.163
.894 1.11 (0.53–2.32) 0.779 0.93 (0.63–1.36) 0.705
.487 1.02 (0.62–1.70) 0.929 0.88 (0.67–1.14) 0.323
.090 0.89 (0.58–1.36) 0.594 0.79 (0.57–1.10) 0.162
.738 1.14 (0.57–2.27) 0.712 1.79 (1.25–2.57) 0.001
.737 1.05 (0.66–1.69) 0.831 1.42 (1.12–1.80) 0.004
.145 0.92 (0.62–1.37) 0.690 0.96 (0.70–1.31) 0.791
.308 13.2 (3.34–51.8) <0.001 1.02 (0.60–1.74) 0.946
.071 8.01 (2.65–24.22) <0.001 1.10 (0.76–1.58) 0.615
.060 3.50 (1.42–8.66) 0.007 1.25 (0.79–1.95) 0.338
val; HR: hazard ratio; MetS: metabolic syndrome.
farction, stroke and chronic lung disease).
treatment for type 2 diabetes.
men, or specific treatment for this lipid abnormality.
d abnormality.
Hg, or treatment of previously diagnosed hypertension.
Table 3 – Time-dependent effects of metabolic syndrome and its components on all-cause and cause-specific mortality,
adjusted for age, gender, smoking status, pre-existing disease at baseline (namely, cancer, angina, acute myocardial














HR (95% CI) P-value
All-cause, n = 1170
MetS 152 (13.0) 0.96 (0.69–1.34) 0.825 75 (13.2) 1.06 (0.84–1.32) 0.634 21 (10.7) 1.23 (1.01–1.51) 0.046
BMI >30 189 (16.2) 0.83 (0.61–1.12) 0.213 103 (18.1) 0.90 (0.74–1.11) 0.329 36 (18.3) 1.05 (0.88–1.25) 0.603
Elevated FPGa 272 (23.3) 0.95 (0.74–1.22) 0.695 141 (29.2) 0.97 (0.82–1.14) 0.677 29 (25.2) 0.99 (0.83–1.18) 0.895
Low HDLb 334 (28.6) 1.06 (0.85–1.32) 0.621 147 (30.4) 1.00 (0.85–1.17) 0.975 59 (36.0) 0.91 (0.76–1.07) 0.253
High Triglyceridec 517 (44.2) 1.08 (0.89–1.32) 0.475 831 (71.0) 1.03 (0.90–1.19) 0.642 33 (27.3) 0.97 (0.83–1.13) 0.655
Hypertensiond 1043 (89.2) 0.93 (0.66–1.30) 0.667 512 (91.3) 1.02 (0.82–1.30) 0.835 157 (80.1) 1.21 (0.94–1.55) 0.139
CHD-death, n = 279
MetS 32 (11.5) 0.46 (0.20–1.03) 0.060 17 (14.2) 0.70 (0.41–1.21) 0.198 8 (21.1) 1.62 (1.02–2.59) 0.044
BMI >30 44 (15.8) 0.67 (0.40–1.18) 0.850 26 (21.7) 0.89 (0.59–1.34) 0.578 11 (29.0) 1.43 (1.01–2.03) 0.045
Elevated FPGa 70 (25.1) 1.08 (0.71–1.64) 0.725 31 (30.4) 1.04 (0.76–1.43) 0.792 9 (47.4) 1.04 (0.71–1.51) 0.847
Low HDLb 71 (25.4) 1.18 (0.69–2.02) 0.541 30 (29.4) 0.94 (0.70–1.26) 0.671 11 (29.0) 0.75 (0.51–1.08) 0.124
High Triglyceridec 124 (44.4) 0.85 (0.57–1.27) 0.437 210 (75.3) 0.96 (0.73–1.25) 0.739 8 (40.0) 1.15 (0.84–1.58) 0.388
Hypertensiond 254 (91.0) 1.07 (0.55–2.10) 0.829 102 (86.4) 1.13 (0.71–1.79) 0.599 30 (81.1) 1.23 (0.69–2.20) 0.488
Stroke-death, n = 130
MetS 10 (7.7) 0.21 (0.04–1.18) 0.076 5 (7.0) 0.34 (0.10–1.12) 0.076 1 (4.4) 0.76 (0.39–1.46) 0.409
BMI >30 11 (8.5) 0.10 (0.02–0.70) 0.020 6 (8.5) 0.20 (0.05–0.74) 0.016 2 (8.7) 0.58 (0.31–1.08) 0.086
Elevated FPGa 26 (20.0) 0.36 (0.14–0.93) 0.034 16 (25.4) 0.52 (0.26–1.00) 0.051 2 (14.3) 0.97 (0.62–1.53) 0.905
Low HDLb 36 (27.7) 1.18 (0.57–2.43) 0.652 21 (33.3) 1.08 (0.65–1.79) 0.759 12 (40.0) 0.97 (0.63–1.48) 0.874
High Triglyceridec 57 (43.9) 1.10 (0.56–2.19) 0.778 91 (70.0) 1.01 (0.63–1.62) 0.975 5 (35.7) 0.89 (0.60–1.33) 0.576
Hypertensiond 121 (93.1) 10.38 (2.57–42.1) 0.001 67 (98.5) 6.15 (2.00–18.95) 0.002 18 (85.7) 2.58 (1.03–6.43) 0.042
Cancer-death, n = 342
MetS 52 (15.2) 1.62 (1.01–2.62) 0.047 19 (12.2) 1.30 (0.94–1.81) 0.113 7 (7.6) 0.90 (0.57–1.44) 0.674
BMI >30 64 (18.7) 1.21 (0.77–1.92) 0.407 26 (16.7) 1.08 (0.79–1.47) 0.638 11 (20.8) 0.88 (0.60–1.30) 0.531
Elevated FPGa 87 (25.4) 0.98 (0.64–1.50) 0.929 38 (28.4) 1.02 (0.76–1.35) 0.914 5 (15.6) 1.08 (0.77–1.51) 0.668
Low HDLb 88 (25.7) 0.98 (0.67–1.43) 0.910 41 (30.4) 0.91 (0.70–1.19) 0.497 12 (28.6) 0.81 (0.58–1.13) 0.214
High Triglyceridec 161 (47.1) 1.70 (1.19–2.43) 0.004 239 (69.9) 1.34 (1.05–1.72) 0.017 8 (23.5) 0.91 (0.66–1.25) 0.564
Hypertensiond 297 (86.8) 0.83 (0.48–1.43) 0.504 141 (91.6) 0.89 (0.62–1.29) 0.537 40 (75.5) 1.00 (0.63–1.57) 0.988
BMI: body mass index; CI: confidence interval; CHD: coronary heart disease; FPG: fasting plasma glucose; HR: hazard ratio; MetS: metabolic
syndrome.
a Fasting plasma glucose 5.6 mmol/L, or previous diagnosis or specific treatment for type 2 diabetes.
b Serum HDL cholesterol <1.03 mmol/L in men and <1.29 mmol/L in women, or specific treatment for this lipid abnormality.
c Serum triglyceride level 1.7 mmol/L or specific treatment for this lipid abnormality.
d Systolic blood pressure 130 mmHg or diastolic blood pressure 85 mmHg, or treatment of previously diagnosed hypertension.
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(Table 2).
After adjusting for age, sex, smoking status and pre-
existing disease status at baseline, the association between
MetS and CHD-death changed with time, with increased risk
of CHD-death at 10-year, and reduced risk at 2- and 5-year
(2-year: HR 0.46 [95% CI 0.20–1.03]; 5-year: HR 0.70 [95% CI 0.41–
1.21]; 10-year: HR 1.62 [95% CI 1.02–2.59]. Conversely, MetS was
associated with a notably higher risk of cancer death at 2-year,
with diminished risk by 10-year (2-year: HR 1.62 [95% CI 1.01–
2.62]; 5-year: HR 1.30 [95% CI 0.94–1.81]; 10-year: HR 0.90 [95% CI
0.57–1.44]). Among the 5 MetS components, high triglyceride
also exhibited a time-dependent association with cancer
death, where the elevation in risk of cancer death at 2-year had
dissipated by the 10-year follow-up (Table 3). There was no
evidence of effect of MetS on stroke-death, although hyper-
tension was associated with an increased risk of stroke death,
with the risk at 2-year, albeit with small numbers, being higher
as compared to later time periods (Table 3).3.3. Time-dependent ROC
We further sought to identify the individual and specific
combinations of MetS components that best predicted all-
cause and cause-specific mortality (Table 4). Among the 5
individual MetS components, triglyceride was the best single
predictor of all-cause and cause-specific mortality (Table 4).
For all-cause mortality, the best model comprised three
components and included triglyceride, HDL-cholesterol and
glucose. In the case of cause-specific mortality, the best model
consisted of four components and were as follows: CHD-
death: triglyceride, HDL-cholesterol, glucose and BP; Stroke-
death: triglyceride, HDL-cholesterol, BMI and BP; Cancer-
death: triglyceride, HDL-cholesterol, glucose and BMI. In the
evaluation of all-cause and cause-specific mortality, there was
significant improvement to the model fit as each new
component was added to the more parsimonious preceding
model (all P < 0.05), with no further improvement thereafter.
The result indicates that when MetS components were
Table 4 – Time-dependent ROC curve, integrated discrimination improvement and net reclassification improvement for
prediction of all-cause and cause-specific mortality.









Best single component of MetS T 0.5281 – – 0.8207 – –
Best 2 components of Mets T + H 0.5399b 0.001 0.045 0.8210 <0.001 <0.001
Best 3 components of Mets T + H + G 0.5458b 0.001 0.046 0.8215 <0.001 <0.001
Best 4 components of Mets T + H + G + BP 0.5501 0.002c 0.048c 0.8217 <0.001 <0.001
5 components of Mets T + H + G + BP + BMI 0.5531 0.000 0.000 0.8218 <0.001 <0.001
CHD-death
Best single component of MetS T 0.5275 – – 0.8723 – –
Best 2 components of Mets T + H 0.5407b 0.004 0.025 0.8727 <0.001 <0.001
Best 3 components of Mets T + H + G 0.5485b 0.004c 0.073c 0.8734 <0.001 <0.001
Best 4 components of Mets T + H + G + BP 0.6340a 0.007c 0.100c 0.8756 <0.001 <0.001
5 components of Mets T + H + G + BP + BMI 0.6351 0.000 0.000 0.8756 <0.001 <0.001
Stroke-death
Best single component of MetS T 0.5305 – – 0.8886 – –
Best 2 components of Mets T + H 0.5435a 0.001 0.031 0.8920 <0.001 <0.001
Best 3 components of Mets T + H + BMI 0.5602 0.002c 0.065 0.8925 <0.001 <0.001
Best 4 components of Mets T + H + BMI + BP 0.5871a 0.003c 0.092c 0.8972 <0.001 <0.001
5 components of Mets T + H + BMI + BP + G 0.6030 0.000 0.000 0.8972 <0.001 <0.001
Cancer-death
Best single component of MetS T 0.5300 – – 0.8096 – –
Best 2 components of Mets T + H 0.5418b 0.001 0.010 0.8103 <0.001 <0.001
Best 3 components of Mets T + H + G 0.5474b 0.004 0.052 0.8111 <0.001 <0.001
Best 4 components of Mets T + H + G + BMI 0.6050a 0.006c 0.098c 0.8111 <0.001 <0.001
5 components of Mets T + H + G + BMI + BP 0.6322 0.006c 0.105c 0.8111 <0.001 <0.001
AUC(t): time-dependent area under curve; IDI: integrated discrimination improvement; NRI: net reclassification improvement; BMI: body mass
index; BP: blood pressure; CHD: coronary heart disease; G: glucose; H: HDL-cholesterol; MetS: metabolic syndrome; T: triglyceride.
Note: Model 1 without including age, sex, smoking status, pre-existing disease at baseline (namely, cancer, angina, acute myocardial infarction,
stroke and chronic lung disease) and Model 2 included above covariates.
a P < 0.05.
b P < 0.001, for comparison of AUC(t) with the model immediately preceding.
c Confidence interval for IDI and NDI estimate was significant (P < 0.05).
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However, after adjusting for age, sex, smoking status and pre-
existing disease status at baseline, none of these models were
statistically enhanced as compared with the preceding model
(Model 2, Table 4).
3.4. Integrated Discrimination Improvement (IDI) and Net
Reclassification Improvement (NRI)
Improvement in mortality risk reclassification was numeri-
cally better in the 4-component model. The components
included triglyceride, HDL-cholesterol, glucose and BP for all-
cause and CHD-death, and triglyceride, HDL-cholesterol, BMI
and BP for stroke-death. For cancer-death, the improvement
in discrimination persisted in the 5-component model (Model
1, Table 4). Generally, the results of IDI and NRI suggested
that combined MetS-components improved the discrimina-
tion of the model significantly (Model 1) (P < 0.05) in the
prediction of all-cause and cause-specific mortality risk
among the Australian elderly population. However, there
was no improvement in the discrimination of death after
including age, sex, pre-existing disease and smoking status
(Model 2, Table 4).4. Discussion
In this prospective cohort study of an Australian white
population participating in the BMES, we found the following:
First, MetS, exhibited a time-dependent association with all-
cause, CHD and cancer deaths. Secondly, the AUC(t), IDI and
NRI analyses showed that different MetS components were
associated with different causes of death. Finally, the
inclusion of age improved the model fitting substantially as
compared to any single or combined MetS components.
To the best of our knowledge, this is the first study to have
fully utilized the information of MetS recorded at baseline and
all-follow-up visits to determine whether its relationship with
mortality changes with time. Longitudinal studies that do not
account for changes in exposure over time will not be able to
distinguish between short and long term effects, and hence
may result in less precise estimates of the exposure effect on
outcomes [27].
In contrast to all-cause and CHD death, MetS was more
likely to be associated with a greater increase in risk of early
cancer death after 2 years, but this increased risk was
attenuated over time. This is likely due to the loss in weight of
cancer patients at end stage of cancers. Previous prospective
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follow-up duration ranging between 7 and 14 years [13,16]
have also found it to predict cancer death. MetS is a
multifactorial condition and the mechanisms behind its
associated increase in cancer mortality are not completely
understood [16]. However, excess glucose has been shown to
promote the formation of reactive oxygen species, which can
promote cancer development [16]. Moreover, previous stud-
ies with follow-up duration ranging between 4.4 and 12.3
years, examining the relationship between baseline MetS and
all-cause or CHD mortality, have reported inconsistencies in
the relationship [5,7,8,11–15]. In studying whether mortality
is associated with MetS, it is important to take into account
the duration of follow-up and changes in the status of MetS
over time.
When we considered only the information about MetS at
baseline, without taking into account changes in MetS status
at follow-up, we did not detect any effects of MetS on CHD and
all-cause mortality even after adjustment for age, sex,
smoking and pre-existing disease status (results not shown).
Therefore, the time-varying effects of MetS on all-cause and
cause-specific mortality would not have been detected if we
had only utilized its baseline information. The results of this
study underscore that the presence of MetS at longer term
follow-up (e.g. 10-year) is more likely to confer a better
prediction of all-cause and CHD death. Conversely, earlier
status of MetS better predicted early cancer death at 2-year
than current status of MetS. This argument is plausible, since
people with cancer are more likely to lose their weight over
time and as BMI is a mandatory component of MetS by
definition, they would not be categorized as having MetS.
However, the induction period between MetS components and
the incidence of cancer which had been started years before
cancer-death would be another main concern.
Interestingly, consistent with the increase in AUC(t), the
result of IDI and NRI tests showed MetS and its components
improved the performance of prediction of mortality.
Triglyceride was the best single predictor of all-cause and
cause-specific mortality in the elderly Australian population.
BMI, a mandatory MetS component based on the IDF criteria,
on its own was not as good a predictor. The findings that these
risk factors clustered, thus leading to an increase in mortality
risk may persuade physicians to treat their patients risk
factors as a whole, rather than treating each risk factor on its
own [35].
Another key finding of this study was that the model fit
improved significantly after adjusting for age, with more than
a 1.5-fold increase in AUC(t). This implied that age more than
any of the MetS components was the single most important
predictor of death in the elderly, and thus should be
appropriately accounted for in the analysis.
While this study has its strength such as a representative
elderly Australian population, high quality data collection,
long-term follow-up, full utilization of MetS information at
each visit, and low likelihood of misclassification error due to
high specificity and sensitivity of death registration, its
drawbacks must also be noted. First, the limited events for
stroke mortality suggest reduced statistical power when
evaluating this outcome in relation to time-dependent MetS.
Second, the prevalence of MetS at baseline (12.4%), 5-year(16.1%) and 10-year (12.1%) in this study was notably lower
than that reported by the Cardiovascular Health Study in USA
(28%) [17] and in other Australian study (23%) [36]. These
differences could be due to differences in age structure and
composition of the populations under study. In the former, US
adults aged 65 years without CVD at baseline were included
[36], while individuals aged 18 years were recruited in the
latter [17].
In conclusion, the time-dependent association between
MetS and all-cause, CHD- as well as cancer death underscores
the importance of fully accounting for the information about
MetS collected at each follow-up in order to better predict all-
cause and major causes of death among the elderly. Hence,
time-dependent models may be clinically more relevant, as
they simulate the real clinical scenarios on changes in MetS
and its components over time, in which physicians better
evaluate and manage the elderly.
Conflict of interest
The authors declare that they have no conflict of interest.
Acknowledgments
The Blue Mountains Eye Study was supported by the
Australian National Health and Medical Research Council
[Grant Nos. 974159, 991407, 211069].
The authors are indebted to Ms Ava Grace Tan and Dr
Erdahl Teber from Centre for Vision Research Westmead
Millennium, Institute University of Sydney, Australia for
helping us to access the data base of the Blue Mountains
Eye Study.
H.G.M. researched, analyzed and wrote the manuscript.
B.C.T. critically reviewed, edited and advised on the statistical
analysis and writing of manuscript. T.Y.W., E.S.T., J.J.W. and
P.M. reviewed, edited and contributed to the discussion of the
manuscript, while, J.L. reviewed/edited the statistical analysis
and results sections.
r e f e r e n c e s
[1] Alberti KGMM, Zimmet P, Shaw J, Diabetes UK. Metabolic
syndrome- a new world-wide definition. A consensus
statement from the International Diabetes Federation.
Diabet Med 2006;23:469–80.
[2] Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The
metabolic syndrome: a global public health problem and a
new definition. J Atheroscler Thromb 2005;12:295–300.
[3] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK,
Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome
and total and cardiovascular disease mortality in middle-
aged men. JAMA 2002;288:2709–16.
[4] Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP,
San Antonio Hearth Study. National Cholesterol Education
Program versus World Health Organization metabolic
syndrome in relation to all-cause and cardiovascular
mortality in the San Antonio Heart Study. Circulation
2004;110:1251–7.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 9 9 ( 2 0 1 3 ) 2 0 9 – 2 1 6216[5] Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K,
Pyorala K, DECODE Study Group. Prevalence of the
metabolic syndrome and its relation to all-cause and
cardiovascular mortality in nondiabetic European men and
women. Arch Intern Med 2004;164:1066–76.
[6] Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess
deaths associated with underweight, overweight, and
obesity. JAMA 2005;293:1861–7.
[7] Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ,
Hannan L, MacInnis RJ, et al. Body-mass index and
mortality among 1.46 million white adults. N Engl J Med
2010;363:2111–9.
[8] Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB,
Polak JF, et al. Risk factors for 5-year mortality in older
adults: the Cardiovascular Health Study. JAMA
1998;279:585–92.
[9] Burke GL, Arnold AM, Bild DE, Cushman M, Fried LP,
Newman A, et al. Factors associated with healthy aging:
the cardiovascular health study. J Am Geriatr Soc
2001;49:254–62.
[10] Wilson PW, D’Agostino RB, Levy D, Belanger AM,
Silbershatz H, Kannel WB. Prediction of coronary heart
disease using risk factor categories. Circulation
1998;97:1837–47.
[11] Zambon S, Zanoni S, Romanato G, Corti MC, Noale M,
Sartori L, et al. Metabolic syndrome and all-cause and
cardiovascular mortality in an Italian elderly population.
The Progetto Veneto Anziani Study. Diabetes Care
2009;32:153–9.
[12] Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S. Metabolic
syndrome and all-cause and cardiovascular disease
mortality Japan Public Health Center-Based Prospective
(JPHC). Study Circ J 2009;73:878–84.
[13] Akbaraly TN, Kivimaki M, Ancelin ML, Barberger-Gateau P,
Mura T, Tzourio C, et al. Metabolic syndrome, its
components, and mortality in the elderly. J Clin Endocrinol
Metab 2010;95:E327–32.
[14] Salminen M, Kuoppama¨ki M, Vahlberg T, Ra¨iha¨ I, Irjala K,
Kivela¨ SL. The metabolic syndrome defined by modified
International Diabetes Federation criteria and mortality: a
9-year follow-up of the aged in Finland. Diabetes Metab
2010;36:437–42.
[15] Sidorenkov O, Nilssen O, Grjibovski AM. Metabolic
syndrome in Russian adults: associated factors and
mortality from cardiovascular diseases and all causes.
BMC Public Health 2010;10:582.
[16] Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE,
Hand GA, et al. Metabolic syndrome and risk of cancer
mortality in men. Eur J Cancer 2009;5:1831–8.
[17] Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS.
Metabolic syndrome and mortality in older adults: the
Cardiovascular Health Study. Arch Intern Med
2008;168:969–78.
[18] Maggi S, Noale M, Gallina P, Bianchi D, Marzari C, Limongi F,
et al. Metabolic syndrome, diabetes and cardiovascular
disease in an elderly Caucasian cohort: the Italian
Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci
2006;61:505–10.
[19] Franks PW, Olsson T. Metabolic syndrome and early death:
getting to the heart of the problem. Hypertension
2007;49:10–2.[20] Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD,
Bouter LM, et al. Metabolic syndrome and 10-year
cardiovascular disease risk in the Hoorn Study. Circulation
2005;112:666–73.
[21] Mitchell P, Smith W, Wang JJ, Cumming RG, Leeder SR,
Burnett L. Diabetes in an older Australian population.
Diabetes Res Clin Pract 1998;41:177–84.
[22] 2003 World Health Organization (WHO)/International
society of hypertension (ISH) statement on management of
hypertension. J Hypertens 2003;21:1983-1992.
[23] Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year
incidence of diabetes in older Australians: the Blue
Mountains Eye Study. Med J Aust 2007;186:131–5.
[24] World Health Organization. Definition, Diagnosis and
Classification of Diabetes Mellitus and its complications.
Part 1: diagnosis and classification of diabetes mellitus.
Geneva: WHO, 1999.
[25] Bosevski M, Pemovska G, Bosevska G, Georgievska-Ismail L.
Clinical role of estimation metabolic syndrome’s
components in type 2 diabetic population with
symptomatic coronary artery disease—a comparison of
two criteria. Med Arh 2010;64:144–6.
[26] Magliano D, Liew D, Pater H, Kirby A, Hunt D, Simes J, et al.
Accuracy of the Australian National Death Index:
comparison with adjudicated fatal outcomes among
Australian participants in the Long-term Intervention with
Pravastatin in Ischaemic Disease (LIPID) study. Aust N Z J
Public Health 2003;27:649–53.
[27] Collett D. Modelling survival data in medical research, 2nd
ed., Chapman & Hall; 2003.
[28] Tai BC, Wee J, Machin D. Analysis and design of
randomised clinical trials involving competing risks
outcomes. Trials 2011;12:127.
[29] Chambless LE, Diao G. Estimation of time-dependent area
under the ROC curve for long-term risk prediction. Stat Med
2006;25:3474–86.
[30] Harrell Jr FE, Califf RM, Pryor DB, Lee KL, Rosati RA.
Evaluating the yield of medical tests. JAMA
1982;247:2543–6.
[31] Harrell Jr FE, Lee KL, Califf RM, Pryor DB, Rosati RA.
Regression modelling strategies for improved prognostic
prediction. Stat Med 1984;3:143–52.
[32] Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, Vasan RS.
Evaluating the added predictive ability of a new marker:
from area under the ROC curve to reclassification and
beyond. Stat Med 2008;27:157–72.
[33] http://www.bepress.com/harvardbiostat/paper107Yates.
Comparing risk scoring systems beyond the ROC paradigm
in survival analysis. Harvard University Biostatistics
Working Paper Series. Working paper 107.
[34] Kerr KF, McClelland RL, Brown ER, Lumley T. Evaluating
the incremental value of new biomarkers with integrated
discrimination improvement. Am J Epidemiol
2011;174:364–74.
[35] Wilken T. The metabolic syndrome, babies and bathwater.
Diabetologia 2005;49:421–2.
[36] Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande
E, Chittleborough C, et al. Population comparison of two
clinical approaches to the metabolic syndrome:
implications of the new International Diabetes Federation
consensus definition. Diabetes Care 2005;28:2777–9.
Clinical and Epidemiologic Research
Metabolic Syndrome and Risk of Age-Related Cataract over
Time: An Analysis of Interval-Censored Data Using a
Random-Effects Model
Haleh Ghaem Maralani,1,2 Bee Choo Tai,1,3 Tien Y. Wong,4–6 E. Shyong Tai,7 Jialiang Li,8
Jie Jin Wang,6,9 and Paul Mitchell 9
PURPOSE. To investigate whether the effect of metabolic
syndrome (MetS) and its components on the incidence of
different cataract subtypes (cortical, nuclear, and posterior
subcapsular cataract [PSC]) change with time.
METHODS. A prospective cohort of persons 49 years of age and
older were followed over 10 years in the Blue Mountains Eye
Study, west of Sydney, Australia. MetS components as defined
by the International Diabetes Federation criteria were mea-
sured at baseline (1992–1994), after 5 years (1997–1999), and
after 10 years (2002–2004). The incidence of different cataract
subtypes was obtained from standard photographic grading at
these intervals (n ¼ 1997). Using a random-effects comple-
mentary log–log regression model with time to cataract
development in discrete time interval, we estimated the effect
of MetS and its components on the incidence of different
cataract subtypes at different time intervals.
RESULTS. After accounting for changes in MetS components
over time and controlling for possible confounders, MetS was
found to be associated with an increased 5-year incidence of
cortical cataract (hazard ratio [HR] 1.48; 95% confidence
interval [CI], 1.05–2.09) and PSC cataract (HR 1.75; 95% CI,
1.01–3.04). Among the five MetS components, high glucose
and obesity predicted an increased 5-year incidence of cortical
cataract. In addition, low high-density lipoprotein and high
glucose were associated with an increased 10-year incidence of
cortical and PSC cataracts, respectively.
CONCLUSIONS. Changes in MetS predicted the 5-year incidence of
cortical and PSC cataracts. Different MetS components
predicted the incidence of cortical and PSC cataracts at
varying time intervals. (Invest Ophthalmol Vis Sci. 2013;
54:641–646) DOI:10.1167/iovs.12-10980
Age-related cataract is a leading cause of blindness and poorvision and a major public health concern globally.1
Metabolic syndrome (MetS) represents a cluster of these
metabolic abnormalities involving central obesity, dyslipide-
mia, hyperglycemia, and high blood pressure (BP).2 A few
studies have investigated the association between cataract and
MetS, and whether some individual components are more
important risk factors than others for specific cataract
subtypes. The Blue Mountains Eye Study (BMES) previously
examined baseline MetS with glucose as a mandatory
component based on the World Health Organization (WHO)
criteria, in relation to 10-year cumulative incidence of the three
principal cataract subtypes (i.e., cortical, nuclear, and posterior
subcapsular [PSC]) and showed that MetS was associated with
an increased risk of all three cataract subtypes.3 A recent cross-
sectional study in Singapore confirmed the relation between
baseline MetS, defined by the Third Report of the National
Cholesterol Education Program Adult Treatment Panel (ATP-3)
and cortical cataract, but not between MetS and either nuclear
or PSC cataracts.4 Other studies have reported that baseline
body mass index (BMI), high BP, or diabetes3,4 is associated
with age-related cataracts, whereas elevated serum triglyceride
(TG) was a predictor of cataracts among females in another
study.5
However, there are a number of unanswered questions.
First, previous studies used different definitions for MetS, that
is, European Group for the Study of Insulin Resistance (EGIR),
WHO, and ATP-3, and it has been reported that these
definitions were not as successful in predicting diabetes,
cardiovascular disease, and other health outcomes.6–9 Thus, in
this study, we define MetS based on the International Diabetes
Federation (IDF)10 criteria. This is a diagnostic tool for both
research purposes and clinical practice, which can be used
relatively easily in any country by any physician to identify
patients at increased risk of developing health-related out-
comes.2 Moreover, previous studies suggested that IDF
provides more reliable criteria for diagnosing MetS in a
predictive model for coronary clinical status in type 2 diabetes
populations.11,12 Second, previous studies, including an earlier
report of BMES,3 used only MetS data at baseline in the
evaluation of its relationship with cataracts. However, exper-
imental studies in rats and humans have shown that the effect
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of glucose and lipid abnormalities on cataract formation may
change over time12,13; therefore, this underscores the impor-
tance of collecting further information on glucose and lipid
abnormalities beyond baseline measurements to better detect
cataract formation.
To our best knowledge, this is the first study to have fully
utilized the information on MetS and its components that were
collected not only at baseline but also at subsequent follow-up
visits (i.e., after 5 and 10 years) to examine the risk of different
cataract subtypes. Further, since the outcome, different
cataract subtypes, was measured in a discrete time interval,
we implement the random-effect complementary log–log
regression since it may be more appropriate for detecting
stronger and more robust relationships14,15 between individual
MetS components, than the logistic regression as used in
previous studies. Thus, to evaluate the effect of MetS and its
components on the incidence of different age-related cataract
subtypes (i.e., cortical, nuclear, and PSC) more precisely, and to
determine whether these associations changed with time, we
utilized full information that was collected at each follow-up
and implemented appropriate statistical models to better
describe the relationships.
METHODS
Study Design and Participants
The BMES is a population-based prospective cohort study of vision,
common eye diseases, and other health outcomes in a suburban
Australian population west of Sydney, Australia.16 Between 1992 and
1994, noninstitutionalized permanent residents 49 years of age and
older were invited to participate, and were requested to return for
follow-up examinations after 5 (1997–1999) and 10 years (2002–2004).
The recruitment details have been described elsewhere.3,16,17
The BMES, approved by the Human Research Ethics Committee of
the University of Sydney, was conducted according to the Declaration
of Helsinki. Written informed consent was obtained from all
participants at each examination.16 At each visit, trained interviewers
completed a comprehensive questionnaire comprising demographic
information, eye, and general medical history, including hypertension,
diabetes, and preexisting diseases (i.e., angina, acute myocardial
infarction [AMI], and stroke), as well as medication used. Height,
weight, and seated BP18 were measured. Fasting pathology tests,
including high-density lipoprotein (HDL) cholesterol, TG,19 and fasting
blood sugar (FBS),20 were also measured within 2 months of each
interview. In addition, information on smoking (never, former, and
current smoker) and alcohol intake were collected. Moreover, history
of eye diseases including cataract, age-related macular degeneration
(AMD), myopia, glaucoma, as well as family history of eye disease or
blindness were obtained and recorded.3 Eye iris color and skin sun-
tanning characteristics were also estimated on a 4-point scale (always
burn, never tan; usually burn, tan with difficulty; burn and tan above
average; rarely burn, tan above average).21
Cataract Grading
Detailed cataract grading was performed according to definitions
described previously.3 Briefly, the population at risk for cataract
comprised participants who had at least one follow-up visit, but whose
lens photographs were retrospectively shown not to show signs of
cataract at baseline. They also had complete information to define MetS
at baseline. Different subtypes of cataract were determined using
standard photographic grading at each of the three examinations. The
Wisconsin Cataract Grading System was used to perform masked
grading of the lens photographs. A 5-point scale was used to assess the
presence and severity of nuclear cataract. Nuclear cataract was defined
as nuclear opacity worse than standard 3. The extent of cortical or PSC
cataract was determined by estimating the lens area involved in
segments of a circular grid overlaying the photographs. Cortical opacity
involving at least 5% of the total lens area or the presence of any PSC
opacity was used to define the presence of the respective cataract
subtypes.3 Thus, distinct types of cataract were categorized and
analyzed independently.
Definition of Metabolic Syndrome
Metabolic syndrome was defined according to IDF criteria22 as obesity
(BMI > 30 kg/m2) plus any two of the following four factors: serum TG
level ‡ 1.7 mM or specific treatment for this lipid abnormality; serum
HDL cholesterol < 1.03 mM in males and <1.29 mM in females, or
specific treatment for this lipid abnormality; systolic BP ‡ 130 mm Hg
or diastolic BP ‡ 85 mm Hg, or treatment of previously diagnosed
hypertension; or fasting plasma glucose ‡ 5.6 mM, or previously
diagnosed type 2 diabetes.
In this study, the baseline MetS components were measured and
recorded when the participant entered the study, and again at the 5-
and 10-year examinations after first recruitment. Data are therefore
available on how MetS and its components change in each subject
throughout the study.
Statistical Analysis
The v2 test and independent sample t-test were used to determine the
relationship between categorical and continuous covariates included in
this study and the 10-year cumulative incidence of cataract, respec-
tively.
Because an individual’s MetS status as well as cataract status were
prospectively evaluated at predefined time intervals (i.e., baseline, 5-
year, and 10-year), the exact time that cataract—the outcome of
interest—developed was therefore not known. Such information
was interval censored, and thus the effect of 10-year changes in MetS
and its components on the incidence of each cataract subtype was
modeled using a random-effects complementary log–log regression
model.14,15 This statistical technique is readily available for survival
analysis with discrete time and is one of the most frequently used
discrete-time hazard functions.23 In this study, the outcomes of
interest, that is, time to development of different cataract subtypes,
were included in the model based on discrete time intervals (i.e., 0–
5 years or 5–10 years), in accordance with the follow-up schedule.
This approach includes indicator variables for the examination time
interval (0–5 and 5–10 years) as covariates.14,15,24,25 The random-
effects model accounts for possible intrasubject correlation in the
assessment of MetS and its components, which were repeatedly
measured at baseline, 5 years, and 10 years. Of note, when the
dichotomous outcome is rare, the complementary log–log regres-
sion is more appropriate. However, Nelder (2001)26 and Hardin and
Hilbe (2007)27 have suggested that when a binary outcome is
common, the complementary log–log regression model may also fit
the data well.
Age, sex, smoking, preexisting disease (i.e., angina, AMI, and
stroke), family history of eye disease (i.e., cataract, AMD, myopia,
glaucoma, and blindness), history of eye disease (i.e., AMD, myopia,
and glaucoma), eye iris color, and skin sun-tanning characteristics
were considered as possible confounders in the model building.
Furthermore, we included interactions between MetS (as well as its
components) and the time interval to evaluate whether its
relationship with the different cataract subtypes varied according
to time interval (i.e., 5- and 10-years).24,25 We further explored
possible interaction between age and sex with MetS and its
components. It should be noted that for each cataract subtype,
the control group included participants without the same cataract
subtype. All statistical evaluations were made assuming a two-sided
test based on a 5% level of significance (STATA, version 11;
StataCorp, College Station, TX).
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RESULTS
Description of Study Population
A total of 1997 subjects with complete information for the
study factors at baseline contributed to the analysis of age-
related cataract. Of these, 1820 individuals contributed
information for the analysis of cortical cataract, 1357 for
nuclear cataract, and 1962 for PSC cataract. Table 1 presents
the baseline characteristics for the study subjects according to
the cumulative incidence of cataract at 10 years. Over the 10-
year follow-up, 857 persons (42.9%) with incident cataract
were detected. Of these, 455 (25.0%) were cortical cataract,
436 (32.1%) were nuclear cataract, and 135 (6.9%) were PSC
cataract. Of the 455 persons with incident cortical cataract,
252 (53.2%) had more than 5% and less than 10% severity and
213 (46.8%) had 10% or more severity in the worse eye. Of the
135 persons with incident PSC cataract, 104 (77.0%) had less
than 5% severity and 31 (23.0%) had 5% or more severity in the
worse eye. The mean age of participants was 63.9 years
(standard deviation [SD], 8.3) with a female predominance
(57.7%). Table 2 shows the changes in MetS and its
components over the 10-year study follow-up. Of those
included in the analysis, prevalent MetS increased slightly to
16.6% (95% confidence interval [CI], 14.9%–18.3%) after 5
years follow-up from 12.3% (95% CI, 10.9%–13.8%) at baseline,
and was 12.8% (95% CI, 11.1%–14.6%) after 10 years (Table 2).
The Figure shows the changes in MetS and its compo-
nents at baseline, 5-year, and 10-year follow-up among
individuals with different cataract subtypes. Generally, a
lower proportion of individuals with nuclear cataract had
MetS or its components as compared with cortical or PSC
cataract. MetS increased from baseline to 5-year follow-up







n ¼ 857 P Value
Baseline mean age (SD) 63.9 (8.3) 62.3 (8.3) 65.9 (7.8) <0.0001
Sex (%)
Male 844 (42.3) 517 (45.3) 327 (38.2) 0.001
Female 1153 (57.7) 623 (54.7) 530 (61.8)
Family history of blindness (%) 83 (4.2) 39 (3.4) 44 (5.1) 0.058
Family history of any eye disease (%)* 643 (32.2) 366 (32.1) 277 (32.3) 0.918
History of any eye disease at baseline (%)† 400 (20.0) 221 (19.4) 179 (20.9) 0.407
Preexisting disease (%)‡ 308 (15.4) 161 (14.1) 147 (17.2) 0.064
Smoking status (%)
Nonsmoker 1046 (52.4) 601 (52.7) 445 (51.9) 0.416
Ex-smoker 698 (34.9) 387 (33.9) 311 (36.3)
Current smoker 253 (12.7) 152 (13.3) 101 (11.8)
Eye iris color (%)
Blue 978 (49.0) 565 (49.5) 413 (48.2) 0.897
Hazel/green 572 (28.6) 323 (28.3) 249 (29.0)
Tan/brown 251 (12.6) 144 (12.6) 107 (12.5)
Dark brown 196 (9.8) 108 (9.5) 88 (10.3)
Sun skin-burned (%)
Always burn, never tan 271 (13.6) 152 (13.3) 119 (13.9) 0.927
Usually burn, tan with difficulty 496 (24.8) 288 (25.3) 208 (24.2)
Burn and tan above average 784 (39.3) 448 (39.4) 336 (39.2)
Rarely burn, tan above average 446 (22.3) 251 (22.0) 194 (22.7)
MetS (%) 246 (12.3) 119 (10.4) 127 (14.8) 0.004
BMI > 30 (%) 346 (17.3) 173 (15.2) 173 (20.2) 0.004
High glucose (%)§ 306 (15.3) 149 (13.1) 157 (18.3) 0.001
Low-HDL (%)|| 591 (29.6) 318 (27.9) 273 (31.9) 0.055
High TG (%)¶ 815 (40.8) 461 (40.4) 354 (41.3) 0.713
High BP (%)# 1689 (84.6) 941 (82.5) 748 (87.3) 0.004
* Includes family history of cataracts, glaucoma, macular, and blindness.
† Includes history of age-related macular degeneration, myopia, and glaucoma at baseline.
‡ Includes history of angina, stroke, and acute myocardial infarction at baseline.
§ Fasting plasma glucose ‡ 5.6 mM, or previous diagnosis or specific treatment for type 2 diabetes.
|| Serum HDL cholesterol < 1.03 mM in males and <1.29 mM in females, or specific treatment for this lipid abnormality.
¶ Serum TG level ‡ 1.7 mM or specific treatment for this lipid abnormality.
# Systolic blood pressure ‡ 130 mm Hg or diastolic blood pressure ‡ 85 mm Hg, or treatment of previously diagnosed hypertension.








MetS (%) 246 (12.3) 319 (16.6) 187 (12.8)
BMI > 30 (%) 346 (17.3) 447 (23.2) 344 (23.5)
High glucose (%)* 306 (15.3) 404 (23.4) 198 (18.5)
Low-HDL (%)† 591 (29.6) 484 (28.0) 418 (32.1)
High TG (%)‡ 815 (40.8) 789 (39.5) 300 (27.3)
High BP (%)§ 1689 (84.6) 1750 (91.3) 1183 (82.6)
* Fasting plasma glucose ‡ 5.6 mM, or previous diagnosis or
specific treatment for type 2 diabetes.
† Serum HDL cholesterol < 1.03 mM in males and <1.29 mM in
females, or specific treatment for this lipid abnormality.
‡ Serum TG level ‡ 1.7 mM or specific treatment for this lipid
abnormality.
§ Systolic blood pressure ‡ 130 mm Hg or diastolic blood pressure
‡ 85 mm Hg, or treatment of previously diagnosed hypertension.
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and decreased by 10-year follow-up among all three subtypes
of cataract.
MetS and Its Components and the Incidence of
Age-Related Cataract
We found MetS (hazard ratio [HR] 1.48; 95% CI, 1.05–2.09),
BMI > 30 (HR 1.59; 95% CI, 1.16–2.17), and elevated glucose
(HR 1.60; 95% CI, 1.15–2.23) to be associated with increased 5-
year incidence of cortical cataract, whereas low-HDL choles-
terol (HR 1.57; 95% CI, 1.10–2.24) was associated with an
excess in incidence of cortical cataract at 10-year follow-up
(Table 3).
However, there was no association between MetS or any of
its components with the incidence of nuclear cataract at either
5 or 10 years, even after accounting for information on MetS
and its components at baseline and follow-up visits as well as
controlling for confounders.
Conversely, MetS was associated with an increase in 5-year
incidence of PSC cataract (HR 1.75; 95% CI, 1.01–3.04),
whereas elevated glucose was associated with an increase in
10-year incidence of PSC cataract (HR 1.90; 95% CI, 1.01–3.61)
(Table 3).
DISCUSSION
In this prospective cohort study of an Australian white
population participating in the BMES, we found the following:
First, after accounting for baseline and further follow-up
information on MetS and its components as defined by the
IDF criteria, MetS, elevated glucose, and BMI levels >30
contributed to an increase in 5-year incidence of cortical
cataract, whereas low-HDL cholesterol was linked to an
increase in 10-year incidence of cortical cataract. Second,
MetS and elevated glucose were positively associated with the
incidence of PSC cataract at 5- and 10-year follow-up,
respectively.
The association between elevated glucose and incidence of
cortical and PSC cataract at different time intervals suggests
that FBS levels best predicted late incidence of PSC cataract
and early incidence of cortical cataract. Mechanisms connect-
ing hyperglycemia with cataract include advanced glycation of
lens proteins,28 hyperosmotic effects of sorbitol on lens fibers
via the aldose reductase pathway,29 with induction of
apoptosis in lens epithelial cells leading to the development
of cataract.30
Additionally, our study demonstrated that BMI levels >30
predicted the 5-year incidence of cortical cataract, suggesting
FIGURE. Changes in metabolic syndrome and its components at baseline, 5-year, and 10-year follow-up among individuals with cortical, nuclear, and
PSC cataract.
TABLE 3. 10-Year Changes in MetS and Its Components on the Incidence of Age-Related Cataract
Factor
Cortical Nuclear PSC
HR (95% CI)* P Value HR (95% CI)* P Value HR (95% CI)* P Value
Incidence at 5 years
MetS 1.48 (1.05–2.09) 0.025 1.01 (0.75–1.36) 0.941 1.75 (1.01–3.04) 0.045
BMI > 30 1.59 (1.16–2.17) 0.004 0.84 (0.64–1.10) 0.210 1.30 (0.76–2.20) 0.337
High glucose† 1.60 (1.15–2.23) 0.006 1.13 (0.87–1.56) 0.372 1.59 (0.93–2.72) 0.091
Low-HDL‡ 1.14 (0.82–1.58) 0.437 0.94 (0.73–1.22) 0.667 1.43 (0.84–2.45) 0.186
High TG§ 1.09 (0.82–1.44) 0.570 0.98 (0.78–1.23) 0.874 1.44 (0.90–2.32) 0.129
High BP|| 1.12 (0.67–1.89) 0.659 1.08 (0.70–1.68) 0.720 1.10 (0.44–2.74) 0.840
Incidence at 10 years
MetS 1.40 (0.88–2.20) 0.151 0.93 (0.54–1.61) 0.802 1.39 (0.70–2.76) 0.347
BMI > 30 1.44 (1.00–2.09) 0.051 1.24 (0.84–1.86) 0.286 1.52 (0.89–2.60) 0.127
High glucose† 1.24 (0.79–1.97) 0.349 1.30 (0.81–2.08) 0.279 1.90 (1.01–3.61) 0.048
Low-HDL‡ 1.57 (1.10–2.24) 0.013 1.03 (0.69–1.54) 0.870 1.45 (0.85–2.46) 0.169
High TG§ 0.76 (0.49–1.16) 0.201 0.97 (0.63–1.51) 0.903 1.50 (0.81–2.76) 0.197
High BP|| 0.96 (0.63–1.47) 0.861 1.27 (0.75–2.15) 0.378 1.11 (0.56–2.19) 0.764
* Adjusted for age, sex, eye disease at baseline (i.e., myopia, macular, and glaucoma), preexisting disease at baseline (i.e., acute myocardial
infarction, angina, and stroke), and family history of blindness.
† Fasting plasma glucose ‡ 5.6 mM, or previous diagnosis or specific treatment for type 2 diabetes.
‡ Serum HDL cholesterol < 1.03 mM in males and <1.29 mM in females, or specific treatment for this lipid abnormality.
§ Serum TG level ‡ 1.7 mM or specific treatment for this lipid abnormality.
|| Systolic blood pressure ‡ 130 mm Hg or diastolic blood pressure ‡ 85 mm Hg, or treatment of previously diagnosed hypertension.
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that the contribution of obesity to cortical cataract formation
may reduce over time. In the Singapore Malay Eye Study and
another study by Lim et al.,31 baseline BMI levels have been
shown to contribute to a higher risk of cortical cataract4 and
PSC cataract.31 The underlying mechanism behind the
relationship between obesity and cataract is unclear.32 To
date, there has not been any study that examined how changes
in BMI over time would affect cataract formation. However, it
has been suggested that obesity was related to cataract by its
associated complications such as diabetes, glucose intolerance,
insulin resistance, and hyperlipidemia.32 Moreover, it has been
shown that the relationship between glucose and cholesterol
with cataract formation changed over time.12,13 Therefore, this
may partly explain why the relationship between obesity and
incidence of cataract may also change with time.
Moreover, our finding has shown an association between
low-HDL cholesterol and an excess in 10-year incidence of
cortical cataract, suggesting that it takes a longer observation
time for low-HDL cholesterol to be confirmed as a predictor of
cortical cataract. A previous BMES report, which considered
only baseline information using logistic regression,3 failed to
detect such a relationship. This finding thus suggests the
importance of full utilization of baseline and follow-up data, to
better describe the discrete time to development of cataract
using a complementary log–log model. Studies have suggested
that inflammation and oxidative stress resulting from low-HDL
cholesterol levels might contribute to cataract formation.33–35
Finally, as a specific entity, our finding demonstrated a
positive association between MetS and 5-year incidence of
cortical and PSC cataracts. In particular, MetS as a whole rather
than its individual components, best predicted PSC cataract at
5 years. Interestingly, when we considered only the effect of
MetS components at baseline (data not shown) without
accounting for its changing status at follow-up, we did not
detect any effects of BMI or low-HDL cholesterol on cortical
cataract, even after adjusting for age, sex, eye diseases, and
preexisting disease status. Therefore, the effects of MetS and its
components on the incidence of cortical cataract at different
time intervals would not have been detected if we had only
utilized the baseline data.
However, based on a previous report of BMES,3 MetS as
defined by the WHO criteria, was a predictor of nuclear
cataract, whereas our study did not confirm this association.
We did an analysis of the data based on MetS defined by WHO
criteria, which was used by a previous report of BMES. Using a
complementary log–log regression model, the results of MetS
defined by the IDF and WHO criteria were the same for nuclear
cataract (result not shown). Therefore, this difference may be
due to differences in technique and sample size. Moreover,
obesity has been shown to have a different pattern in its
relation with nuclear cataract, with a lower BMI level being an
independent risk factor for nuclear cataract.32 This suggests
the possibility of distinct etiologic pathways for different
cataract subtypes.32 Since obesity was a mandatory component
in defining MetS in our study, this may partially explain why
there was no effect of MetS on nuclear cataract.
The strengths of this study include (1) its representative
elderly Australian population, (2) high-quality data collection,
(3) population-based study of long-term incidence of cataract,
(3) full use of MetS data at each visit, (4) applying a random-
effects complementary log–log regression model that can
detect stronger and more robust relationships14,15 between
individual MetS components and cataract subtypes where
occurrences are measured in discrete time interval, and (5)
cataract diagnosis based on standardized lens photographic
grading, which has been shown to have high reproducibili-
ty.17,36 However, some drawbacks should also be noted.
Statistical significance was not achieved for the relationship
between MetS components and PSC cataract, mainly because
of the lack of statistical power due to the limited number of
PSC cases. This warrants further investigation in studies with
more PSC cases.
In conclusion, changes in MetS predicted the 5-year
incidence of cortical and PSC cataract. Different MetS
components predicted the incidence of cortical and PSC
cataracts at varying time intervals. This underscores the
importance of fully accounting for the data on MetS
components collected at each follow-up visit for physicians
to better predict the risk of different cataract subtypes in older
persons at varying time intervals.
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a b s t r a c t
Aims: To determine the relationship between body mass index (BMI) including its 5-year
changes and mortality, and compare the results obtained using Cox and competing risks
models.
Methods: Our study subjects included 2216 persons aged 49 years who participated in the Blue
Mountains Eye Study, Australia between 1992 and 1994, and returned for further follow-up
examinationsbetween1997and1999.WeexaminedtherelationshipbetweenBMIandmortality
using cubic spline. The Cox and competing risks models were used to assess the associations
between baseline BMI and its 5-year changes with all-cause and cause-specific mortality.
Results: Amongst subjects aged 70 years, the relationship between BMI and all-cause
mortality was U-shaped. For those aged >70 years, an L-shaped relationship was seen with
no elevation in risk amongst the overweight/obese. Based on the competing risks model,
obesity at baseline was associated with increased risk of cardiovascular death and reduction
in BMI at 5-year was linked to an increase risk of cancer death amongst those aged 70 years.
The cause-specific Cox model showed that reduction in BMI at 5-year was associated with
cancer-death regardless of age, and with cardiovascular deaths among subjects aged 70
years. Cox regression model showed larger magnitude of effect with wider confidence
interval as compared with competing risks model.
Conclusions: Conditions associated with obesity are more likely to affect mortality among
subjects aged 70 years, but not among those aged over 70 years. Cox model shows larger
magnitude of effect in comparison with competing risks model.
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The prevalence of obesity in younger adults and elderly will
increase, with significant consequences for public health care
[1,2]. Obesity is commonly associated with hypertension,
diabetes, cardiovascular disease (CVD) and disability [1,2].
Previous prospective cohort studies have tried to describe
the impact of obesity on all-cause and cause-specific mortal-
ity, however, conflicting results remains amongst middle-
aged and elderly, with a lack of evidence to prove the strength
of association between obesity and mortality [3–12]. Variation
in age of participants in different studies may contribute to the
conflicting findings in these studies, with some studies
suggesting that overweight and obesity may not be a risk
factor for mortality in the elderly [11,12]. Moreover, the impact
of changing BMI over a period of time on mortality remains
uncertain [13]. Some studies reported that an increase or
decrease in BMI over time predicts a greater risk of CVD, cancer
or all-cause mortality among middle-aged or elderly [14–17],
while others have not noted this association [4,18].
Additionally, obesity is associated with increases in mor-
tality from multiple causes. Most studies that have examined
the associations between obesity and cause-specific mortality
fail to take into account ‘‘competing risks’’ from other causes of
death. Cox regression model is adequate when competing risks
are rare (i.e. among younger adults). However, in the presence of
strong competing risks, as with frail or elderly populations [19],
standard Cox regression model may substantially overestimate
the absolute risk of event of interest, because subjects with a
competing (and thus censored) event are treated as if they could
experience the event of interest in the future [20]. In addition,
predictions from a standard survival analysis in the presence of
competing risks have been said to refer to the risk of failing from
the event of interest in a virtual world where the competing risk
is absent [21–23]. For clinical decision-making in the real world,
where competing risks do occur, actual rather than virtual
absolute risks are often more relevant [24,25]. Therefore,
competing risks models are well suited for outcomes involving
multiple failure types (such as cancer- and cardiovascular-
deaths), as it appropriately account for each competing risk in
the analysis, yielding a more accurate estimation of exposure
(BMI) effect on different causes of death [20,26]. To our best
knowledge, competing risk models have not been used to
evaluate the relationship between BMI and its changes with
cause-specific mortality.
Therefore, in this study, we sought to determine the
associations between baseline BMI, the 5-year change in BMI,
with all-cause and cause-specific mortality in the Blue
Mountains Eye Study (BMES), and compare the results
obtained using standard survival models such as the
Kaplan–Meier and Cox with the competing risks model.
2. Materials and methods
2.1. Participants
The BMES is a prospective cohort study of vision and other
health outcomes [27] in white Australians. Two adjoiningurban postcode areas in the Blue Mountains area, west of
Sydney, in New South Wales, Australia, were selected as
target population. All non-institutionalised, permanent
residents aged 49 years and over at the time of the census
were eligible. Permanent residents were defined as living in
the dwelling for more than six months of a year [28]. At
baseline examination (1992–1994), 3654 (82.4%) of eligible
subjects were interviewed and examined. At 5-year follow-up
(i.e. between 1997 and 1999), 2335 participants (63.9% of the
original cohort or 75.1% of survivors) were examined.
Mortality subsequent to the 5-year visits was assessed via
demographic data linkage to the Australian National Death
Index (NDI) database. Each examination survey of this cohort
was approved by the Human Research Ethics Committees of
the Western Sydney Area Health Service and the University of
Sydney, and the study adhered to the Helsinki Declaration.
Signed informed consent was obtained from all participants
at each examination. More details of the BMES have been
described previously [27,28].
In this study, we included 2216 subjects with complete
information from both the baseline and 5-year examinations.
Participants who died shortly after the study baseline visits
were excluded from the analysis as in a previous study [4], to
control for the relation between reduced BMI, morbidity and
early death [29].
2.2. Data collection
At each visit, a comprehensive questionnaire comprising
demographic information, smoking status (current, former
and never smoker), alcohol intake (gram per week) and a
detailed history of diseases, including hypertension, diabetes,
angina, acute myocardial infarction (AMI), stroke and cancer
as well as medication was recorded at face-to-face interviews
using a standardised questionnaire conducted by trained
interviewers [27]. We defined pre-existing disease(s) as a
binary variable based on past history or medication of at least
one of the above-mentioned diseases. In addition, self-
reported physical activity based on time spent on activities
per week using the International Physical Activity Question-
naire [30] were collected. The activities captured included
occupational, household and leisure activities.
2.3. Study factors
Participants had their weight (after removal of shoes and
heavy clothing) measured by standing on an automated scale,
to which a vertical height measure was attached [31]. The BMI
was calculated as weight (kg)/height (m2). Baseline BMI was re-
categorised using the classification of the World Health
Organisation Expert Committee on Physical Status [32]:
underweight: <18.5 kg/m2, normal weight: 18.5 to <25 kg/
m2, overweight: 25 to <30 kg/m2, and obese: 30 kg/m2.
Normal weight was considered as the reference group in all
analyses.
Five-year change in BMI from baseline was categorised as
follows: stable: <1 BMI unit change, gain: 1 BMI unit gain,
reduction: 1 BMI unit loss [17]. Stable BMI was regarded as the
reference group in all analyses involving changes in BMI from
the baseline to 5-year visit.
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Deaths occurring after baseline recruitment (1992–1994) until
31 December 2007 were confirmed by matching the demo-
graphic information of the participants with the Australian
National Death Index (NDI), by using probabilistic record
linkage. Causes of death were provided by the NDI using the
International Classification of Diseases (ICD) 9th revision and
the International Statistical Classification of Diseases, 10th
revision [33]. Cardiovascular death included the following
codes from ICD-9 (3949, 4029, 4109, 4119, 4140, 4148, 4149, 4151,
4240, 4241, 4254, 4269, 4273, 4274, 4275, 4278, 4280, 4281, 4289,
4290, 4291, 4410, 4411, 4413, 4414, 4415, and 4439) and ICD-10
(I059, I10, I132, I219, I249, I251, I255, I259, I269, I271, I350, I352,
I358, I429, I469, I48, I500, I514, I515, I516, I709, and I711). Stroke
death (thrombotic, haemorrhagic) included the following
codes from ICD-9 (430.0–438.9) and ICD-10 (160.0–169.9) [33].
In addition, cancer death was defined as C00–C97 in ICD-9 and
C140–C234 in ICD-10. Deaths and cause(s) of death were
confirmed by medical certifiers, which include the physician
in attendance, coroner or medical examiner, regardless of
whether the death occurred in a hospital or in the community
[33]. The sensitivity and specificity of the Australian NDI has
been estimated at 93.7% and 100% for all-cause deaths, and
92.5% and 89.6%, respectively, for cardiovascular deaths.
Validation of stroke- and cancer-death was, however, not
possible [33].
2.5. Statistical analyses
We first explored the relationship between baseline BMI
(continuous) and the risk of death via non-parametric
regression model based on cubic spline [34] with four internal
knots at the 5th, 15th, 75th and 90th percentiles of the BMI
distribution. In the graphical display we selected the upper
bound of the reference group (normal weight) at 23.5 kg/m2 as
reference.Table 1 – Baseline characteristics of 2216 study subjects accor
Variable Total (n = 2216)Underweight (n = 31)Norm
Age (year)
70 1671 (75.4) 20 (64.5) 
>70 545 (24.6) 11 (35.5) 
Gender (%)
Female 1277 (57.6) 23 (74.2) 
Male 939 (42.4) 8 (25.8) 
Smoking status (%)
Current smoker 282 (12.7) 7 (22.6) 
Ex-smoker 788 (35.6) 9 (29.0) 
Nonsmoker 1146 (51.7) 15 (48.4) 
Diabetes (%) 142 (6.5) 1 (3.2) 
Hypertension (%) 680 (30.7) 4 (12.9) 
History of stroke (%) 75 (3.4) 1 (3.2) 
History of angina (%) 250 (11.3) 2 (6.5) 
History of AMI (%) 177 (8.0) 2 (6.5) 
History of cancer (%) 170 (7.7) 79 (8.8) 
Pre-existing disease(s) (%) 1025 (46.2) 373 (41.3) 
Abbreviations: AMI, acute myocardial infarction; BMI, body mass index.In examining associations between BMI and all-cause
mortality, we used the Cox proportional hazards model. We
implemented the competing risks model [26] to study the
associations between BMI (baseline and 5-year change) with
cause-specific mortality. Time-to-death (year) is the primary
outcome variable. We further compared the results of the
competing risks methods based on cumulative incidence
[20,35–37] and competing risks regression [26,38] with the
Kaplan–Meier (KM) estimates and cause-specific Cox models
respectively. Of note, in the competing risks model, the effect
estimate is summarised by subdistribution hazard ratio (SHR),
where the subdistribution hazard is directly interpretable in
terms of the cumulative incidence function [20,38].
Sex, smoking status and pre-existing disease(s) at baseline
remained significant in the multivariable analyses. We further
explored effect modification of age, sex and pre-existing
disease(s) on BMI. The effect estimate and its 95% confidence
interval (CI) were presented according to age groups, as the
interaction effect was significant. The proportional hazards
assumption was checked for individual covariates and
globally.
All statistical evaluations were made assuming a two-sided
test based on a 5% level of significance. The non-parametric
plot of cubic spline was generated using R statistical package
(www.r-project.org). All other statistical analyses were carried
out using STATA version 11.
3. Results
3.1. Demographic profile of subjects
Table 1 provides a description of the baseline characteristics of
the 2216 participants. Generally, underweight persons were
more likely to be younger (65%) and predominantly female
(74%). Moreover, obese persons were more likely to be younger
(78%) or have a history of pre-existing disease(s) (58%) atding to BMI categories.
al weight (n = 902)Overweight (n = 907)Obese (n = 376)P-value
649 (71.9) 710 (78.3) 292 (77.7) 0.005
253 (28.0) 197 (21.7) 84 (22.3)
541 (60.0) 456 (50.2) 257 (68.4) <0.001
361 (40.0) 451 (49.7) 119 (31.6)
134 (14.9) 99 (10.9) 42 (11.2) 0.068
301 (33.4) 343 (37.8) 135 (35.9)
467 (51.8) 465 (51.3) 199 (52.9)
37 (4.1) 59 (6.6) 45 (12.2) <0.001
230 (25.5) 287 (31.6) 159 (42.3) <0.001
32 (3.6) 29 (3.2) 13 (3.5) 0.980
82 (9.1) 119 (13.2) 47 (12.6) 0.031
60 (6.7) 81 (8.9) 34 (9.1) 0.257
2 (6.4) 59 (6.5) 30 (8.0) 0.332
9 (29.0) 423 (46.6) 220 (58.5) <0.001
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 3 ( 2 0 1 4 ) 4 2 – 5 0 45baseline. There were 599 (27%) deaths reported until December
2007. Of these, 234 (39%) were cardiovascular-deaths and 167
(28%) were cancer-deaths. During a median follow-up dura-
tion of 14.7 years, 12 (39%) underweight and 109 (29%) obese
subjects had died. Of the obese subjects who died during the
study follow-up, the prevalence of pre-existing disease at
baseline were higher amongst those aged 70 years than older
subjects (history of diabetes 44% vs 27%, hypertension 26% vs
17%, stroke 13% vs 11%, angina 28% vs 9%, AMI 29% vs 12% and
cancer 24% vs 15%) (Appendix 1).
3.2. Relationship between baseline BMI with all-cause and
cause-specific mortality
Interaction effect was noted between age and baseline BMI for
all-cause (P = 0.049) and cardiovascular-death (P = 0.044). As
such, we have reported the results of our analysis according to
age. Fig. 1 shows the risk of all cause-death was U shaped with
the highest mortality rates at the two extreme ranges of BMI
for all subjects as well as for those aged 70 years. However,
for persons aged over 70 years at baseline, the L-shaped
relationship suggests a higher risk of death amongst the
underweight, with no elevation in the mortality risk for the
overweight or obese, as compared with the normal weight.
Consistent with Fig. 1, Table 2 shows that for persons aged
70 years at baseline, there was an increased risk of all-cause
mortality amongst the obese (hazard ratio (HR) 1.44, 95% CI:
1.05–1.98). There was also suggestion that being underweight
may increase the risk of all-cause death. Similarly, obesity was
associated with a greater risk of cardiovascular mortality in
this age group based on competing risk (SHR 2.06, 95% CI 1.14–
3.70) and Cox regression (HR 2.07, 95% CI 1.15–3.72) (Table 2).
Amongst persons aged over 70 years, there was no evidence of
association between baseline BMI and all-cause or cause-
specific mortality (Table 2). Although the conclusions drawnFig. 1 – Cubic splines describing the nonlinear relationship betw
death. Four knots were placed at the 5th, 15th, 75th and 90th per
is the upper bound of the reference group (i.e. normal weight).based on the two methods were largely similar, the magnitude
of effect was larger, and with wider CI based on the cause-
specific Cox model as compared with the competing risk
regression in most instances (Table 2).
3.3. Changes in BMI and all-cause or cause-specific
mortality
Over the 5-year period, reduction in BMI was observed in 278
(13%) subjects, while 1098 (50%) of them experienced an
increase in BMI. Generally, persons with reduced or increased
BMI tended to be younger (61% and 80%, respectively). A higher
proportion with pre-existing disease(s) at baseline was noted
amongst those with a decrease in BMI in subsequent 5 years,
as compared with the other groups (Table 3). The overall
mortality rate was the highest amongst those with a BMI
decrease (49%) and the lowest amongst those with a BMI
increase (22%). The magnitude of 5-year changes in BMI
according to age group is shown in Appendix 2. In particular,
the proportion with BMI reductions among elderly subjects (<
5 [1.5%], 5 to 3 [3.7%], <3 to 1 [11.1%]) were higher as
compared to younger subjects (< 5 [0.6%], 5 to 3 [1.7%], <
3 to 1 [6.4%]). Moreover, a higher proportion of those who
were obese at baseline experienced BMI reduction (16.8%)
while, a lower proportion of those who were underweight at
baseline experienced BMI reduction (5.0%) among those aged
70 years. Among the elderly subjects, the proportions with
BMI reduction in the obese and underweight groups were
30.9% and 9.1%, respectively (Appendix 3).
Fig. 2 shows the Kaplan–Meier cumulative incidence curve
for cancer- and cardiovascular-deaths according to changing
BMI status. The estimates were larger than those obtained
using the competing risks method for all BMI groups under
consideration. Reduced BMI was associated with a higher risk
of all-cause mortality regardless of age (Age 70 years: HR 2.22,een body mass index (kg/m2) and the relative hazard of
centiles of the BMI distribution. The reference point at 23.5
Table 2 – Age-specific associations between baseline BMI and its 5-year changes with all/cause and cause-specific


































Age  70 years
Underweight (n = 20) 6 1.82 (0.80–4.15) 2 0.95 (0.14–6.53) 2 1.34 (0.18–7.25) 0.96 (0.13–6.81) 1.73 (0.17–7.50)
Overweight (n = 710) 118 1.07 (0.82–1.41) 37 0.97 (0.61–1.54) 37 1.43 (0.84–2.42) 0.99 (0.62–1.59) 1.43 (0.85–2.41)
Obese (n = 292) 64 1.44 (1.05–1.98) 23 1.51 (0.88–2.59) 22 2.06 (1.14–3.70) 1.58 (0.98–2.68) 2.07 (1.15–3.72)
Age > 70 years
Underweight (n = 11) 6 1.20 (0.53–2.72) 2 0.68 (0.09–4.94) 4 1.73 (0.55–5.40) 0.90 (0.12–6.64) 1.95 (0.60–5.45)
Overweight (n = 197) 116 0.98 (0.77–1.25) 27 1.01 (0.60–1.69) 53 0.85 (0.60–1.22) 1.02 (0.61–1.69) 0.87 (0.61–1.24)
Obese (n = 84) 45 0.94 (0.67–1.32) 11 1.07 (0.54–2.15) 20 0.78 (0.47–1.31) 1.12 (0.56–2.25) 0.81 (0.49–1.33)
Change in BMI (kg/m2)
Age  70 years
Reduction (n = 169) 55 2.22 (1.60–3.09) 23 3.03 (1.76–5.23) 14 1.55 (0.83–2.89) 3.20 (1.86–5.50) 1.85 (1.02–3.46)
Gain (n = 875) 124 0.88 (0.68–1.14) 41 1.01 (0.63–1.60) 34 0.74 (0.46–1.18) 1.01 (0.63–1.60) 0.78 (0.49–1.25)
Age > 70 years
Reduction (n = 109) 81 1.76 (1.32–2.35) 19 1.42 (0.78–2.60) 35 1.07 (0.69–1.65) 1.89 (1.04–3.43) 1.40 (0.92–2.14)
Gain (n = 223) 113 0.86 (0.66–1.11) 25 0.92 (0.53–1.58) 54 0.81 (0.56–1.17) 0.92 (0.52–1.58) 0.82 (0.55–1.19)
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; SHR, subdistribution hazard ratio.
Note: model is adjusted for sex, smoking status and pre-existing disease(s) at baseline. For baseline BMI, normal weight and for BMI changes,
stable BMI regarded as reference group.
Stable BMI: <1 unit BMI change, BMI gain/reduction: 1 unit BMI change.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 3 ( 2 0 1 4 ) 4 2 – 5 04695% CI 1.60–3.09; Age >70 years: 1.76, 95% CI 1.32–2.35) (Table
2). Amongst subjects aged 70 years, reduction in BMI was
significantly associated with cardiovascular death (HR 1.85,
95% CI: 1.02–3.46) and cancer-death (HR 3.20, 95% CI: 1.86–5.50)
in the cause-specific Cox model, although this association was
not confirmed by the competing risks model for cardiovas-Table 3 – Baseline characteristics of 2216 study subjects accor
Total (n = 2216) Stable BMI (n = 
Age (year)
70 627 (74.6) 
>70 213 (25.4) 
Sex (%)
Female 1277 (57.6) 421 (50.1) 
Male 939 (42.4) 419 (49.9) 
Smoking status (%)
Current smoker 282 (12.7) 99 (11.8) 
Ex-smoker 788 (35.6) 329 (39.2) 
Non-smoker 1146 (51.7) 412 (49.0) 
Diabetes (%) 142 (6.5) 54 (6.5) 
Hypertension (%) 680 (30.7) 260 (30.9) 
History of stroke (%) 75 (3.4) 34 (4.1) 
History of angina (%) 250 (11.3) 91 (10.9) 
History of AMI (%) 177 (8.0) 58 (6.9) 
History of cancer (%) 170 (7.7) 66 (7.9) 
Pre-existing disease(s) (%) 1025 (46.2) 392 (46.7) 
Abbreviations: AMI, acute myocardial infarction; BMI, body mass index.
Note: Stable BMI: <1 unit BMI change, BMI gain/reduction:  1 unit BMcular-death (SHR 1.55, 95% CI: 0.83–2.89) (Table 2). Subjects
aged >70 years with reduced BMI were also found to have an
elevated risk of cancer death (HR 1.89, 95% CI: 1.04–3.43) in the
cause-specific Cox model only (Table 2).
Supplementary analysis showed BMI reduction in the
overweight/obese group to be significantly associated withding to 5-year changes in BMI.
840) Reduction (n = 278) Gain (n = 1098) P-value
169 (60.8) 875 (79.7) <0.001
109 (39.2) 223 (20.3)
181 (65.1) 675 (61.5) <0.001
97 (34.9) 423 (38.5)
46 (16.5) 137 (12.5) 0.025
91 (32.7) 368 (33.5)
141 (50.7) 593 (54.0)
32 (11.9) 56 (5.1) <0.001
108 (38.8) 312 (28.4) 0.003
15 (5.4) 26 (2.4) 0.018
42 (15.2) 117 (10.7) 0.095
29 (10.5) 90 (8.2) 0.162
25 (9.0) 79 (7.2) 0.584
156 (56.1) 477 (43.4) 0.001
I change.
Fig. 2 – Comparison of cumulative incidence of cardiovascular and cancer mortality according to 5-year BMI changes:
competing risks versus Kaplan–Meier methods. CR method: competing risks method; KM method: Kaplan–Meier method.
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2.52, 95% CI 1.70–3.73) and cancer-death (Age  70: SHR, 2.33
95% CI 1.21–4.48; Age > 70: SHR 3.87 95% CI 1.69–8.90) among
both age groups. Cox-specific regression model additionally
showed that BMI reduction in the overweight/obese group was
positively linked to increased cardiovascular mortality (HR
1.89, 95% CI 1.08–3.32) among elderly subjects (Appendix 4).
3.4. The associations of baseline BMI and its 5-year
changes with all-cause and cause-specific mortality amongst
subjects without baseline pre-existing diseases
Of the 2216 study subjects, 1191 (54%) had no history of pre-
existing disease at baseline. Being underweight at baseline
was associated with all-cause death in both age groups
(Age  70 year: HR 3.29, 95% CI: 1.40–7.69; Age > 70 year: HR
2.82, 95% CI 1.01–7.89), while obesity was linked to increase
risk of cancer-death amongst younger subjects (SHR 2.26, 95%
CI 1.07–4.78) (Appendix 5). As before, the magnitude of effect
was larger, and with wider CIs based on the cause-specific Cox
model as compared with the competing risk regression in
most instances.
With regard to BMI changes over 5-year follow-up since
baseline, BMI reduction was associated with increase risk inall-cause death in both age groups (Age  70 year: HR 2.91, 95%
CI: 1.78–4.75; Age > 70 year: HR 1.74, 95% CI 1.05–2.88), and
cancer-death amongst those aged 70 years (Appendix 5). For
the latter, the Cox regression model again showed a higher
magnitude of effect as compared with the competing risk
model.
4. Discussion
In this population-based prospective cohort study of the
Australian middle-aged and elderly population, we found the
following: first, amongst the younger subjects, the relation-
ship between baseline BMI and all-cause mortality was U-
shaped, with both the underweight and obese groups
predisposed to have a greater risk of death; obesity was also
associated with increased risk of cardiovascular death in this
age group. Amongst elderly persons, an L-shaped relationship
was seen: only low but not excessive BMI was found to be
associated with increased risk of all-cause death. Second, a
reduction in BMI between baseline and the 5-year follow-up
visit was associated with all-cause mortality in both age
groups and cancer deaths among those aged  70 years.
Finally, the cause-specific Cox regression model showed larger
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 3 ( 2 0 1 4 ) 4 2 – 5 048magnitude of effect of between 1 and 33%, as compared with
the competing risks model.
4.1. All-cause mortality risk
Our study has shown that the pattern of relationship between
BMI and mortality is dependent on age. The U-shaped
relationship between BMI and mortality in subjects aged  70
70 years at baseline is consistent with the findings of
Berrington de Gonzalez et al. [7] and Adams et al. [8]. However,
this pattern of relationship was not noted amongst the elderly
who were aged above 70 years. In particular, there was no
elevation in risk of death amongst those who were overweight
or obese. This observation is consistent with that reported by
Tsai and Hsiao, who found a similar L-shaped relationship
between BMI and all-cause death among Taiwanese over 65
years old [10]. The L-shaped association between baseline BMI
and mortality in those of age >70 suggests that overweight/
obesity does not predispose the elderly subjects to be at a
greater risk of mortality. Although, it is unclear why excess
weight protects older adults, we considered three possibilities.
Firstly, the advantage of being overweight could be that fat
mass stores energy that can be used during negative energy
balance [39]. For example, extra weight could give older people
reserves to recover from stresses such as surgery or
pneumonia. Secondly, even though obesity is associated with
higher rates of chronic disease (such as diabetes), the impact
of these conditions on mortality may be reduced when they
occur in elderly individuals. For example, Tan et al. showed
that diabetes mellitus that was diagnosed after age of 65 was
not associated with increased mortality in Scotland [40],
whereas it was associated with increased mortality when
diagnosed below this age. In the Asia Pacific Cohort Studies
Collaboration, Woodward et al. also showed that the effect of
diabetes on the risk of CVD and death decreased with
increasing age at risk [41]. Thirdly, we also considered the
possibility that our findings could have been confounded by
the presence pre-existing diseases at baseline (i.e. cancer, AMI,
angina, stroke, hypertension and diabetes) that could have
resulted in weight loss and caused premature mortality.
However, we analysed the data excluding subjects with these
underlying conditions and again found overweight/obesity to
have no association with death.
4.2. Cause-specific mortality risk
In our study, obesity was associated with increased risk of
cardiovascular mortality in subjects aged 70 years. This was
consistent with a study in USA that showed obesity to be
associated with coronary heart disease mortality among
subjects aged 35–74 years [42]. Obesity is associated with
multiple cardiovascular risk factors including diabetes,
hypertension and dyslipidemia [43]. As BMI reduction even
in obese is a risk factor for death among both middle-aged and
elderly subjects and obesity is associated with all-cause and
cardiovascular death amongst subjects aged 70 years, it may
be important to control weight and modify lifestyle years
before the ageing process sets in. Moreover, our data does not
necessarily suggest that weight loss may not be beneficial in
some instances in older individuals because inference ofcausality between BMI reduction and mortality cannot be fully
established.
A unique aspect of our study is the ability to demonstrate
changes in BMI over time. BMI changes in fact occurred in
about 60% of the study population over the 5-year period since
baseline. As in previous studies [16,18,44], we also found that a
reduction in BMI was associated with increased risk of all-
cause mortality in both the middle-aged and the elderly.
Further, BMI reduction was a predictor for cancer related
mortality amongst those 70 years. In general, a decrease in
BMI prior to death in the elderly is more likely to be related to
underlying health status [29]. We therefore excluded partici-
pants who died shortly after the study baseline visits in the
analysis, as did a previous study [4], and included only subjects
who were alive at the 5-year follow-up visits with a minimum
of 4 years follow-up duration. We also consider possible effect
modification of disease status as well as medication used on
BMI but found no evidence of their interactions with either
baseline pre-existing disease status (no disease, prevalent
disease) or status of pre-existing disease over 5-year follow-up
(no disease, prevalent disease, incident disease). These
analyses do not exclude the possibility that other disease
could have developed during follow up that could have
resulted in both weight loss and increased mortality.
Considering only subjects who were free of pre-existing
disease at baseline, obesity was found to be associated with
cancer death only among the subgroup of healthy subjects
aged 70 years.
Importantly, consistent with previous studies [20,26,35–37],
when we analysed the relationship between baseline BMI and
its 5-year changes using cause-specific Cox regression model,
the effect estimates were larger than those of competing risks
model by as much as 1–33%. The differences were appreciable
especially in the older age group for cancer- (31%) and
cardiovascular-death (33%). This finding underscores that,
as population ages, the presence of competing risks would be
more common especially among the frail population. Hence,
we encourage the use competing risks models as a standard
tool for developing predictive models involving competing
risks endpoints especially among frail population, as it
provides a more accurate estimate of exposure [20].
The limitations of this study need to be considered. First,
there was limited number of underweight subjects resulting
in low statistical power. Thus, the findings relating to the
underweight should be interpreted with caution. In addition,
the possibility of Type II error may exist especially when we
analysed the data amongst subgroup of healthy subjects.
Further, when the p value reported in our study is less than
0.05, we may make Type I error due to chance as several
endpoints and subgroups were evaluated. Second, the results
could have been biased by residual confounding factors, such
as varying levels of body composition, visceral adiposity or
physical fitness [11], which were not measured in this study.
Third, we had no information about whether BMI loss was
achieved intentionally or unintentionally. Fourth, the cause
of mortality was determined by the NDI and the death
certificates may be biased by the choices of the physicians
who filled them out. The strengths of this study include
its representative study population, the high quality of
data collection involving standardised measures at each
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 3 ( 2 0 1 4 ) 4 2 – 5 0 49examination, thus eliminating bias in self-reporting, long-
term follow-up and the low likelihood of misclassification in
the causes of death.
In conclusion, we have shown that the association between
BMI and mortality is modified by age, with obesity associated
with greater risk of all-cause and cardiovascular-specific
mortality amongst subjects 70-years old. With respect to
changes in BMI over 5 years, BMI reduction, a marker of greater
severity of mortality-related diseases, was associated with
increased risk of all-cause mortality regardless of age, and
cancer-related mortality amongst subjects aged 70 years old.
Competing risk model appears to provide more accurate and
precise estimates for the association between BMI and cause-
specific mortality.
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Summary: 
The evaluation of age modified relationship between metabolic syndrome and its 
components with age-related macular disease (AMD) using the mixed-effects 
model showed metabolic syndrome, obesity, glucose and triglyceride associated 












Purpose: To investigate the relationship between metabolic syndrome (MetS) and 
its components with risk of early and late stage age-related macular degeneration 
(AMD).  
Methods: A prospective cohort of individuals aged ≥49 years were followed up 
over a period of 10-years in the Blue Mountains Eye Study, Australia. MetS 
components were measured at baseline (1992-1994), 5-year (1997-1999) and 10-
year (2002-2004) follow-up. Incident cases of early and late AMD were 
diagnosed using standard photographic grading of retinal images of 2218 
participants at risk. Mixed-effect logistic regression was conducted to explore the 
relationship between MetS (and its components) with subsequent development of 
early/late AMD.  
Results: Over the 10-year follow-up, early AMD developed in 12% and late 
AMD in 3% of participants at risk. Amongst subjects aged ≤70 years, MetS was 
associated with incidence of late AMD. Of the five MetS components, obesity, 
high glucose and high triglyceride were associated with increased incidence of 
late AMD during the 10-year follow-up. There was no evidence of effect of MetS 
and its components on risk of early AMD. 
Conclusion: MetS, obesity, high glucose, and high triglycerides were predictors 
of progression to late AMD. These data provide additional insights into the 
pathogenesis of AMD. 
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Age-related macular degeneration (AMD) is the leading cause of blindness and 




 and other 




Metabolic Syndrome (MetS) represents a cluster of metabolic 
abnormalities involving central obesity, dyslipidemia, hyperglycemia, and high 
blood pressure (BP).
5
 MetS components have long been postulated to be 
associated with AMD.
6-8
 However, there have been conflicting reports about the 
independent associations of individual MetS components (e.g. BMI, BP or high 
serum lipid levels) and the development of AMD.
9-13
 For example, in the Blue 
Mountains Eye Study (BMES), obesity was significantly associated with the 
prevalence of early AMD,
14
 while total and high density lipoprotein (HDL) serum 
cholesterol were associated with incident late AMD.
15
 In the Beaver Dam Eye 
Study, total serum cholesterol was inversely associated with incident neovascular 
AMD but was positively associated with incident geographic atrophy.
16
 To date, 
most of the epidemiological data have not been consistent regarding the 
association of diabetes with AMD.
17-22
 Furthermore, previous studies on AMD 
have analyzed association with individual MetS risk factors, usually measured at 
baseline, and in isolation.
14,15
 Thus, there is uncertainty as to the relationship of a 
combination of risk factors, defined by the MetS, and AMD.  
 The aim of the current study is to examine MetS defined according to the 
International Diabetes Federation (IDF) criteria,
23
 and risk of AMD. Furthermore, 
we explored age-specific (≤70 versus >70 years) relationship between MetS and 
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its components, which were repeatedly measured at baseline, 5- and 10-year 
follow-up with the subsequent development of early or late AMD via the mixed-
model. 
 
Material and Methods 
Study design and participants 
The BMES is a population-based cohort study of vision, common eye diseases 
and other health outcomes of a suburban Australian population in the west of 
Sydney. Details about this study are published elsewhere.
24
 In brief, between 1992 
and 1994, non-institutionalized permanent residents aged 49 years and older were 
recruited into the study. The survivors were asked to return for follow-up 
examinations at 5 (1997-1999) and 10 (2002-2004) years. Participants, who did 
not return for the 5-year follow-up, were also invited to attend the 10-year follow-




At each visit, trained interviewers filled out a comprehensive 
questionnaire comprising demographic information, eye and general medical 
history including hypertension, diabetes, and pre-existing cardiovascular disease 
(namely, angina, acute myocardial infarction (AMI), stroke) as well as 
medications used. Height, weight and seated BP
25
 were measured. Fasting 
pathology tests, including total cholesterol (mmo/L), HDL cholesterol (mmo/L), 
triglyceride (mmo/L)
26
 and fasting plasma glucose (FPG) (mmo/L),
27
 were 
measured within a month of each interview and delivered by courier within the 
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same day to Westmead Hospital Sydney for hematology and clinical biochemistry 
assessment.
2
 In addition, information on smoking (never, former and current 
smoker), alcohol consumption (gram / week), history of eye diseases including 
cataract, AMD, myopia and glaucoma as well as family history of these eye 
diseases and blindness were obtained and recorded.
15
 Eye iris color (blue, hazel/ 
green, tan/ brown, dark brown) and skin sun-tanning characteristics were also 
estimated on a 4-point scale (always burn, never tan; usually burn, tan with 
difficulty; burn and tan above average; rarely burn, tan above average).
28
 The 
BMES was approved by the Human Research Ethics Committee of the University 
of Sydney and conducted according to the Declaration of Helsinki. Written 




AMD grading  
The population at risk for AMD comprised participants who had at least one 
follow-up visit, and whose retinal photographs were retrospectively shown not to 
contain AMD at baseline. The primary outcomes, namely early and late stage of 
AMD, were repeatedly measured at baseline, 5- and 10-year follow-up. 
Photographic grading for AMD was based on the Wisconsin Age-Related 
Maculopathy Grading System.
29,30
 Late-stage AMD was defined to include 
neovascular AMD and geographic atrophy (GA).
31
 Early-stage AMD was defined 
as the absence of late-stage AMD and the presence of either (1) large (≥125 µm 
diameter) indistinct soft or reticular drusen or (2) both large distinct soft drusen 





 within the macular area.
30
 Patients with only distinct soft 
drusen or retinal pigmentary abnormalities but not both lesions at baseline who 
went on to develop complementary lesions that contributed to the diagnosis of 
early AMD were included as incident early AMD cases.  
 
Definition of metabolic syndrome  
MetS was defined according to the IDF criteria
23
 as obesity (i.e. body mass index 
(BMI) >30 kg/m
2
) plus any two of the following four factors - serum triglyceride 
level ≥1.7 mmol/L or specific treatment for this lipid abnormality; serum HDL 
cholesterol  <1.03 mmol/L in men and <1.29 mmol/L in women, or specific 
treatment for this lipid abnormality; systolic BP ≥130 mmHg or diastolic BP ≥85 
mmHg, or treatment of previously diagnosed hypertension; or FPG ≥5.6 mmol/L, 
or previously diagnosed type 2 diabetes. The IDF criteria have been suggested to 
be more reliable for diagnosing MetS in predictive model for coronary clinical 
status in type 2 diabetes populations as compared with other MetS criteria such as 
the Third Report of the National Cholesterol Education Program Adult Treatment 
Panel (ATP-3), the European Group for the Study of Insulin Resistance (EGIR) 
and the World Health Organisation (WHO).
23
  
 At the time when the participant entered the study, the baseline values of 
MetS components were measured and recorded. The MetS components were 
again measured at 5- and 10-year after first recruitment. Data are thereafter 
available on how prevalent MetS as well as its components changes in each 





The χ2 test was used to determine the relationship between categorical covariates 
included in this study and the 10-year cumulative incidence of both early and late 
stage AMD.   
 Mixed-effect logistic regression model
32
 with repeated measurements of 
MetS (and its components) at baseline, 5- and 10-year follow-up visits, was used 
to explore the relationship between Mets and its components with the subsequent 
development of early or late AMD over 10-year follow-up. The mixed-effect 
model comprises both the fixed and random effects. The random effects are 
estimated when the data structure consists of repeated measures of data over time, 
in this case, MetS and its components as well as AMD at baseline, 5- and 10-year, 
within each individual. Age, sex, smoking, pre-existing cardiovascular disease 
(angina, AMI and stroke), family history of eye disease (cataract, AMD, myopia, 
glaucoma and blindness), patient’s history of eye disease (cataract, myopia and 
glaucoma), eye iris color, and skin sun-tanning characteristics were regarded as 
fixed-effect covariates in the model. The regression coefficients of MetS and its 
components in mixed effects model may be interpreted as subject specific 
estimate of their effect on AMD. When repeated measures (i.e. MetS at baseline, 
5- and 10-year) were made on the same subjects, it would be appropriate to adjust 
for possible intra-subject correlation by using random effects to achieve a more 





However, among the fixed effect covariates as mentioned earlier, only 
age, sex and pre-existing cardiovascular disease were statistically significant in 
the bivariate model. We further explored possible interaction between age and sex 
with MetS or its components in these logistic regression models. All statistical 
evaluations were made assuming a two-sided test based on a 5% level of 
significance using STATA version 11.  
 
Results 
Overall, 2218 subjects with complete information for the study factors at baseline 
contributed to the analysis of incidence of AMD over 10-year follow-up. Of these, 
2114 contributed to the analysis of early-stage AMD and 2218 to late-stage AMD. 
Over the 10-year follow-up, 262 (12.4%) cases of early AMD and 70 (3.2%) 
cases of late AMD were detected. Of the participants included in the present 
study, 76.5% were aged ≤ 70 years at baseline and 58% were females. Age, sex 
and pre-existing cardiovascular disease were associated with both early and late 
AMD (Table 1).  
The prevalence of MetS increased slightly to 16.4% (95% confidence 
interval (CI) 14.9-18.1) after 5 years of follow-up from 12.2% (95% CI 10.9-13.6) 
at baseline. It was 14.2% (95% CI 12.5-16.0) after 10 years of follow-up. Of the 
five MetS components, the prevalence of obesity increased over time (baseline 
17%, 5-year 23% and 10-year 24%). The prevalence of high glucose was 15% at 
baseline and reached to 24% at 5- year and decreased by 10-year (21%). The 
prevalence of high triglyceride was highest at baseline (41%) and 5-year (40.5%) 
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and decreased by 10-year (28%). Moreover, the low HDL cholesterol had highest 
prevalence at baseline (30%) and decreased to 27% at 5-year and again slightly 
increased by 10-year (29%). Moreover, the 10-year changes in prevalence of high 
BP were as follow (baseline 85%, 5-year 91% and 10-year 81%) (Table 2).  
Amongst those who developed late AMD and were aged ≤ 70 years 
(n=32), there were notably higher proportions with MetS, increased BMI, high 
glucose and high triglyceride over time. However, amongst those who developed 
early AMD and were aged ≤70 years, the changing status of MetS and its 
components was not appreciable. The observation is similar for those who 
developed early AMD and were age >70 years, with little change in status of 
MetS over time. In fact, declines in some Mets components were noted over time 
for early AMD (Figure 1). 
 
Longitudinal information of MetS and its components and early or late AMD  
There was no evidence of any relationship between MetS and its components with 
early AMD in the mixed model (Table 3). However, there was an evidence of 
interaction effect between MetS, obesity and high glucose with age in their 
relationship with late AMD (all P < 0.05). After adjusting for sex, pre-existing 
cardiovascular diseases and inclusion of interaction between age and MetS (or its 
components), we found that MetS was significantly associated with late AMD 
(Adjusted odds ratio (OR) 2.16 [95% CI 1.01-4.65], P =0.049) amongst those 
aged ≤70 years (Table 3). Furthermore, amongst the five MetS components, BMI 
>30 (adjusted OR 2.22 [95% CI 1.09-4.49], P =0.027); high glucose (Adjusted 
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OR 3.12 [95% CI 1.48-6.56], P =0.003) and high triglyceride (adjusted OR 2.06 
[95% CI 1.01-4.22), P = 0.047) were positively linked to the incidence of late 
AMD during the 10-year follow-up period (Table 3). 
 
Discussion 
Our study investigated the relationship between MetS and the subsequent 
development of AMD over a 10 year period in a cohort of Australian white 
persons. We found that age modified the relationship of MetS, obesity and high 
glucose with late stage AMD. Amongst younger participants aged ≤70 years, 
MetS was associated with increase in incidence of late AMD during the 10-year 
follow-up. Amongst the MetS components, obesity (i.e. BMI >30), high glucose 
and high triglyceride were found to be significant predictors of incidence of late 
AMD in the younger age group. No relationship was seen for MetS and early 
AMD. 
The finding that the associations between MetS and its components with 
late AMD emerged during the 10 year follow-up and that, this was observed only 
in those age ≤70 years at baseline add to the existing literature.  For example, 
while Delcourt et al.,
12
 and Clemons et al.,
21
 have shown a significant association 
between obesity and late AMD, others have not confirmed this association.
8,14,34
 
The mechanism connecting obesity and AMD formation may be possibly 
explained by an increase in oxidative damage and inflammation in obese 
persons.
10
 Obesity is also associated with an increase in C-reactive protein, a 
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 We also observed an association between high glucose and late AMD in 
this age group.  The Beaver Dam Eye Study
17,18
 and the Barbados Eye Study
20
 
have also demonstrated an association between prevalent diabetes mellitus and 
any AMD. The mechanism behind the association between diabetes and AMD has 
been shown in eyes of long-term diabetic persons through the thickening of 
basement membrane of the choriocapillaris walls, luminal narrowing, dropout of 




We further observed a positive association between high triglyceride and 
increased incidence of late AMD during 10-year in this group of subjects. The 
observed relationship may be explained by the vascular model which suggests 
that AMD is the result of the accumulation of lipid in the sclera and the Bruch 
membrane, thus progressively increasing the stiffness of these tissues.
6
  
Importantly, our study examined changes in MetS over time in contrast to 
previous studies which only used baseline information of MetS 
components.
7,12,14,15,17,18
  In contrast, when we analysed baseline data using the 
conventional logistic regression model, only high glucose was significantly 
associated with 10-year cumulative incidence of late AMD amongst those aged ≤ 
70 years (Appendix 1). This was in contrast to the mixed model regression which 
we used which detected significant interaction not only between high glucose and 
age, but also between MetS and obesity with age, with the OR for MetS, BMI, 
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high glucose and high triglyceride reaching statistical significance amongst those 
aged ≤ 70 years. Hence, our current analysis considered all available information 
of Mets components at baseline and subsequent follow-up visits to provide a more 
comprehensive understanding of the risks of AMD associated with MetS and its 
components. 
 The strengths of this study include (a) a representative elderly Australian 
population; (b) high quality data collection; (c) a population-based study of long-
term incidence of AMD; (d) use of standard method of assessing AMD incidence, 
including photographic grading by the same personnel at all examinations, and a 
detailed side-by-side comparison of baseline and follow-up examination 
photographs to ensure negligible misclassification for AMD diagnosis;
15
 and (e) 
applying Mixed-effect logistic regression model which can detect stronger and 
more robust relationships
32,33
 between individual MetS components and AMD 
where occurrence as well as study main exposure namely MetS and its 
components are measured during the study follow-up at baseline, 5- and 10-year. 
However, the drawbacks of this study should be noted. The low prevalence of 
Mets at baseline and follow-up visits (ranging between 12.2-16.4%) may limit our 
ability to detect the relationship between MetS and early AMD. In addition, the 
possibility of chance finding exists, especially when we analyzed the data related 
to late AMD in age group ≤ 70 years involving small number of cases. Further, 
the possibility of residual confounding effect cannot be ruled out, and the 
observed associations could have been due to confounding factors, not the MetS 
or its components per se.    
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In conclusion, our study demonstrated that MetS and three of its 
components, namely BMI >30, high glucose and high triglyceride were predictors 
of progression to late-stage AMD amongst younger Australian white population 
aged ≤70 years. MetS is not a disease in itself, but a constellation of risk factors 
for cardiovascular disease and our study now extends its relevance to AMD. 
Importantly, components of MetS are modifiable through lifestyle modification 
including dietary changes and increased physical activity.  If confirmed in 
subsequent studies, these may become additional strategies for the prevention of 
AMD. These findings also demonstrate the efficiency of mixed-effect model and 
the use of multiple measurements in statistical models to detect associations with 













Figure legend  
Figure 1. Prevalence of Metabolic Syndrome and its Components at Baseline, 5- 
and 10-year Follow-up among Individuals with Early and Late Stage AMD 
according to Age Group 
AMD=age-related macular degeneration; BMI=body mass index; BP=blood 
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Table 1. Baseline Characteristics of Study Subjects according to 10-year Cumulative Incidence of Age-Related Macular Degeneration  
 Total 
(n=2218) 
Early AMD  
(n=2114) 













Age (year) (%),   ≤ 70 












Sex (%), Male  












Smoking status,  Never 
                            Former  

















Pre-existing cardiovascular disease (%)
a
 359 (16.2) 268 (14.5) 65 (24.8) < 0.001 342 (15.9) 17 (24.3) 0.062 
Sun skin-burned (%)  
   Always burn, never tan 
   Usually burn, tab with difficulty  
   Burn and tab above average 






























Eye iris color (%) 
    Blue 
    Hazel/Green 
   Tan\Brown  






























Family history of any eye disease (%)
b
 695 (31.3) 582 (31.4) 81 (30.9) 0.868 667 (31.0) 28 (40.0) 0.112 
History of any eye disease at baseline (%)
c
 914 (41.2) 737 (39.8) 119 (45.4) 0.083 879 (40.9) 35 (50.0) 0.129 
MetS (%) 271 (12.2) 236 (12.7) 24 (9.2) 0.098 263 (12.2) 8 (11.4) 0.838 
BMI > 30 (%) 386 (17.4) 329 (17.8) 38 (14.5) 0.192 373 (17.4) 13 (18.6) 0.793 
High glucose (%)
d
 345 (15.5) 291 (15.7) 40 (15.3) 0.853 330 (15.4) 15 (21.4) 0.168 
Low-HDL (%)
e
 664 (29.9) 564 (30.4) 72 (27.5) 0.326 637 (29.7) 27 (38.6) 0.109 
High triglyceride (%)
f
 916 (41.3) 765 (41.3) 110 (42.0) 0.835 882 (41.1) 34 (48.6) 0.209 
High BP (%)
g
 1890 (85.2) 1565 (84.5) 229 (87.4) 0.220 1825 (85.0) 65 (92.9) 0.067 
AMD= age-related macular degeneration; BMI=body mass index; MetS=metabolic syndrome; HDL=high density lipoprotein BP=blood pressure; 
a 
Includes history of angina, stroke and AMI; 
b
Includes family history of cataract, glaucoma, macular and blindness; 
 c 
Includes history of cataract, myopia and 
glaucoma ; 
d fasting plasma glucose ≥ 5.6 mmol/L, or previous diagnosis or specific treatment for type 2 diabetes;  e serum HDL cholesterol  < 1.03 mmol/L in 
men and < 1.29 mmol/L in women, or specific treatment  for this lipid abnormality; 
f serum triglyceride level ≥ 1.7 mmol/L or specific treatment for this lipid 
abnormality;




Table 2: Prevalence of MetS and its Components over 10-year Follow-up 






MetS (%) 271 (12.2) 348 (16.4) 227 (14.2) 
BMI > 30 (%) 386 (17.4) 488 (23.0) 379 (23.7) 
High glucose (%)
a
 345 (15.5) 479 (24.0) 307 (21.5) 
Low-HDL (%)
b
 664 (29.9) 548 (27.2) 586 (29.0) 
High triglyceride (%)
c
 916 (41.3) 898 (40.5) 327 (27.8) 
High BP (%)
d
 1890 (85.2) 1929 (91.0) 1352 (81.1) 
BMI=body mass index; BP=blood pressure; MetS=metabolic syndrome; HDL=high density 
lipoprotein 
 
a fasting plasma glucose ≥ 5.6 mmol/L, or previous diagnosis or specific treatment for type 2 
diabetes; 
b 
serum HDL cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in women, or 
specific treatment for this lipid abnormality; 
c serum triglyceride level ≥ 1.7 mmol/L or specific 
treatment for this lipid abnormality;
 d systolic blood pressure ≥ 130 mmHg or diastolic blood 










Table 3. Age-Specific Associations between Metabolic Syndrome and its Components on 
Incidence of  Early and Late AMD over 10-year  Follow-up according to Age  
 Age ≤ 70 years  
 
Age > 70 years 
 OR (95% CI)
  
 




Early AMD     
MetS 0.93 (0.59-1.45) 0.733 0.91 (0.44-1.90) 0.806 
BMI > 30  0.88 (0.60-1.30) 0.521 0.95 (0.51-1.79) 0.879 
High glucose
 a
 0.77 (0.49-1.22) 0.271 1.05 (0.61-1.83) 0.855 
Low-HDL
 b
 0.84 (0.59-1.19) 0.324 0.66 (0.38-1.14) 0.141 
High triglyceride
 c
 0.60 (0.41-0.88) 0.009 1.37 (0.85-2.20) 0.202 
High BP
 d
 1.18 (0.74-1.87) 0.496 0.56 (0.27-1.13) 0.107 
Late AMD     
MetS 2.16 (1.01-4.65) 0.049 0.42 (0.09-1.91) 0.260 
BMI > 30  2.22 (1.09-4.49) 0.027 0.24 (0.05-1.11) 0.068 
High glucose
 a
 3.12 (1.48-6.56) 0.003 1.03 (0.38-2.76) 0.956 
Low-HDL
b
 1.78 (0.89-3.57) 0.103 0.61 (0.25-1.49) 0.275 
High triglyceride
 c
 2.06 (1.01-4.22) 0.047 1.03 (0.47-2.25) 0.943 
High BP
 d
 0.84 (0.34-2.06) 0.696 0.56 (0.19-1.61) 0.278 
AMD= age-related macular degeneration; BMI=body mass index; BP=blood pressure; HDL=high 
density lipoprotein; CI=confidence interval; OR=odds ratio. 
a 
fasting plasma glucose ≥ 5.6 mmol/L, or previous diagnosis or specific treatment for type 2 
diabetes; 
b 
serum HDL cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in women, or 
specific treatment for this lipid abnormality; 
c serum triglyceride level ≥ 1.7 mmol/L or specific 
treatment for this lipid abnormality;
 d systolic blood pressure ≥ 130 mmHg or diastolic blood 
pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension. 
*Adjusted for sex, pre-existing cardiovascular disease (namely, angina, acute myocardial 
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AMD=age-related macular degeneration; BMI=body mass index; BP=blood pressure; 
MetS=metabolic syndrome; HDL=high density lipoprotein. 
 
Figure 1. Prevalence of Metabolic Syndrome and its Components at Baseline, 5- and 10-











Appendix 1. Age-Specific Associations between Baseline Metabolic Syndrome and its 
Components with 10-year Cumulative Incidence of Early and Late AMD according to Age via 
Conventional Logistic Regression  
 Age ≤ 70 years  
 
Age > 70 years 
 OR (95% CI)
  
 




Early AMD     
MetS 0.58 (0.33-1.02) 0.056 0.98 (0.46-2.07) 0.952 
BMI > 30  0.74 (0.47-1.16) 0.187 0.84 (0.43-1.63) 0.608 
High glucose
 a
 0.75 (0.46-1.23) 0.253 1.51 (0.85-2.70) 0.162 
Low-HDL
 b
 0.82 (0.57-1.18) 0.284 0.91 (0.54-1.52) 0.727 
High triglyceride
 c
 0.91 (0.66-1.27) 0.593 1.28 (0.80-2.03) 0.298 
High BP
 d
 1.07 (0.69-1.66) 0.764 0.75 (0.30-1.87) 0.537 
Late AMD     
MetS 1.50 (0.61-3.70) 0.375 0.43 (0.10-1.86) 0.258 
BMI > 30  1.67 (0.76-3.66) 0.198 0.61 (0.21-1.79) 0.367 
High glucose
 a
 2.29 (1.09-4.80) 0.029 0.61 (0.21-1.79) 0.368 
Low-HDL
b
 1.84 (0.91-3.75) 0.091 1.35 (0.66-2.77) 0.410 
High triglyceride
 c
 1.22 (0.60-2.49) 0.589 1.01 (0.50-2.00) 0.994 
High BP
 d
 1.96 (0.59-6.48) 0.270 1.07 (0.24-4.76) 0.931 
AMD= age-related macular degeneration; BMI=body mass index; BP=blood pressure; HDL=high 
density lipoprotein; CI=confidence interval; OR=odds ratio. 
a fasting plasma glucose ≥ 5.6 mmol/L, or previous diagnosis or specific treatment for type 2 
diabetes; 
b 
serum HDL cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in women, or 
specific treatment for this lipid abnormality; 
c serum triglyceride level ≥ 1.7 mmol/L or specific 
treatment for this lipid abnormality;
 d systolic blood pressure ≥ 130 mmHg or diastolic blood 
pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension. 
*Adjusted for sex, pre-existing cardiovascular disease (namely, angina, acute myocardial 
infarction and stroke) and including interaction between age and MetS (or its components) 
 
